• 1.

    Package insert (for brands listed after the nonproprietary name heading in a monograph; date of package insert given as part of citation)

  • 2.

    Physicians’ desk reference. 63rd ed. Montvale, NJ: Thomson PDR; 2009.

  • 3.

    Kirkland WD, Jones RW, Ellis JR et al. Compatibility studies of parenteral admixtures. Am J Hosp Pharm. 1961; 18:694–9.

  • 4.

    McEvoy GK, ed. AHFS drug information 2011. Bethesda, MD: American Society of Health-System Pharmacists; 2011.

  • 5.

    Sweetman SC, ed. Martindale: the complete drug reference. 37th aed. London, England: The Pharmaceutical Press; 2011.

  • 6.

    Parker EA. Staphcillin injection. Am J Hosp Pharm. 1970; 27:67–8.

  • 7.

    Parker EA. Compatibility digest. Am J Hosp Pharm. 1970; 27:672–3. [PubMed 5451542]

  • 8.

    Trissel LA. Trissel’s stability of compounded formulations. 4th ed. Washington, DC: American Pharmacists Association; 2009.

  • 9.

    Patel JA, Phillips GL. Guide to physical compatibility of intravenous drug admixtures. Am J Hosp Pharm. 1966; 23:409–11.

  • 10.

    Bogash RC. Compatibilities and incompatibilities of some parenteral medication. Bull Am Soc Hosp Pharm. 1955; 12:445–8.

  • 11.

    Dunworth RD, Kenna FR. Preliminary report: incompatibility of combinations of medications in intravenous solutions. Am J Hosp Pharm. 1965; 22:190–1.

  • 12.

    Moorhatch P, Chiou WL. Interactions between drugs and plastic intravenous fluid bags, part i: sorption studies on 17 drugs. Am J Hosp Pharm. 1974; 31:72–8. [PubMed 4810168]

  • 13.

    Levin HJ, Fieber RA. Stability data for Tubex filled by hospital pharmacists. Hosp Pharm. 1973; 8:310–1.

  • 14.

    Powers S. Incompatibilities of pre-op medications. Hosp Formul Manage. 1970; 5:22.

  • 15.

    Intravenous additive incompatibilities. Bethesda, MD: Pharmacy Department, National Institutes of Health; 1970 Jan.

  • 16.

    Cantania PN, King JC. Physico-chemical incompatibilities of selected cardiovascular and psychotherapeutic agents with sodium ethacrynate. Am J Hosp Pharm. 1972; 29:141–6. [PubMed 5020599]

  • 17.

    USP-NF Online: 2020 U.S. Pharmacopeia National Formulary USP 42 NF 37. Rockville, MD: The United States Pharmacopeial Convention; 2020. www.uspnf.com. Updated 2019 Jun 3. Accessed 2020 Jun 5.

  • 18.

    Kramer W, Inglott A. Some physical and chemical incompatibilities of drugs for i.v. administration. Drug Intell Clin Pharm. 1971; 5:211–28.

  • 19.

    McEvoy GK, ed. American hospital formulary service drug information. Bethesda, MD: American Society of Health-System Pharmacists; prior editions.

  • 20.

    Parker EA. Compatibility digest. Am J Hosp Pharm. 1969; 26:412–3.

  • 21.

    Parker EA. Compatibility digest. Am J Hosp Pharm. 1969; 26:653–5.

  • 22.

    Parker EA. Compatibility digest. Am J Hosp Pharm. 1970; 27:327–9. [PubMed 5446269]

  • 23.

    Parker EA. Compatibility digest. Am J Hosp Pharm. 1974; 31:1076. [PubMed 4432859]

  • 24.

    Parker EA. Compatibility digest. Am J Hosp Pharm. 1971; 28:805.

  • 25.

    Souney PF, Solomon MA. Visual compatibility of cimetidine hydrochloride with common preoperative injectable medications. Am J Hosp Pharm. 1984; 41:1840–1. [PubMed 6496520]

  • 26.

    Riley BB. Incompatibilities in intravenous solutions. J Hosp Pharm. 1970; 28:228–40.

  • 27.

    Parker EA, Levin HJ. Compatibility digest. Am J Hosp Pharm. 1975; 32:943–4. [PubMed 242217]

  • 28.

    Misgen R. Compatibilities and incompatibilities of some intravenous solution admixtures. Am J Hosp Pharm. 1965; 22:92–4.

  • 32.

    Frank JT. Intralipid compatibility study. Drug Intell Clin Pharm. 1973; 7:351–2.

  • 33.

    Yeo MT, Gazzaniga AB, Bartlett RH et al. Total intravenous nutrition experience with fat emulsions and hypertonic glucose. Arch Surg. 1973; 106:792–6. [PubMed 4196215]

  • 34.

    Melly MA, Meng HC. Microbial growth in lipid emulsions used in parenteral nutrition. Arch Surg. 1975; 110:1479–81. [PubMed 982]

  • 35.

    Deitel M, Kaminsky V. Total nutrition by peripheral vein—the lipid system. Can Med Assoc J. 1974; 111:152–4. [PubMed 4210395][Free Fulltext PMC]

  • 36.

    Cashore WJ, Sedaghatian MR. Nutritional supplements with intravenously administered lipid, protein hydrolysate, and glucose in small premature infants. Pediatrics. 1975; 56:8–16. [PubMed 808789]

  • 37.

    Lynn B. Intralipid compatibility study. Drug Intell Clin Pharm. 1974; 8:75.

  • 38.

    Electronic Medicines Compendium. London, England: Datapharm Communications Ltd.

  • 39.

    Fortner CL, Grove WR, Bowie D et al. Fat emulsion vehicle for intravenous administration of an aqueous insoluble drug. Am J Hosp Pharm. 1975; 32:582–4. [PubMed 1155469]

  • 40.

    Riffkin C. Incompatibilities of manufactured parenteral products. Am J Hosp Pharm. 1963; 20:19–22.

  • 41.

    Edward M. pH—an important factor in the compatibility of additives in intravenous therapy. Am J Hosp Pharm. 1967; 24:440–9. [PubMed 6075729]

  • 42.

    Turner FE, King JC. Spectrophotometric analysis of intravenous admixtures containing metaraminol and corticosteroids. Am J Hosp Pharm. 1970; 27:540–7. [PubMed 5431052]

  • 43.

    Anderson RW, Latiolais CJ. Physico-chemical incompatibilities of parenteral admixtures—Aramine and Solu-Cortef. Am J Hosp Pharm. 1973; 30:128–33. [PubMed 4690467]

  • 44.

    Smith MC. The dextrans. Am J Hosp Pharm. 1965; 22:273–5.

  • 45.

    Stokes TF, Sumner ED. Particulate contamination and stability of three additives in 0.9% sodium chloride injection in plastic and glass large-volume containers. Am J Hosp Pharm. 1975; 32:821–6. [PubMed 1146840]

  • 46.

    Parker EA. Solution additive chemical incompatibility study. Am J Hosp Pharm. 1967; 24:434–9. [PubMed 6075728]

  • 47.

    Parker EA. Compatibility digest. Am J Hosp Pharm. 1969; 26:543–4. [PubMed 5823457]

  • 48.

    Parker EA. Parenteral incompatibilities. Hosp Pharm. 1969; 4:14–22.

  • 49.

    Beatrice MG, Stanaszek WF, Allen LV et al. Physicochemical stability of a preanesthetic mixture of hydroxyzine hydrochloride and atropine sulfate. Am J Hosp Pharm. 1975; 32:1133–7. [PubMed 242215]

  • 50.

    Leff RD, Roberts RJ. Effect of intravenous fluid and drug solution coadministration on final-infusate osmolality, specific gravity, and pH. Am J Hosp Pharm. 1982; 39:468–71. [PubMed 7072733]

  • 51.

    Crevar GE, Slotnick IJ. A note on the stability of actinomycin D. J Pharm Pharmacol. 1964; 16:429. [PubMed 14200405]

  • 52.

    Coles CLJ, Lees KA. Additives to intravenous fluids. Pharm J. 1971; 206:153–4.

  • 53.

    Rudd L. Pethidine stability in intravenous solutions. Med J Aust. 1978; 2:34. [PubMed 683109]

  • 54.

    Webb JW. A pH pattern for i.v. additives. Am J Hosp Pharm. 1969; 26:31–5. [PubMed 5763886]

  • 55.

    Jones RW, Stanko GL. Pharmaceutical compatibilities of Pentothal and Nembutal. Am J Hosp Pharm. 1961; 18:700–4.

  • 56.

    Turco SJ, Sherman NE, Zagar L et al. Stability of aminophylline in 5% dextrose in water. Hosp Pharm. 1975; 10:374–5.

  • 57.

    Hodby ED, Hirsch J. Influence of drugs upon the anticoagulant activity of heparin. Can Med Assoc J. 1972; 106:562–4. [PubMed 5027639][Free Fulltext PMC]

  • 58.

    Pamperl H, Kleinberger G. Morphologic changes of Intralipid 20% liposomes in all-in-one solutions during prolonged storage. Infusiontherapie. 1982; 9:86–91.

  • 59.

    Parker EA. Compatibility digest. Am J Hosp Pharm. 1974; 31:775.

  • 60.

    Wolfert RR, Cox RM. Room temperature stability of drug products labeled for refrigerated storage. Am J Hosp Pharm. 1975; 32:585–7. [PubMed 1155470]

  • 61.

    Anon. Intravenous fat. Lancet. 1976; 1:1059–60. [PubMed 57458]

  • 62.

    Sachtler G. Dilantin for i.v. use. Drug Intell Clin Pharm. 1973; 7:418.

  • 63.

    Burke WA. I.V. drug incompatibilities—Dilantin. Am J IV Ther. 1975; 2:16–8.

  • 64.

    Baldwin J, Amerson AB. Intramuscular use of diphenylhydantoin. Am J Hosp Pharm. 1973; 30:837–8. [PubMed 4733637]

  • 65.

    Tobias DC, Kellick KA. Dilantin for i.v. use. Drug Intell Clin Pharm. 1973; 7:418.

  • 66.

    Chan NL. Dilantin for i.v. use. Drug Intell Clin Pharm. 1973; 7:419.

  • 67.

    Ammar HO, Salama HA. Studies on the stability of injectable solutions of some phenothiazines, part i: effect of pH and buffer systems. Pharmazie. 1975; 30:368–9. [PubMed 240174]

  • 68.

    Pickering LK, Rutherford I. Effect of concentration and time upon inactivation of tobramycin, gentamicin, netilmicin, and amikacin by azlocillin, carbenicillin, mecillinam, mezlocillin, and piperacillin. J Pharmacol Exp Ther. 1981; 217:345–9. [PubMed 6453219]

  • 69.

    Ho NFH, Goeman JA. Prediction of pharmaceutical stability of parenteral solutions. Drug Intell Clin Pharm. 1970; 4:69–71.

  • 72.

    Trissel LA, Davignon JP, Kleinman LM, et al. NCI investigational drugs pharmaceutical data. Bethesda, MD: National Cancer Institute; 1988.

  • 73.

    Muhlhauser I, Broermann C, Tsotsalas M et al. Miscibility of human and bovine ultralente insulin with soluble insulin. BMJ. 1984; 289:1656–7. [PubMed 6439364][Free Fulltext PMC]

  • 74.

    Grant HR. Compatibilities of intravenous admixtures. Hosp Pharmacist. 94 (Mar-Apr) 1962; 15:67–70.

  • 75.

    Hanson DB, Hendeles L. Guide to total dose intravenous iron dextran therapy. Am J Hosp Pharm. 1974; 31:592–5. [PubMed 4407476]

  • 76.

    Duke AB, Kelleher J. Serum iron and iron binding capacity after total dose infusion of iron-dextran for iron deficiency anaemia in pregnancy. J Obstet Gynaecol Br Commonw. 1974; 81(11):895–900. [PubMed 4436730]

  • 77.

    Parker EA. Compatibility digest. Am J Hosp Pharm. 1975; 32:214. [PubMed 237417]

  • 78.

    Gardella LA, Kesler H, Carter JE et al. Intropin (dopamine hydrochloride) intravenous admixture compatibility, part ii: stability with some commonly used antibiotics in 5% dextrose injection. Am J Hosp Pharm. 1976; 33:537–40. [PubMed 1274971]

  • 79.

    Gardella LA, Zaroslinski JF. Intropin (dopamine hydrochloride) intravenous admixture compatibility, part i: stability with common intravenous fluids. Am J Hosp Pharm. 1975; 32:575–8. [PubMed 239594]

  • 80.

    Garnett W. Diluents for antineoplastic drugs. Drug Intell Clin Pharm. 1971; 5:261.

  • 81.

    Landersjo L, Stjernstrom G. Studies on the stability and compatibility of drugs in infusion fluids V. Effect of lactate and metal ions on the stability of benzylpenicillin. Acta Pharm Suec. 1978; 15:161–8. [PubMed 31058]

  • 82.

    Notari RE, Chin ML. Arabinosylcytosine stability in aqueous solutions: pH profile and shelf life predictions. J Pharm Sci. 1972; 61:1189–96. [PubMed 5050364]

  • 83.

    Murty BSR, Kapoor JN. Properties of mannitol injection (25%) after repeated autoclavings. Am J Hosp Pharm. 1975; 32:826–7. [PubMed 238390]

  • 84.

    Rosch JM, Pazin GJ, Fireman P. Reduction of amphotericin B nephrotoxicity with mannitol. JAMA. 1976; 235:1995–6. [PubMed 946511]

  • 85.

    Bergman N, Vellar ID. Potential life-threatening variations of drug concentrations in intravenous infusion systems—potassium chloride, insulin, and heparin. Med J Aust. 1982; 2:270–2. [PubMed 6755202]

  • 86.

    Parker EA. Compatibility digest. Am J Hosp Pharm. 1970; 27:492–3.

  • 87.

    Feigen RD, Moss KS. Antibiotic stability in solutions used for intravenous nutrition and fluid therapy. Pediatrics. 1973; 51:1016–26. [PubMed 4196987]

  • 88.

    Zost ED, Yanchick VA. Compatibility and stability of disodium carbenicillin in combination with other drugs and large volume parenteral solutions. Am J Hosp Pharm. 1972; 29:135–40. [PubMed 4623176]

  • 89.

    Lynn B. Recent work on parenteral penicillins. J Hosp Pharm. 1971; 29:183–194.

  • 90.

    Tourville J. Sodium nitroprusside. Drug Intell Clin Pharm. 1975; 9:361–4.

  • 91.

    Anon. Editorial: Sodium nitroprusside in anaesthesia. Br Med J. 1975; 2:524–5.

  • 92.

    Hargrave RE. Degradation of solutions of sodium nitroprusside. J Hosp Pharm. 1974; 32:188–9.

  • 93.

    Anon. Sodium nitroprusside for hypertensive crisis. Med Lett Drugs Ther. 1975; 17:82–3. [PubMed 1177815]

  • 94.

    Anderson RA, Rae W. Stability of sodium nitroprusside solutions. Aust J Pharm Sci NS1. 1972; (July):45–6.

  • 95.

    Schumacher GE. Sodium nitroprusside injection. Am J Hosp Pharm. 1966; 23:532.

  • 96.

    Cruz JE, Maness DD, Yakatan GJ. Kinetics and mechanism of hydrolysis of furosemide. Int J Pharm. 1979; 2:275–81.

  • 97.

    Thomas R. Meperidine HCl and heparin sodium precipitation. Hosp Pharm. 1979; 2:275–81.

  • 98.

    Fleischer NM. Promethazine hydrochloride-morphine sulfate incompatibility. Am J Hosp Pharm. 1973; 30:665. [PubMed 4722839]

  • 99.

    Lynn B. Pharmaceutical aspects of semi-synthetic penicillins. J Hosp Pharm. 1970; 28:71–86.

  • 100.

    Meisler JM, Skolaut MW. Extemporaneous sterile compounding in intravenous additives. Am J Hosp Pharm. 1966; 23:557–63. [PubMed 5953067]

  • 101.

    Guthaus MR (Medical Services, The Upjohn Company, Kalamazoo, MI): Personal communication; 1973 Aug 9.

  • 102.

    HamLin WE, Riebe KW, Scothorn WW, et al. Pharmacy profile of cleocin phosphate. Presented at 10th annual ASHP midyear clinical meeting. Washington, DC: 1975 Dec 11.

  • 103.

    Riebe KW, Oesterling TO. Parenteral development of clindamycin-2–phosphate. Bull Parenter Drug Assoc. 1972; 26:139–45. [PubMed 5035118]

  • 104.

    Therapeutic profile: cleocin phosphate. Kalamazoo, MI: The Upjohn Company; 1973.

  • 105.

    Wyatt RG, Okamato GA. Stability of antibiotics in parenteral solutions. Pediatrics. 1972; 49:22–9. [PubMed 5059308]

  • 106.

    Halasi S, Nairn JD. Stability studies of hydralazine hydrochloride in aqueous solutions. J Parenter Sci Technol. 1990; 44:30–4. [PubMed 2313490]

  • 107.

    Whiting DA. Treatment of chromoblastomycosis with local concentrations of amphotericin B. Br J Dermatol. 1967; 79:345–51. [PubMed 6027196]

  • 108.

    Kirschenbaum BE, Latiolais CJ. Injectable medications—a guide to stability and reconstitution. New York, NY: McMahon Group; 1993.

  • 109.

    Bair JN, Carew DP. Therapeutic availability of antibiotics in parenteral solutions. Bull Parenter Drug Assoc. 1965; 19:153–63. [PubMed 5837809]

  • 110.

    Dancey JW, Carew DP. Availability of antibiotics in combination with other additives in intravenous solutions. Am J Hosp Pharm. 1966; 23:543–51. [PubMed 5915776]

  • 111.

    Prasad VK, Granatek AP. Physical compatibility and chemical stability of cephapirin sodium in combination with antibiotics and large-volume parenteral solutions, part i. Curr Ther Res Clin Exp. 1974; 16:505–39. [PubMed 4365711]

  • 112.

    Lynn B. Carbenicillin plus gentamicin. Lancet. 1971; 1:654. [PubMed 4101265]

  • 113.

    Jacobs J, Kletter D, Superstine E et al. Intravenous infusions of heparin and penicillins. J Clin Pathol. 1973; 26:742–6. [PubMed 4750455][Free Fulltext PMC]

  • 114.

    Lynn B. Penicillin instability in infusions. Br Med J. 1971; 1:174. [PubMed 5539433][Free Fulltext PMC]

  • 115.

    Information for health professionals. Wellington, New Zealand: New Zealand Medicines and Medical Devices Safety Authority.

  • 117.

    McEvoy GK, ed. American hospital formulary service drug information 95. Bethesda, MD: American Society of Health-System Pharmacists; 1995.

  • 118.

    Harrison DC. Practical guidelines for the use of lidocaine. Prevention and treatment of cardiac arrhythmias. JAMA. 1975; 233:1202–4. [PubMed 1174178]

  • 119.

    Collinsworth K. Clinical pharmacology of lidocaine as an antiarrhythmic drug. West J Med. 1976; 124:36–43. [PubMed 1251605][Free Fulltext PMC]

  • 120.

    Anon. Prophylactic use of lidocaine in myocardial infarction. Med Lett Drugs Ther. 1976; 18:1–2. [PubMed 1105126]

  • 121.

    Dundee JW, Gamble JA, Assaf RA. Plasma diazepam levels following intramuscular injection by nurses and doctors. Lancet. 1974; 2:1461.

  • 123.

    Tortorici MP. Stability data on frozen i.m. and i.v. solutions. Pharm Times. 1975; 41:68–72.

  • 124.

    Barbara AC, Clemente C. Physical incompatibility of sulfonamide compounds and polyionic solutions. N Engl J Med. 1966; 274:1316–7. [PubMed 5936416]

  • 125.

    Brooke D, Bequette RJ. Chemical stability of cyclophosphamide in parenteral solutions. Am J Hosp Pharm. 1973; 30:134–7. [PubMed 4690468]

  • 126.

    Brooke D, Scott JA. Effect of briefly heating cyclophosphamide solutions. Am J Hosp Pharm. 1975; 32:44–5. [PubMed 235840]

  • 127.

    Gallelli JF. Stability studies of drugs used in intravenous solutions, part i. Am J Hosp Pharm. 1967; 24:425–33. [PubMed 6075727]

  • 128.

    Dupont Pharmaceuticals. Nubain, physical compatibility. Wilmington, DE; undated.

  • 129.

    Kramer W, Tanja JJ. Precipitates found in admixtures of potassium chloride and dextrose 5% in water. Am J Hosp Pharm. 1970; 27:548–53. [PubMed 5431053]

  • 130.

    Lawson DH. Clinical use of potassium supplements. Am J Hosp Pharm. 1975; 32:708–11. [PubMed 1146831]

  • 131.

    Lundgren P, Landersjo L. Studies on the stability and compatibility of drugs in infusion fluids, ii: factors affecting the stability of benzylpenicillin. Acta Pharm Suec. 1970; 7:509–26. [PubMed 5275184]

  • 132.

    Weber CR, Gupta VD. Stability of phenylephrine hydrochloride in intravenous solutions. J Hosp Pharm. 1970; 28:200–8.

  • 133.

    Chiou WL, Moorhatch P. Interaction between vitamin A and plastic intravenous fluid bags. J Am Med Assoc. 1973; 223:328.

  • 134.

    Komesaroff D, Field JE. Pancuronium bromide: a new non-depolarizing muscle relaxant. Med J Aust. 1969; 1:908–11. [PubMed 4182379]

  • 135.

    Simberkoff MS, Thomas L, McGregor D et al. Inactivation of penicillins by carbohydrate solutions at alkaline pH. N Engl J Med. 1970; 283:116–9. [PubMed 5423147]

  • 136.

    Hicks CI, Gallardo JPB. Stability of sodium bicarbonate injection stored in polypropylene syringes. Am J Hosp Pharm. 1972; 29:210–6. [PubMed 5028472]

  • 137.

    DeLuca PP, Kowalski RJ. Problems arising from the transfer of sodium bicarbonate injection from ampuls to plastic disposable syringes. Am J Hosp Pharm. 1972; 29:217–22. [PubMed 5028473]

  • 138.

    D’Arcy PF, Thompson KM. Stability of chlorpromazine hydrochloride added to intravenous infusion fluids. Pharm J. 1973; 210:28.

  • 139.

    Nahata MC, Zingarelli JR, Hipple TF. Stability of caffeine injection stored in plastic and glass syringes. DICP. 1989; 23:1035. [PubMed 2603448]

  • 140.

    Murabito AS (Smith Kline & French Laboratories, Philadelphia, PA): Personal communication; 1986 Dec 15.

  • 141.

    Mann JM, Coleman DL. Stability of parenteral solutions of sodium cephalothin, cephaloridine, potassium penicillin G (buffered), and vancomycin HCl. Am J Hosp Pharm. 1971; 28:760–3. [PubMed 5125170]

  • 142.

    Appleby DH, John JF. Effect of peritoneal dialysis solution on the antimicrobial activity of cephalosporins. Nephron. 1982; 30:341–4. [PubMed 7110465]

  • 143.

    Upshaw MD (Medical Information Services, Eli Lilly and Company, Indianapolis, IN): Personal communication; 1972 Jan 10.

  • 144.

    Gallelli JF, MacLowry JD. Stability of antibiotics in parenteral solutions. Am J Hosp Pharm. 1969; 26:630–5. [PubMed 5352570]

  • 145.

    Dienstag JL, Neu HC. Tobramycin: new aminoglycoside antibiotic. Clin Med. 1975; 82:13–9.

  • 146.

    Struhar M, Heinrich J. K sorpcii pentoxifyllinu na infuznu supravu Luer. Farm Obz. 1988; 57:405–10.

  • 147.

    Bergstrom RF, Fites AL. Stability of parenteral solutions of tobramycin sulfate. Am J Hosp Pharm. 1975; 32:887–8. [PubMed 242216]

  • 148.

    Huber RC, Riffkin C. Inline final filters for removing particles from amphotericin B infusions. Am J Hosp Pharm. 1975; 32:173–6. [PubMed 237416]

  • 149.

    Rebagay T, Rapp R, Bivins B et al. Residues in antibiotic preparations, i: scanning electron microscopic studies of surface topography. Am J Hosp Pharm. 1976; 33:433–43. [PubMed 5888]

  • 150.

    Gallelli JF. Assay and stability of amphotericin B in aqueous solutions. Drug Intell. 1967; 1:102–5.

  • 151.

    Piecoro JJ, Goodman NL, Wheeler WE et al. Particulate matter in reconstituted amphotericin B and assay of filtered solutions of amphotericin B. Am J Hosp Pharm. 1975; 32:381–4. [PubMed 1093398]

  • 152.

    Gotz V, Simon W. Inline filtration of amphotericin B infusions. Am J Hosp Pharm. 1975; 32:458. [PubMed 1146813]

  • 153.

    Chatterji D, Hiranaka PK. Stability of sodium oxacillin in intravenous solutions. Am J Hosp Pharm. 1975; 32:1130–2. [PubMed 1190234]

  • 154.

    Facts and Comparisons, Inc. Drug facts and comparisons. St. Louis, MO; 2003.

  • 155.

    Parodi JF. Stability of frozen antibiotic solutions in Viaflex infusion containers. Hosp Pharm. 1976; 11:178–9.

  • 156.

    Larsen SS. Studies on stability of drugs in frozen systems. IV. The stability of benzylpenicillin sodium in frozen aqueous solutions. Dan Tidsskr Farm. 1971; 45:307–16. [PubMed 5156696]

  • 157.

    Noone P, Pattison JR. Therapeutic implications of interaction of gentamicin and penicillins. Lancet. 1971; 2:575–8. [PubMed 4106106]

  • 158.

    Boulet M, Marier JR. Effect of magnesium on formation of calcium phosphate precipitates. Arch Biochem Biophys. 1962; 96:629–36. [PubMed 13871819]

  • 159.

    van den Berg L, Soliman FS. Composition and pH changes during freezing of solutions containing calcium and magnesium phosphate. Cryobiology. 1969; 6:10–4. [PubMed 5810544]

  • 160.

    Ong JTH, Kostenbauder HB. Effect of self-association on rate of penicillin G degradation in concentrated aqueous solutions. J Pharm Sci. 1975; 64:1378–80. [PubMed 239209]

  • 161.

    Shoup LK, Thur MP. Stability of frozen buffered penicillin G potassium injection. Hosp Formul Manage. 1968; 3:38–9.

  • 162.

    Boylan JC, Simmons JL. Stability of frozen solutions of sodium cephalothin and cephaloridine. Am J Hosp Pharm. 1972; 29:687–9. [PubMed 4559536]

  • 163.

    Grant NH, Clark DE. Imidazole- and base-catalyzed hydrolysis of penicillin in frozen systems. J Am Chem Soc. 1961; 83:4476–7.

  • 164.

    Lindsay RE, Hem SL. Dosage form for potassium penicillin G intravenous infusion solutions. Drug Devel Commun. 1974–5; 1:211–222.

  • 165.

    Im S, Latiolais CJ. Physico-chemical incompatibilities of parenteral admixtures—penicillin and tetracyclines. Am J Hosp Pharm. 1966; 23:333–43.

  • 166.

    Pfeifer HJ, Webb JW. Compatibility of penicillin and ascorbic acid injection. Am J Hosp Pharm. 1976; 33:448–50. [PubMed 5890]

  • 167.

    Rusmin S, DeLuca PP. Effect of inline filtration on the potency of potassium penicillin G. Bull Parenter Drug Assoc. 1976; 30:64–71. [PubMed 949563]

  • 168.

    Stolar MH, Carlin HS. Effect of freezing on the stability of sodium methicillin injection. Am J Hosp Pharm. 1968; 25:32–5. [PubMed 5640122]

  • 169.

    Lynn B. Stability of methicillin in dextrose solutions at alkaline pH. J Hosp Pharm. 1972; 30:81–3.

  • 170.

    Lynn B. Pharmaceutics of the semi-synthetic penicillins. Chem Drug. 1967; 187:134–6.

  • 171.

    Lynn B. Inactivation of methicillin in dextrose solutions at alkaline pH. N Engl J Med. 1971; 285:690. [PubMed 5563485]

  • 172.

    Mattson CJ, Clark ST, Colangelo A. Stability of clindamycin phosphate in plastic syringes. Presented at 20th annual ASHP midyear clinical meeting. New Orleans, LA: 1985 Dec.

  • 173.

    Clark ST, Colangelo A. Stability of clindamycin phosphate in plastic syringes. Presented at 20th annual ASHP midyear clinical meeting. New Orleans, LA: 1985 Dec.

  • 174.

    Cohon MS (Drug Information Services, Upjohn Company, Kalamazoo, MI): Personal communications; 1986 Dec 12, 1988 Jan 27, 1988 Feb 3.

  • 176.

    Owen RT (UK Medical Information Section, The Wellcome Foundation Ltd., Cheshire, England): Personal communication; 1993 Aug 19.

  • 177.

    Lesson LJ, Weidenheimer JF. Stability of tetracycline and riboflavin. J Pharm Sci. 1969; 58:355–7. [PubMed 5782032]

  • 178.

    Turco SJ, Burke WA. Methods of ordering and use of intravenous phosphate (mEq vs mM). Hosp Pharm. 322, 326 (Aug) 1975; 10:320.

  • 179.

    Pinkus TF, Jeffrey LP. Incompatibility of calcium and phosphate in parenteral alimentation solutions. Am J IV Ther. 1976; 3:22–4.

  • 180.

    Kaminski MV, Harris DF, Collin CF et al. Electrolyte compatibility in synthetic amino acid hyperalimentation solution. Am J Hosp Pharm. 1974; 31:244–6. [PubMed 4206614]

  • 181.

    Schlicht JR. Adjustments in etoposide infusion flow rates when using controllers. Am J Hosp Pharm. 1990; 47:2656. [PubMed 2278277]

  • 182.

    FASS, Karolinska Institutet, Huddinge, Sweden. Available at edu.ofa.ki.effica/

  • 183.

    Lee FA, Gwinn JL. Roentgen patterns of extravasation of calcium gluconate in the tissues of the neonate. J Pediatr. 1975; 86:598–601. [PubMed 1127506]

  • 184.

    Weiss Y, Ackerman C. Localized necrosis of scalp in neonates due to calcium gluconate infusions: a cautionary note. Pediatrics. 1975; 56:1084–6. [PubMed 1196761]

  • 185.

    Ramamurthy RS, Harris V. Subcutaneous calcium deposition in the neonate associated with intravenous administration of calcium gluconate. Pediatrics. 1975; 55:802–6. [PubMed 1134881]

  • 186.

    Laegeler WL, Tio JM. Stability of certain amino acids in a parenteral nutrition solution. Am J Hosp Pharm. 1974; 31:776–9. [PubMed 4212349]

  • 187.

    Kleinman LM, Tangrea JA, Gallelli JF et al. Stability of solutions of essential amino acids. Am J Hosp Pharm. 1973; 30:1054–7. [PubMed 4751187]

  • 188.

    Rowlands DA. Compatibility of calcium and phosphate in amino acids solution. Am J Hosp Pharm. 1975; 32:360. [PubMed 1130408]

  • 189.

    Saudek EC (The Upjohn Company): Personal communication; 1973 Jan 3.

  • 190.

    Rowlands DA, Wilkinson WR. Storage stability of mixed hyperalimentation solutions. Am J Hosp Pharm. 1973; 30:436–8. [PubMed 4574336]

  • 191.

    Aro R (Senior Clinical Research Associate, Fujisawa USA): Personal communication, February 22, 1994.

  • 192.

    Rodriguez Penin I, Yanez Gonzalez A, Camba Rodriguez A et al. Estabilidad de la mezcla morfina-midazolam en un dispositivo de infusion continua. Farm Hosp. 1991; 15:407–9.

  • 193.

    Nahata MC, Zingarelli JR, Durrell DE. Stability of caffeine injection in intravenous admixtures and parenteral nutrition solutions. DICP. 1989; 23:466–7. [PubMed 2500782]

  • 194.

    Hull RL. Use of trace elements in intravenous hyperalimentation solutions. Am J Hosp Pharm. 1974; 31:759–61. [PubMed 4212506]

  • 195.

    Johnson C, Cloyd J. Parenteral hyperalimentation. Drug Intell Clin Pharm. 1975; 9:493–9.

  • 196.

    Hankins DA, Riella MC, Scribner BH et al. Whole blood trace element concentrations during total parenteral nutrition. Surgery. 1976; 79:674–7. [PubMed 818725]

  • 197.

    Hamann MA. Trace element requirements in hyperalimentation. Am J Hosp Pharm. 1974; 31:1035. [PubMed 4215316]

  • 198.

    Hull RL. Trace element requirements in hyperalimentation. Am J Hosp Pharm. 1974; 31:1038.

  • 199.

    Heird WC, Winters RW. Total intravenous alimentation in pediatric patients. South Med J. 1975; 68:1173–6. [PubMed 808861]

  • 200.

    Baker JA, Kirkman H, Woodley C et al. Computer-assisted pediatric hyperalimentation. Am J Hosp Pharm. 1974; 31:752–8. [PubMed 4211882]

  • 201.

    Parish R. Hyperalimentation procedures. Am J Hosp Pharm. 1974; 31:1160. [PubMed 4218449]

  • 202.

    Pomerance HH, Rader RE. Crystal formation: a new complication of total parenteral nutrition. Pediatrics. 1973; 52:864–6. [PubMed 4203556]

  • 203.

    Bohart RD, Ogawa G. An observation on the stability of cis-dichlorodiammineplatinum (II): a caution regarding its administration. Cancer Treat Rep. 1979; 63:2117–8. [PubMed 575070]

  • 204.

    Prestayko AW, Cadiz M. Incompatibility of aluminum-containing iv administration equipment with cis-dichlorodiammineplatinum (II) administration. Cancer Treat Rep. 1979; 63:2118–9. [PubMed 575071]

  • 205.

    Shils ME. Minerals in total parenteral nutrition. Drug Intell Clin Pharm. 1972; 6:385–93.

  • 206.

    Flack HL, Gans JA, Serlick SE et al. The current status of parenteral hyperalimentation. Am J Hosp Pharm. 1971; 28:326–35. [PubMed 4999686]

  • 207.

    McRae MP, King JC. Compatibility of antineoplastic, antibiotic, and corticosteroid drugs in intravenous admixtures. Am J Hosp Pharm. 1976; 33:1010–3. [PubMed 973628]

  • 208.

    Warren E, Synder RJ, Thompson CO et al. Stability of ampicillin in intravenous solutions. Mayo Clin Proc. 1972; 47:34–5. [PubMed 5008254]

  • 209.

    Raffanti EF, King JC. Effect of pH on the stability of sodium ampicillin solutions. Am J Hosp Pharm. 1974; 31:745–51. [PubMed 4851691]

  • 210.

    Savello DR, Shangraw RF. Stability of sodium ampicillin solutions in the frozen and liquid states. Am J Hosp Pharm. 1971; 28:754–9. [PubMed 5125169]

  • 211.

    Jacobs J, Nathan I, Superstine E et al. Ampicillin and carbenicillin stability in commonly used infusion solutions. Drug Intell Clin Pharm. 1970; 4:204–8.

  • 212.

    Hiranaka P, Frazier AG. Stability of sodium ampicillin in aqueous solutions. Am J Hosp Pharm. 1972; 29:321–2. [PubMed 5025262]

  • 213.

    Stratton M, Sandmann BJ. Stability studies of ampicillin sodium in intravenous fluids using optical activity. Bull Parenter Drug Assoc. 1975; 29:286–95. [PubMed 1131]

  • 214.

    Pincock RE, Kiovsky TE. Kinetics of reactions in frozen solutions. J Chem Educ. 1966; 43:358–60.

  • 215.

    Hou JP, Poole JW. Kinetics and mechanism of degradation of ampicillin in solution. J Pharm Sci. 1969; 58:447–54. [PubMed 5787442]

  • 216.

    Shils ME, Wright WL, Turnbull A et al. Long-term parenteral nutrition through an external arteriovenous shunt. N Engl J Med. 1970; 283:341–4. [PubMed 4987877]

  • 217.

    Zia H, Tehrani M. Kinetics of carbenicillin degradation in aqueous solutions. Can J Pharm Sci. 1974; 9:112–7.

  • 218.

    Riff LJ, Jackson GG. Laboratory and clinical conditions for gentamicin inactivation by carbenicillin. Arch Intern Med. 1972; 130:887–91. [PubMed 5082469]

  • 219.

    McLaughlin JE, Reeves DS. Clinical and laboratory evidence for inactivation of gentamicin by carbenicillin. Lancet. 1971; 1:261–4. [PubMed 4100015]

  • 220.

    Klastersky J. Carbenicillin plus gentamicin. Lancet. 1971; 1:653–4. [PubMed 4101264]

  • 221.

    Levison ME, Kaye D. Carbenicillin plus gentamicin. Lancet. 1971; 2:45–6. [PubMed 4103685]

  • 222.

    Eykyn S, Phillips I. Gentamicin plus carbenicillin. Lancet. 1971; 1:545–6. [PubMed 4100453]

  • 223.

    Riff L, Jackson GG. Gentamicin plus carbenicillin. Lancet. 1971; 1:592. [PubMed 4100919]

  • 224.

    Zost ED, Yanchick VA. Stability of gentamicin in combination with carbenicillin. Am J Hosp Pharm. 1972; 29:388–90. [PubMed 5035580]

  • 225.

    Jacoby GA. Carbenicillin and gentamicin. N Engl J Med. 1971; 284:1096–8. [PubMed 5205659]

  • 226.

    Kleinberg ML (Professional Services, Immunex, Seattle, WA): Personal communication; 1993 Jun 14.

  • 227.

    Baldini JT (Professional Services, Schering Laboratories, Kenilworth, NJ): Personal communication; 1972 Feb 11.

  • 228.

    Koup JR, Gerbracht L. Combined use of heparin and gentamicin in peritoneal dialysis solutions. Drug Intell Clin Pharm. 1975; 9:388.

  • 229.

    Reeves DS, Bywater MJ, Wise R et al. Availability of three antibiotics after intramuscular injection into thigh and buttock. Lancet. 1974; 2:1421–2. [PubMed 4140333]

  • 230.

    Jackson GG. Gentamicin. Practitioner. 1967; 198:855–66. [PubMed 4859870]

  • 231.

    Preskey D, Kayes JB. Stability of sulfadiazine sodium as used in admixture with intravenous infusion fluids. J Clin Pharm. 1976; 1:39–48.

  • 232.

    Physicians’ desk reference. 49th ed. Oradell, NJ: Medical Economics Company; 1995.

  • 233.

    Larsen SS, Jensen VG. Studies on stability of drugs in frozen systems. II. The stabilities of hexobarbital sodium and phenobarbital sodium in frozen aqueous solutions. Dan Tidsskr Farm. 1970; 44:21–31. [PubMed 5440939]

  • 234.

    NCI investigational drugs pharmaceutical data. Bethesda, MD: National Cancer Institute; 1988, 1990, 1994.

  • 235.

    Halpern NA, Colucci RD, Alicea M et al. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Clin Pharmacol Ther Toxicol. 1989; 27:250–4. [PubMed 2737791]

  • 236.

    Anon. Kidney toxicity—main source of methotrexate complications. J Am Med Assoc. 1975; 223:1036–7.

  • 237.

    Baker MBC Hospital Products Division, Abbott Laboratories, Abbott Park, Illinois: Personal Communication; 2003 Aug 27.

  • 238.

    Hoeprich PD, Huston AC. Stability of four antifungal antimicrobics in vitro. J Infect Dis. 1978; 137:87–93. [PubMed 624855]

  • 239.

    Selam JL, Lord P, van Antwerp WP et al. Heparin addition to insulin in implantable pumps to prevent catheter obstruction. Diabetes Care. 1989; 12:38–9. [PubMed 2714165]

  • 240.

    Wang DP. Stability of procaine in aqueous systems. Analyst. 1983; 108:851–6.

  • 241.

    Lapidas B. Cautions regarding the preparation of high-dose methotrexate infusions. Am J Hosp Pharm. 1976; 33:760.

  • 242.

    Pelsor FR. Cautions regarding the preparation of high-dose methotrexate infusions. Am J Hosp Pharm. 1976; 33:760.

  • 243.

    Pritchard J. Stability of heparin solutions. J Pharm Pharmacol. 1964; 16:487–9. [PubMed 14207092]

  • 244.

    Turco SJ. I.V. drug incompatibilities—heparin sodium USP. Am J IV Ther. 1976; 3:16–9.

  • 245.

    Kakkar VV, Corrigan TP. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: an international multicentre trial. Lancet. 1975; 2:45–51. [PubMed 49649]

  • 246.

    Sherry S. Low-dose heparin prophylaxis for postoperative venous thromboembolism. N Engl J Med. 1975; 293:300–2. [PubMed 1138184]

  • 247.

    Gallus AS, Hirsch J, O’Brien SE et al. Prevention of venous thrombosis with small, subcutaneous doses of heparin. JAMA. 1976; 235:1980–2. [PubMed 946507]

  • 248.

    Hopefl AW. Low-dose heparin for the prevention of venous thromboembolism. Hosp Pharm. 1976; 11:223.

  • 249.

    Wessler S. Heparin as an antithrombotic agent. Low-dose prophylaxis. JAMA. 1976; 236:389–91. [PubMed 947059]

  • 250.

    Erdi A, Kakkar VV, Thomas DP et al. Effect of low-dose subcutaneous heparin on whole-blood viscosity. Lancet. 1976; 2:342–4. [PubMed 60572]

  • 251.

    Hadgraft JW. Adding drugs to intravenous infusions. Lancet. 1970; 2:1254. [PubMed 4098681]

  • 252.

    Stock SL, Warner N. Heparin in acid solutions. Br Med J. 1971; 3:307. [PubMed 5557553][Free Fulltext PMC]

  • 253.

    Chessells JM, Braithwaite TA. Dextrose and sorbitol as diluents for continuous intravenous heparin infusion. Br Med J. 1972; 2:81–2. [PubMed 5018311][Free Fulltext PMC]

  • 254.

    Mitchell JF, Barger RC. Heparin stability in 5% dextrose and 0.9% sodium chloride. Am J Hosp Pharm. 1976; 33:540–2.

  • 255.

    Thomas RB, Salter FJ. Heparin locks: their advantages and disadvantages. Hosp Formul. 1975; 10:536–8. [PubMed 10237817]

  • 256.

    Deeb EN, DiMattia PE. The key question: how much heparin in the lock?. Am J IV Ther. 1976; 3:22–6.

  • 257.

    DeFina E. How we use heparin locks. Am J IV Ther. 33 (Dec-Jan) 1976; 3:27.

  • 258.

    Hanson RL, Grant AM. Heparin-lock maintenance with ten units of sodium heparin in one milliliter of normal saline solution. Surg Gynecol Obstet. 1976; 142:373–6. [PubMed 1251318]

  • 259.

    Rebagay T, DeLuca PP. Residues in antibiotic preparations, ii: effect of pH on the nature and level of particulate matter in sodium cephalothin intravenous solutions. Am J Hosp Pharm. 1976; 33:443–8. [PubMed 5889]

  • 260.

    Albano D (Manager Drug Information, Wyeth-Ayerst). Personal Communication; 1994 Jan 5.

  • 261.

    Hopefl AW. Room temperature stability of drug products. Am J Hosp Pharm. 1975; 32:1084. [PubMed 1190223]

  • 262.

    Barger RC. Room temperature stability of drug products. Am J Hosp Pharm. 1975; 32:1089. [PubMed 811118]

  • 263.

    Rosenbloom AL. Advances in commercial insulin preparations. Am J Dis Child. 1974; 128:631–3. [PubMed 4422292]

  • 264.

    Rosenberg JM, Simon WA, Sangkachand P et al. Mixing insulin preparations. Hosp Pharm. 1976; 11:186.

  • 265.

    Shainfeld FJ. Errors in insulin doses due to the design of insulin syringes. Pediatrics. 1975; 56:302–3. [PubMed 1161379]

  • 266.

    Weisenfeld S, Podolsky S, Goldsmith L et al. Adsorption of insulin to infusion bottles and tubing. Diabetes. 1968; 17:766–71. [PubMed 5726255]

  • 267.

    Petty C, Cunningham NL. Insulin adsorption by glass infusion bottles, polyvinylchloride infusion containers, and intravenous tubing. Anesthesiology. 1974; 40:400–4. [PubMed 4856440]

  • 268.

    Kraegen EW, Lazarus L, Meler H et al. Carrier solutions for low-level intravenous insulin infusion. Br Med J. 1975; 3:464–6. [PubMed 1156820][Free Fulltext PMC]

  • 269.

    Semple P, Ratcliffe JG. Carrier solutions for low-level intravenous insulin infusion. Br Med J. 1975; 4:228–9. [PubMed 1192006][Free Fulltext PMC]

  • 270.

    Hays DP, Mehl B. I.V. drug incompatibilities—insulin. Am J IV Ther. 1976; 3:30–2.

  • 271.

    Owen JA. The insulin revolution. Hosp Formul. 1976; 11:343.

  • 272.

    Galloway JA (Medical Research Division, Eli Lilly and Company, Indianapolis, IN): Personal communication; 1967 Aug 29.

  • 273.

    Rubin J, Humphries J, Smith G et al. Antibiotic activity in peritoneal dialysate. Am J Kidney Dis. 1983; 3:205–8. [PubMed 6356892]

  • 274.

    De Vroe C, De Muynck C, Remon JP et al. The availability of diltiazem: a study on the sorption by intravenous delivery systems and on the stability of the drug. J Pharm Pharmacol. 1989; 41:273–5. [PubMed 2568471]

  • 275.

    Kochevar M, Fry LK. Insulin and dead space volume. Drug Intell Clin Pharm. 1974; 8:33–4.

  • 276.

    Bornstein M, Thomas PN, Coleman DL et al. Stability of parenteral solutions of cefazolin sodium. Am J Hosp Pharm. 1974; 31:296–98. [PubMed 4206616]

  • 277.

    Carone SM, Bornstein M, Coleman DL et al. Stability of frozen solutions of cefazolin sodium. Am J Hosp Pharm. 1976; 33:639–41. [PubMed 7955]

  • 278.

    Royston DA (Consumer Technical Services, Eli Lilly and Company, Indianapolis, IN): Personal communication; 1976 Feb 19.

  • 279.

    Brudney N, Eustace BT. Some formulations and compatibility problems with dimenhydrinate (Gravol). Can Pharm J. 1963; 96:470–1.

  • 280.

    Acred P, Brown DM, Knudsen ET et al. New semi-synthetic penicillin active against pseudomonas pyocyanea. Nature (London). 1967; 215:25–30.

  • 281.

    Schwartz MA, Buckwalter FH. Pharmaceutics of penicillin. J Pharm Sci. 1962; 51:1119–28. [PubMed 13987384]

  • 282.

    Thur MP (Parenteral Products, Travenol Laboratories, Deerfield, IL): Personal communication; 1976 Sep 20.

  • 283.

    Ziemba LJ (Medical Information, ICI Pharmaceuticals Group, Wilmington, DE): Personal communication; 1990 Mar 15.

  • 284.

    Yamana T, Tsuji A. Comparative stability of cephalosporins in aqueous solution: kinetics and mechanisms of degradation. J Pharm Sci. 1976; 65:1563–74. [PubMed 11330]

  • 285.

    Kleinman LM, Davignon JP, Cradock JC et al. Investigational drug information. Drug Intell Clin Pharm. 1976; 10:48–9.

  • 286.

    Chang SY, Evans TL. The stability of melphalan in the presence of chloride ion. J Pharm Pharmacol. 1979; 31:853–4. [PubMed 43372]

  • 287.

    Mitenko PA, Ogilvie RI. Rational intravenous doses of theophylline. N Engl J Med. 1973; 289:600–3. [PubMed 4723589]

  • 288.

    Simons FER, Pierson WE. Current status of the use of intravenously administered aminophylline. South Med J. 1975; 68:802–4. [PubMed 1154069]

  • 289.

    Weinberger MW, Matthay RA, Ginchansky EJ et al. Intravenous aminophylline dosage. Use of serum theophylline measurement for guidance. JAMA. 1976; 235:2110–3. [PubMed 946537]

  • 290.

    Nedich RL. Vitamin A absorption from plastic IV bags. JAMA. 1973; 224:1531–2. [PubMed 4739965]

  • 291.

    Kaplan MA, Coppola WP, Nunning BC et al. Pharmaceutical properties and stability of amikacin, part i. Curr Ther Res Clin Exp. 1976; 20:352–8. [PubMed 12916]

  • 292.

    Nunning BC, Granatek AP. Physical compatibility and chemical stability of amikacin sulfate in large-volume parenteral solutions, part ii. Curr Ther Res Clin Exp. 1976; 20:359–68. [PubMed 12917]

  • 293.

    Nunning BC, Granatek AP. Physical compatibility and chemical stability of amikacin sulfate in combination with antibiotics in large-volume parenteral solutions, part iii. Curr Ther Res Clin Exp. 1976; 20:369–416. [PubMed 188596]

  • 294.

    Nunning BC, Granatek AP. Physical compatibility and chemical stability of amikacin sulfate in combination with non-antibiotic drugs in large-volume parenteral solutions, part iv. Curr Ther Res Clin Exp. 1976; 20:417–91. [PubMed 12918]

  • 295.

    Koup JR, Gerbracht L. Reduction in heparin activity by gentamicin. Drug Intell Clin Pharm. 1975; 9:568.

  • 296.

    McKinley JD (M.D. Anderson Hospital and Tumor Institute, Houston, TX): Personal communication; 1976 Aug 23.

  • 297.

    Weiner B, McNeely DJ, Kluge RM et al. Stability of gentamicin sulfate injection following unit dose repackaging. Am J Hosp Pharm. 1976; 33:1254–9. [PubMed 998642]

  • 298.

    Dinel BA, Ayotte DL, Behme RJ et al. Comparative stability of antibiotic admixtures in minibags and minibottles. Drug Intell Clin Pharm. 1977; 11:226–39. [PubMed 10304770]

  • 299.

    Dinel BA, Ayotte DL, Behme RJ et al. Stability of antibiotic admixtures frozen in minibags. Drug Intell Clin Pharm. 1977; 11:542–8.

  • 300.

    Lynn B. Pharmaceutics of the semi-synthetic penicillins. Chem Drug. 1967; 187:157–60.

  • 301.

    Stanaszek WF, Pan IH. Analysis of hydroxyzine hydrochloride, meperidine hydrochloride and atropine sulfate in glass and plastic syringes. Am J Hosp Pharm. 1978; 35:1084–7. [PubMed 29485]

  • 302.

    Fraser GL. Incompatibility of magnesium sulfate and hydrocortisone sodium succinate. Am J Hosp Pharm. 1978; 35:783. [PubMed 665692]

  • 303.

    Kresel JJ, McDermott JS, Huffer LM et al. Stability of carbenicillin and oxacillin frozen in syringes. Am J Hosp Pharm. 1978; 35:310–2. [PubMed 626211]

  • 304.

    Manning RE. Predicted expiration times for penicillin G in combination with multivitamin injections. Am J Hosp Pharm. 1976; 33:870. [PubMed 984050]

  • 305.

    Cloyd JC, Bosch DE. Concentration-time profile of phenytoin after admixture with small volumes of intravenous fluids. Am J Hosp Pharm. 1978; 35:45–8. [PubMed 623117]

  • 306.

    Bauman JL, Siepler JK. Phenytoin crystallization in intravenous fluids. Drug Intell Clin Pharm. 1977; 11:646–9.

  • 307.

    Ashwin J, Lynn B. Ampicillin stability in saline or dextrose infusions. Pharm J. 1975; 214:487–9.

  • 308.

    O’Brien MJ, Portnoff JB. Cefoxitin sodium compatibility with intravenous infusions and additives. Am J Hosp Pharm. 1979; 36:33–8. [PubMed 31790]

  • 309.

    Stevens JS. Incompatibility of diphenhydramine hydrochloride (Benadryl) with meglumine iodipamide (Cholografin). Radiology. 1975; 117:224–5. [PubMed 1162066]

  • 310.

    Petrick RJ, Wolleben JE. Stability of frozen solutions of doxycycline hyclate for injection. Am J Hosp Pharm. 1978; 35:1386–7. [PubMed 707508]

  • 311.

    Melberg SG, Havelund S, Villumsen J et al. Insulin compatibility with polymer materials used in external pump infusion systems. Diabet Med. 1988; 5:243–7. [PubMed 2967145]

  • 312.

    Gardella LA, Kesler H, Amann A et al. Intropin (dopamine hydrochloride) intravenous admixture compatibility, part 3: stability with miscellaneous additives. Am J Hosp Pharm. 1978; 35:581–4. [PubMed 655182]

  • 313.

    Schuetz DH, King JC. Compatibility and stability of electrolytes, vitamins and antibiotics in combination with 8% amino acids solution. Am J Hosp Pharm. 1978; 35:33–44. [PubMed 623116]

  • 314.

    El-Nakeeb MA, Souccar N. Inactivation of various antibiotics by some vitamins. Can J Pharm Sci. 1976; 11:85–9.

  • 315.

    Dixon FW, Weshalek J. Physical compatibility of nine drugs in various intavenous solutions. Am J Hosp Pharm. 1972; 29:822–3. [PubMed 5075118]

  • 316.

    Earhart RH. Instability of cis-dichlorodiammineplatinum in dextrose solution. Cancer Treat Rep. 1978; 62:1105–6. [PubMed 688249]

  • 317.

    Greene RF, Chatterji DC, Hiranaka PK et al. Stability of cisplatin in aqueous solution. Am J Hosp Pharm. 1979; 36:38–43. [PubMed 758783]

  • 318.

    Morrison RA, Oseekey KB. 5-Fluorouracil and methotrexate sodium: an admixture incompatibility?. Am J Hosp Pharm. 1978; 35:15. [PubMed 623109]

  • 319.

    King JC. 5-Fluorouracil and methotrexate sodium: an admixture incompatibility?. Am J Hosp Pharm. 1978; 35:18. [PubMed 623110]

  • 320.

    Rusmin S, Welton S, DeLuca P et al. Effect of inline filtration on the potency of drugs administered intravenously. Am J Hosp Pharm. 1977; 34:1071–4. [PubMed 920741]

  • 321.

    Morris ME. Compatibility and stability of diazepam injection following dilution with intravenous fluids. Am J Hosp Pharm. 1978; 35:669–72. [PubMed 665679]

  • 322.

    Allen LV, Levinson RS. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm. 1977; 34:939–43. [PubMed 20779]

  • 323.

    Arnold TR, Eder J. Compatibility of primary-piggyback solution combinations. Am J Hosp Pharm. 1978; 35:249–50. [PubMed 626204]

  • 324.

    Jansen JR. Volume control sets and incompatibilities. Am J Hosp Pharm. 1975; 32:1225. [PubMed 1211393]

  • 325.

    Aisenstein A, Kahn S. Study of the stability of some frozen antibiotics. Hosp Pharm. 1969; 4:17–21.

  • 326.

    Parker WA. Physical compatibilities of preanesthetic medications. Can J Hosp Pharm. 1976; 29:91–2.

  • 327.

    Cradock JC, Kleinman LM. Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate. Am J Hosp Pharm. 1978; 35:402–6. [PubMed 25579]

  • 328.

    Sarubbi FA, Wilson B, Lee M et al. Nosocomial meningitis and bacteremia due to contaminated amphotericin B. JAMA. 1978; 239:416–8. [PubMed 413939]

  • 329.

    The Upjohn Company. Solu-Medrol IV admixture, dilution, and compatibility information. 1978 Aug.

  • 330.

    Parker WA, Morris ME. Incompatibility of diazepam injection in plastic intravenous bags. Am J Hosp Pharm. 1979; 36:505–7. [PubMed 433936]

  • 331.

    Ingallinera T, Kapadia AJ, Hagman D et al. Compatibility of glycopyrrolate injection with commonly used infusion solutions and additives. Am J Hosp Pharm. 1979; 36:508–10. [PubMed 433937]

  • 332.

    Bateman NE, Graham MD. Solubility of an ephedrine-phenobarbitone complex in water. Australas J Pharm. 1967; 48:S68–9.

  • 333.

    Chang CH, Ashford WR, Ives DAJ et al. Stability of oxytocin in various infusion solutions. Can J Hosp Pharm. 1972; 25:152.

  • 334.

    Lynn B. Administration of carbenicillin and ticarcillin—pharmaceutical aspects. Eur J Cancer. 1973; 9:425–33. [PubMed 4214701]

  • 335.

    Block ER, Bennett JE. Stability of amphotericin B in infusion bottles. Antimicrob Agents Chemother. 1973; 4:648–9. [PubMed 4793885][Free Fulltext PMC]

  • 336.

    Gupta VD, Stewart KR. Quantitation of carbenicillin disodium, cefazolin sodium, cephalothin sodium, nafcillin sodium, and ticarcillin disodium by high-pressure liquid chromatography. J Pharm Sci. 1980; 69:1264–7. [PubMed 7452453]

  • 337.

    Anon. Label changes on albumin—a reminder. FDA Drug Bull. 1978; 8:32.

  • 338.

    Knoppert DC, Freeman D, Webb D. Stability of ceftizoxime in 5 percent dextrose and 0.9 percent sodium chloride. Can J Hosp Pharm. 1993; 46:13–6.

  • 339.

    Koup JR, Schentag JJ, Vance JW et al. System for clinical pharmacokinetic monitoring of theophylline therapy. Am J Hosp Pharm. 1976; 33:949–56. [PubMed 790952]

  • 340.

    Jusko WJ, Koup JR, Vance JW et al. Intravenous theophylline therapy: nomogram guidelines. Ann Intern Med. 1977; 86:400–4. [PubMed 848801]

  • 341.

    Travenol Laboratories. Product information on Travasol. Deerfield, IL; 1994 Jan.

  • 342.

    McGaw Laboratories. Product information on FreAmine III. Irvine, CA; 1991 Sep.

  • 343.

    Odne MAL, Lee SC. Rationale for adding trace elements to total parenteral nutrient solutions—a brief review. Am J Hosp Pharm. 1978; 35:1057–9. [PubMed 100008]

  • 344.

    Jeejeebhoy KN, Langer B, Tsallas G et al. Total parenteral nutrition at home: studies in patients surviving 4 months to 5 years. Gastroenterology. 1976; (Dec):943–53. [PubMed 825411]

  • 345.

    Hull RL, Cassidy D. Trace element deficiencies during total parenteral nutrition. Drug Intell Clin Pharm. 1977; 11:536–41.

  • 346.

    Shils ME. More on trace elements in total parenteral nutrition solutions. Am J Hosp Pharm. 1975; 32:141–2. [PubMed 806226]

  • 347.

    Okada A, Takagi Y, Itakura T et al. Skin lesions during intravenous hyperalimentation: zinc deficiency. Surgery. 1976; 80:629–35. [PubMed 824754]

  • 348.

    Matoi JR, Jeffreys LP. Formulation of a trace element solution for long-term parenteral nutrition. Am J Hosp Pharm. 1978; 35:165–8. [PubMed 415604]

  • 349.

    Athanikar N, Boyer B, Deamer R et al. Visual compatibility of 30 additives with a parenteral nutrient solution. Am J Hosp Pharm. 1979; 36:511–3. [PubMed 107797]

  • 350.

    Finlayson JS. The birth and demise of “salt-poor” albumin. Am J Hosp Pharm. 1978; 35:898–900. [PubMed 677130]

  • 351.

    Winsnes M, Jeppsson R. Diazepam adsorption to infusion sets and plastic syringes. Acta Anaesthesiol Scand. 1981; 25:93–6. [PubMed 7324831]

  • 352.

    Bonner DP, Mechlinski W, Schaffner CP. Stability studies with amphotericin B and amphotericin B methyl ester. J Antibiot. 1975; 28:132–5. [PubMed 234414]

  • 353.

    Shadomy S, Brummer DL. Light sensitivity of prepared solutions of amphotericin B. Am Rev Resp Dis. 1973; 107:303–4. [PubMed 4683593]

  • 354.

    Fields BT Jr, Bates JH, Abernathy RS. Effect of rapid intravenous infusion on serum concentrations of amphotericin B. Appl Microbiol. 1971; 22:615–7. [PubMed 5130433][Free Fulltext PMC]

  • 355.

    Janknegt R, van den Berg T, de Jong M et al. Compatibility study with midazolam. Ziekenhuisfarmacie. 1986; 2:45–8.

  • 356.

    Arbuthnot R, Dullea A. Controlling thrombophlebitis from amphotericin B. Am J Hosp Pharm. 1978; 35:129. [PubMed 626193]

  • 357.

    Rosch JM, Pazin G. Mannitol and amphotericin B. JAMA. 1977; 237:27. [PubMed 576127]

  • 358.

    Moore DE, Sithipitaks V. Photolytic degradation of frusemide. J Pharm Pharmacol. 1983; 35:489–93. [PubMed 6137532]

  • 359.

    Roberts JR. Cutaneous and subcutaneous complications of calcium infusions. JACEP. 1977; 6:16–20. [PubMed 830982]

  • 360.

    Smith Kline & French Laboratories. Product information on Tagamet. Philadelphia, PA; 1978 Oct.

  • 361.

    Winters RE, Chow AW, Hecht RH et al. Combined use of gentamicin and carbenicillin. Ann Intern Med. 1971; 75:925–7. [PubMed 5134902]

  • 362.

    Waitz JA, Drube CG, Moss EL et al. Biological aspects of the interaction between gentamicin and carbenicillin. J Antibiot. 1972; 25:219–25. [PubMed 4626239]

  • 363.

    Ervin FR, Bullock WE. Inactivation of gentamicin by penicillins in patients with renal failure. Antimicrob Agents Chemother. 1976; 9:1004–11. [PubMed 938018][Free Fulltext PMC]

  • 364.

    Peterson CD, Kaatz BL. Ticarcillin and carbenicillin. Drug Intell Clin Pharm. 1977; 11:482–6.

  • 365.

    Davies M, Morgan JR. Interactions of carbenicillin and ticarcillin with gentamicin. Antimicrob Agents Chemother. 1975; 7:431–4. [PubMed 1147579][Free Fulltext PMC]

  • 366.

    Weibert R, Keane W, Shapiro F. Carbenicillin inactivation of aminoglycosides in patients with severe renal failure. Trans Am Soc Artif Int Organs. 1976; 22:439–43.

  • 367.

    Weibert RT, Keane WF. Carbenicillin-gentamicin interaction in acute renal failure. Am J Hosp Pharm. 1977; 34:1137–9. [PubMed 920745]

  • 368.

    Bodey GP, Feld R. β-Lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients. Am J Med Sci. 1976; 271:179–86. [PubMed 773180]

  • 369.

    Schimpff S, Satterlee W, Young UM et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971; 284:1061–5. [PubMed 4994878]

  • 370.

    Hendeles L. Are carbenicillin and gentamicin synergists or antagonists? Hosp Pharm. 1972; (Sep)7:297–8.

  • 371.

    Kole-James A. Electrolyte content of common intravenous solutions and antibiotics. Hosp Pharm. 1977; 12:394.

  • 372.

    Donnelly RF, Tirona RG. Stability of citrated caffeine injectable solution in glass vials. Am J Hosp Pharm. 1994; 51:512–4. [PubMed 8017419]

  • 373.

    Turco SJ, Hasan I. Comparison of features of Kefzol and Ancef. Hosp Pharm. 1976; 11:482.

  • 374.

    Vukovich RA, Sugerman AA. Effect of 2% procaine hydrochloride solution on the bioavailability of cephradine after intramuscular injection. Curr Ther Res Clin Exp. 1975; 18:711–9. [PubMed 812649]

  • 375.

    Stennett DJ, Simonson W. Effect of membrane filtration on 10–mg/mL cefazolin admixtures. Am J Hosp Pharm. 1979; 36:657–60. [PubMed 453218]

  • 376.

    Klink PR, Frable RA, Bornstein M. Stability of mandol in parenteral fluids, frozen solutions and admixtures containing other drugs. Presented at 13th annual ASHP midyear clinical meeting. San Antonio, TX: 1978 Dec.

  • 377.

    Henney JE, Von Hoff DD, Rozencweig M et al. Thrombophlebitic potential of intravenous cytotoxic agents. Drug Intell Clin Pharm. 1977; 11:266–7.

  • 378.

    Sillers BR. Irritant properties of diazepam. Br Dent J. 1968; 124:295. [PubMed 5238618]

  • 379.

    Roche Products Ltd. Irritant properties of diazepam—reply. Br Dent J. 1968; 124:295. [PubMed 5238618]

  • 380.

    Friedenberg W, Barker JD Jr. Intravenous diazepam administration. JAMA. 1973; 224:901–2. [PubMed 4739691]

  • 381.

    Jusko WJ, Gretch M, Gassett R. Precipitation of diazepam from intravenous preparationsi. JAMA. 1973; 225:176.

  • 382.

    Kortilla K, Sothman A. Polyethylene glycol as a solvent for diazepam: bioavailability and clinical effects after intramuscular administration, comparison of oral, intramuscular and rectal administration, and precipitation from intravenous solutions. Acta Pharmacol Toxicol (Copenh). 1976; 39:104–17. [PubMed 782157]

  • 383.

    Hillestad L, Hansen T, Melsome H et al. Diazepam metabolism in normal man I. Serum concentrations and clinical effects after intravenous, intramuscular and oral administration. Clin Pharmacol Ther. 1974; 16:479–84. [PubMed 4412803]

  • 384.

    Assaf RA, Dundee JW, Gamble JA. The influence of the route of administration on the clinical action of diazepam. Anaesthesia. 1975; 30:152–8. [PubMed 1093426]

  • 385.

    Baxter MT, McKenzie DD. Dilution of diazepam in intravenous fluids. Am J Hosp Pharm. 1977; 34:124. [PubMed 842538]

  • 386.

    Thong YH, Abramson DC. Continuous infusion of diazepam in infants with severe recurrent convulsions. Med Ann DC. 1974; 43:63–5. [PubMed 4521743]

  • 387.

    Khalid MS, Schultz H. Treatment and management of emergency status epilepticus. Epilepsia. 1976; 17:73–6. [PubMed 817894]

  • 388.

    Gibberd FB. Diseases of the central nervous system—epilepsy. Br Med J. 1975; 4:270–2. [PubMed 811306][Free Fulltext PMC]

  • 389.

    Kawathekar P, Anusuya SR, Sriniwas P et al. Diazepam (Calmpose) in eclampsia: a preliminary report of 16 cases. Curr Ther Res Clin Exp. 1973; 15:845–55. [PubMed 4201598]

  • 390.

    Baskett TF, Bradford CR. Active management of severe pre-eclampsia. Can Med Assoc J. 1973; 109:1209–11. [PubMed 4796621][Free Fulltext PMC]

  • 391.

    Prensky AL, Raff MC, Moore MJ et al. Intravenous diazepam in the treatment of prolonged seizure activity. N Engl J Med. 1967; 276:779–84. [PubMed 4960697]

  • 392.

    Tehrani JB, Cavanaugh A. Diazepam infusion in the treatment of tetanus. Drug Intell Clin Pharm. 1977; 11:491.

  • 393.

    McLean WN. Safety of diazepam infusion questioned. Drug Intell Clin Pharm. 1977; 11:690.

  • 394.

    Trissel LA, Kleinman LM, Davignon JP et al. Investigational drug information—daunorubicin hydrochloride and streptozotocin. Drug Intell Clin Pharm. 1978; 12:404–6.

  • 395.

    Elsberry VA, Grangeia JM, Giorgianni SJ et al. The lipid phase in TPN. Am J IV Ther. 1977; 4:22–8.

  • 396.

    Belin RP, Bivins BA, Jona JZ et al. Fat overload with a 10% soybean oil emulsion. Arch Surg. 1976; 111:1391–3. [PubMed 826237]

  • 397.

    McNiff BL. Clinical use of 10% soybean oil emulsion. Am J Hosp Pharm. 1977; 34:1080–6. [PubMed 411372]

  • 398.

    Roche Laboratories, Nutley, NJ: Personal communication.

  • 399.

    McGaw Laboratories. McGaw compatibility studies: a preliminary report. Irvine, CA; 1978.

  • 400.

    Bundgaard H, Norgaard T, Nielsen NM. Photodegradation and hydrolysis of furosemide and furosemide esters in aqueous solutions. Int J Pharm. 1988; 42:217–24.

  • 401.

    Kresel JJ, Smith AL. Stability of gentamicin in plastic syringes. Am J Hosp Pharm. 1977; 34:570. [PubMed 879174]

  • 402.

    McNeely DJ, Weiner B, Stewart RB et al. Stability of gentamicin in plastic syringes. Am J Hosp Pharm. 1977; 34:570. [PubMed 879174]

  • 403.

    Chrai SS, Ambrosio TJ. Gentamicin sulfate injection repackaging in syringes. Am J Hosp Pharm. 1977; 34:920. [PubMed 906990]

  • 404.

    Davis SM (Medical Information Manager, Astra Zeneca, Wilmington, Delaware): Personal communication, August 21, 2003.

  • 405.

    Sohn C, Cupit GC. Concentration of heparin in heparin-locks. Drug Intell Clin Pharm. 1978; 12:112.

  • 406.

    Okuno T, Nelson CA. Anticoagulant activity of heparin in intravenous fluids. J Clin Pathol. 1975; 28:494–7. [PubMed 1141451][Free Fulltext PMC]

  • 407.

    Joy RT, Hyneck ML, Berardi RR et al. Effect of pH on the stability of heparin in 5% dextrose solutions. Am J Hosp Pharm. 1979; 36:618–21. [PubMed 36753]

  • 408.

    Brown J, Stead K. Anti-human lymphocyte globulin-­heparin precipitate. Drug Intell Clin Pharm. 1976; 10:654.

  • 409.

    Raab WP, Windisch J. Antagonism of neomycin by heparin. Further observations on the anaphylactoid activity of neomycin. Arzneimittelforschung. 1973; 23:1326–8. [PubMed 4801230]

  • 410.

    Stella VJ. A case for prodrugs: Fosphenytoin. Adv Drug Del Rev. 1996; 19:311–30.

  • 411.

    Dupuis LL, Wong B. Stability of propafenone hydrochloride in i.v. solutions. Am J Health-Syst Pharm. 1997; 54:1293–5. [PubMed 9179350]

  • 412.

    Dupuis LL, Trope A, Giesbrecht E et al. Compatibility and stability of propafenone hydrochloride with five critical-care medications. Can J Hosp Pharm. 1998; 51:55–7.

  • 413.

    Storvick WO, Henry HJ. Effect of storage temperature on stability of commercial insulin preparations. Diabetes. 1968; 17:499–502. [PubMed 5668013]

  • 414.

    Jackson RL, Storvick WO, Hollinden CS et al. Neutral regular insulin. Diabetes. 1972; 21:235–45. [PubMed 5017379]

  • 415.

    Page MM, Alberti KGMM, Greenwood R et al. Treatment of diabetic coma with continuous low-dose infusion of insulin. Br Med J. 1974; 2:687–90. [PubMed 4855253][Free Fulltext PMC]

  • 416.

    Kidson W, Casey J, Kraegen E et al. Treatment of severe diabetes mellitus by insulin infusion. Br Med J. 1974; 2:691–94. [PubMed 4855256][Free Fulltext PMC]

  • 417.

    Semple PF, White C. Continuous intravenous infusion of small doses of insulin in treatment of diabetic ketoacidosis. Br Med J. 1974; 2:694–8. [PubMed 4211890][Free Fulltext PMC]

  • 418.

    Campbell LV, Lazarus L, Casey JH et al. Routine use of low-dose intravenous insulin infusion in severe hyperglycaemia. Med J Aust. 1976; 2:519–22. [PubMed 994952]

  • 419.

    Martin MM, Martin ALA. Continuous low-dose infusion of insulin in the treatment of diabetic ketoacidosis in children. J Pediatr. 1976; 89:560–4. [PubMed 822144]

  • 420.

    Drop SLS, Duval-Arnould BJM, Gober AE et al. Low-dose intravenous insulin infusion versus subcutaneous insulin injection: A controlled comparative study of diabetic ketoacidosis. Pediatrics. 1977; 59:733–8. [PubMed 404621]

  • 421.

    Fisher JN, Shahshahani MN. Diabetic ketoacidosis: low-dose insulin therapy by various routes. N Engl J Med. 1977; 297:238–41. [PubMed 406561]

  • 422.

    Goldberg NJ, Levin SR. Insulin adsorption to an inline membrane filter. N Engl J Med. 1978; 298:1480. [PubMed 652022]

  • 423.

    Kristofferson J, Skobba TJ. Adsorption of insulin to infusion equipment. Nor Farm Tidsskr. 1977; 85:220–4.

  • 424.

    Hirsch JI, Fratkin MJ, Wood JH et al. Clinical significance of insulin adsorption by polyvinyl chloride infusion systems. Am J Hosp Pharm. 1977; 34:583–8. [PubMed 406784]

  • 425.

    Weber SS, Wood WA. Availability of insulin from parenteral nutrient solutions. Am J Hosp Pharm. 1977; 34:353–7. [PubMed 404875]

  • 426.

    Whalen FJ, LeCain WK. Availability of insulin from continuous low-dose insulin infusions. Am J Hosp Pharm. 1979; 36:330–7. [PubMed 420226]

  • 427.

    Clarke BF, Campbell IW, Fraser DM et al. Direct addition of small doses of insulin to intravenous infusion in severe uncontrolled diabetes. Br Med J. 1977; 2:1395–6. [PubMed 589229][Free Fulltext PMC]

  • 428.

    Peterson L, Caldwell J. Insulin adsorbance to polyvinyl chloride surfaces with implications for constant-infusion therapy. Diabetes. 1976; 25:72–4. [PubMed 1245268]

  • 429.

    Sadeghi A, Mehrbanpour J, Behmard S et al. A trial of total dose infusion iron therapy as an outpatient procedure in rural Iranian villages (a three month follow-up). Curr Ther Res Clin Exp. 1976; 19:595–602. [PubMed 819219]

  • 430.

    Leach JK, Strickland RD, Millis DL et al. Biological activity of dilute isoproterenol solution stored for long periods in plastic bags. Am J Hosp Pharm. 1977; 34:709–12. [PubMed 18933]

  • 431.

    Browning ML. IM MgSO4 ampuls for IV use. Hosp Pharm. 1976; 11:325.

  • 432.

    Epperson E, Nedich RL. Mannitol crystallization in plastic containers. Am J Hosp Pharm. 1978; 35:1337.

  • 433.

    Chatterji DC, Gallelli JF. Thermal and photolytic decomposition of methotrexate in aqueous solutions. J Pharm Sci. 1978; 67:526–31. [PubMed 641762]

  • 434.

    Muller HJ, Berg J. Stabilitatsstudie zu tramadolhydrochlorid im PVC-infusionbeutel. Krankenhauspharmazie. 1997; 18:75–9.

  • 435.

    Duttera MJ, Gallelli JF, Kleinman LM et al. Intrathecal methotrexate. Lancet. 1972; 2:540. [PubMed 4115593]

  • 436.

    Hartshorn EA. Oxidation of methyldopate hydrochloride in alkaline media. Am J Hosp Pharm. 1975; 32:244. [PubMed 237419]

  • 437.

    Parker EA. Oxidation of methyldopate hydrochloride in alkaline media. Am J Hosp Pharm. 1975; 32:244. [PubMed 237419]

  • 438.

    Hartline JV, Zachman RD. Vitamin A delivery in total parenteral nutrition solution. Pediatrics. 1976; 58:448–51. [PubMed 822390]

  • 439.

    Sina A, Youssef MK, Kassem AA et al. Stability of oxytetracycline in solutions and injections. Can J Pharm Sci. 1974; 9:44–9.

  • 440.

    Colding H, Anderson GE. Stability of antibiotics and amino acids in two synthetic L-amino acid solutions commonly used for total parenteral nutrition in children. Antimicrob Agents Chemother. 1978; 13:555–8. [PubMed 27137][Free Fulltext PMC]

  • 441.

    Schneider E (Knoll AG, Milan, Italy): Personal communication; 2000 Feb 25.

  • 442.

    Perrier D, Rapp R, Young B et al. Maintenance of therapeutic phenytoin plasma levels via intramuscular administration. Ann Intern Med. 1976; 85:318–21. [PubMed 822764]

  • 443.

    Sellers EM, Kalant H. Alcohol intoxication and withdrawal. N Engl J Med. 1976; 294:757–62. [PubMed 3733]

  • 444.

    Nahata MC. Formulation of caffeine injection for i.v. administration. Am J Hosp Pharm. 1987; 44:1308, 1312. [PubMed 3618604]

  • 445.

    Anon. Intravenous phenytoin. N Engl J Med. 1976; 295:1078.

  • 446.

    Anon. Intravenous phenytoin. N Engl J Med. 1976; 295:1078.

  • 447.

    Frank JT. Author’s response. Drug Intell Clin Pharm. 1973; 7:419.

  • 448.

    Woo E, Greenblatt DJ. Choosing the right phenytoin dosage. Drug Ther. 1977; 7:131–9.

  • 449.

    Bighley LD, Wille J. Mixing of additives in glass and plastic intravenous fluid containers. Am J Hosp Pharm. 1974; 31:736–9. [PubMed 4853231]

  • 450.

    Schondelmeyer S, Gatlin L. Intravenous phenytoin (concluded). N Engl J Med. 1977; 296:111.

  • 451.

    Bauman JL, Siepler JK. Intravenous phenytoin (concluded). N Engl J Med. 1977; 296:111. [PubMed 830292]

  • 452.

    Sistare F, Greene R. Phenytoin crystallization in intravenous fluids. Drug Intell Clin Pharm. 1978; 12:120.

  • 453.

    Biberdorf RI, Spurbeck GH. Phenytoin in IV fluids: results endorsed. Drug Intell Clin Pharm. 1978; 12:300–1.

  • 454.

    Williams RHP. Potassium overdosage: a potential hazard of non-rigid parenteral fluid containers. Br Med J. 1973; 1:714–5. [PubMed 4694694][Free Fulltext PMC]

  • 455.

    Woodside W, King JA. Addition of potassium to non-rigid plastic intravenous infusion containers: a potential hazard. J Hosp Pharm. 1973; 31:192–4.

  • 456.

    Lankton JW, Siler JN. Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers. Anesthesiology. 1973; 39:660–1. [PubMed 4761028]

  • 457.

    Vrabel RB, Amerson AB. Reconstitution of sodium nitroprusside. Am J Hosp Pharm. 1975; 32:140–1. [PubMed 1136957]

  • 458.

    Challen RG. Stability of sodium nitroprusside solutions. Australas J Pharm. 1967; 48:S110.

  • 459.

    Martin T, Patel JA. Determination of sodium nitroprusside in aqueous solution. Am J Hosp Pharm. 1969; 26:51–3. [PubMed 5763890]

  • 460.

    Frank MJ, Johnson JB. Spectrophotometric determination of sodium nitroprusside and its photodegradation products. J Pharm Sci. 1976; 65:44–8. [PubMed 1255433]

  • 461.

    Ammar HO. Stability of injection solutions of vitamin B1. Pharmazie. 1976; 31:373–4. [PubMed 785487]

  • 462.

    Anon. Correction: sodium in ticarcillin and carbenicillin. Med Lett Drugs Ther. 1977; 19:28. [PubMed 846458]

  • 463.

    Yamaji A, Yasuko F, Okuda H et al. Photodegradation of vitamin K1 and vitamin K2 injections in preservation and in intravenous admixtures. J Nippon Hosp Pharm Assoc Sci Ed. 1978; 4:7–11.

  • 464.

    Kobayashi NH, King JC. Compatibility of common additives in protein hydrolysate/dextrose solutions. Am J Hosp Pharm. 1977; 34:589–94. [PubMed 406785]

  • 465.

    Humphreys A, Marty JJ, Gooey SL et al. Stability of methotrexate in an intravenous fluid. Aust J Hosp Pharm. 1978; 8:66–7.

  • 466.

    Clayton SK. Stability of intravenous additive preparations; studies on hydralazine as an additive. J Clin Pharm. 1978; 2:247–56.

  • 467.

    Anon. Mixing chlorpromazine and morphine. Br Med J. 1974; 3:681. [Free Fulltext PMC]

  • 468.

    Crapper JB. Mixing chlorpromazine and morphine. Br Med J. 1975; 1:33. [Free Fulltext PMC]

  • 469.

    Baird GM, Willoughby MLN. Photodegradation of dacarbazine. Lancet. 1978; 2:681.

  • 470.

    Georget S, Vigneron J, Blaise N et al. Stability of refrigerated and frozen solutions of tropisetron in either polyvinylchloride or polyolefin infusion bags. J Clin Pharm Ther. 1997; 22:257–60. [PubMed 9548206]

  • 471.

    Bergman HD. Cefamandole. Drug Intell Clin Pharm. 1979; 13:144–9.

  • 472.

    Indelicato JM, Wilham WL. Conversion of cefamandole nafate to cefamandole sodium. J Pharm Sci. 1976; 65:1175–8. [PubMed 10412]

  • 473.

    Palmer MA, Fraterrigo CC. Production of carbon dioxide gas after reconstitution of cefamandole nafate. Am J Hosp Pharm. 1979; 36:596–7. [PubMed 453208]

  • 474.

    Klink PR, McKeechan CW. Production of carbon dioxide gas after reconstitution of cefamandole nafate. Am J Hosp Pharm. 1979; 36:597. [PubMed 453209]

  • 475.

    Bornstein M, Klink PR, Farrell BT et al. Stability of frozen solutions of cefamandole nafate. Am J Hosp Pharm,. 1980; 37:98–101.

  • 476.

    Buckles J, Walters V. Stability of amitriptyline hydrochloride in aqueous solution. J Clin Pharm. 1976; 1:107–12.

  • 477.

    Enever RP, Po ALW, Millard BJ et al. Decomposition of amitriptyline hydrochloride in aqueous solution: identification of decomposition products. J Pharm Sci. 1975; 64:1497–9. [PubMed 1185565]

  • 478.

    Enever RP, Po ALW. Factors influencing decomposition rate of amitriptyline hydrochloride in aqueous solution. J Pharm Sci. 1977; 66:1087–9. [PubMed 408476]

  • 479.

    Holman BL, Dewanjee MK. Potential pH incompatibility of pharmacological and isotopic adjuncts to arteriography. Radiology. 1974; 110:722–3. [PubMed 4811701]

  • 480.

    Kawilarang CRT, Georghiou K. The effect of additives on the physical properties of a phospholipid-stabilized soybean oil emulsion. J Clin Hosp Pharm. 1980; 5:151–60.

  • 481.

    Bristol Laboratories. Stadol Q&A. Syracuse, NY; 1978 Nov:7.

  • 482.

    Jacobs RS. Calcitonin-Salmon. Drug Intell Clin Pharm. 1975; 9:557–9.

  • 483.

    Nahata MC, Zingarelli J, Durrell DE. Stability of caffeine citrate injection in intravenous admixtures and parenteral nutrition solutions. J Clin Pharm Ther. 1989; 14:53–5. [PubMed 2493462]

  • 484.

    Davignon JP, Yang KW, Wood HB et al. Formulation of three nitrosoureas for intravenous use. Cancer Chemother Rep 3. 1973; 4(3):7–11. [PubMed 4201309]

  • 485.

    Buckles J, Walters V. Stability of imipramine hydrochloride solutions. J Clin Pharm. 1976; 1:113–8.

  • 486.

    Andreu A, Garcia B, Pastor C et al. Estudio de la estabilidad in vitro de la ranitidine i.v. en una solucion de nutricion parenteral total conteniendo lipidos. Nutr Hosp. 1988; 3:50–5.

  • 487.

    Smith JL, Canham JE, Wells PA. Effect of phototherapy light, sodium bisulfite, and pH on vitamin stability in total parenteral nutrition admixtures. J Parenter Enteral Nutr. 1988; 12:394–402.

  • 488.

    Lauper RD. Leucovorin calcium administration and preparation. Am J Hosp Pharm. 1978; 35:377. [PubMed 306195]

  • 489.

    Tavoloni N, Guarino AM. Photolytic degradation of adriamycin. J Pharm Pharmacol. 1980; 32:860–2. [PubMed 6110755]

  • 490.

    Black CD, Popovich NG. Stability of intravenous fat emulsions. Arch Surg. 1980; 115:891. [PubMed 6770794]

  • 491.

    Bacon L. A review of two safety factors in the use of paraldehyde. J R Coll Gen Pract. 1980; 30:622–4. [PubMed 7452603][Free Fulltext PMC]

  • 492.

    Horton JK, Stevens MFG. Search for drug interactions between the antitumor agent DTIC and other cytotoxic agents. J Pharm Pharmacol. 1979; 31(Suppl):64P. [PubMed 42741]

  • 493.

    Zaccardelli DS, Krcmarik CS, Wolk R et al. Stability of imipenem and cilastatin sodium in total parenteral nutrient solution. JPEN J Parenter Enteral Nutr. 1990; 14:306–309. [PubMed 2112647]

  • 494.

    Kuehnle C, Moore TD. Sodium chloride residue provides potential for drug incompatibilities. Am J Hosp Pharm. 1979; 36:881. [PubMed 474576]

  • 495.

    Trissel LA, Kleinman LM, Cradock JC et al. Investigational drug information—ifosfamide and semustine. Drug Intell Clin Pharm. 1979; 13:340–3.

  • 496.

    Horton JK, Stevens MFG. A new light on the photo-­decomposition of the antitumour drug DTIC. J Pharm Pharmacol. 1981; 33:808–11. [PubMed 6121862]

  • 497.

    Earp CM, Barriere SL. The lack of inactivation of tobramycin by cefazolin, cefamandole, and moxalactam in vitro. Drug Intell Clin Pharm. 1985; 19:677–9. [PubMed 4042863]

  • 498.

    Elliott TSJ, Eley A, Cowlishaw A. Stability of tobramycin in combination with selected new beta-lactam antibiotics. J Antimicrob Chemother. 1986; 17:680–1. [PubMed 3722037]

  • 499.

    Gu L, Chiang HS, Becker A. Kinetics and mechanisms of the autoxidation of ketorolac tromethamine in aqueous solution. Int J Pharm. 1988; 41:95–104.

  • 500.

    Brown AF, Harvey DA, Hoddinott DJ. Freeze thaw stability of ceftazidime. Br J Parenter Ther. 1985; 6:43–5.

  • 501.

    Grimble GK, Hunjan MK, Payne-James JJ et al. Zantac and TPN. Br J Intensive Care. 1991; 32:7.

  • 502.

    Vieth R, Ledermann SE, Kooh SW et al. Losses of calcitrol to peritoneal dialysis bags and tubing. Peritoneal Dial Int. 1989; 9:277–80.

  • 503.

    McNiff BL, McNiff EF. Potency and stability of extemporaneous nitroglycerin infusions. Am J Hosp Pharm. 1979; 36:173–7. [PubMed 105634]

  • 504.

    Giamarellou H, Mavroudis K, Petrikkos G et al. In vitro and in vivo interactions of recent cephalosporins with gentamicin and amikacin. Chemioterapia. 1984; 3:183–7. [PubMed 6529775]

  • 505.

    Milano G, Etienne MC, Cassuto-Viguier E et al. Long-term stability of 5-fluorouracil and folinic acid admixtures. Eur J Cancer. 1993; 29A:129–32.

  • 506.

    Sturek JK, Sokolski TD, Winsley WT et al. Stability of nitroglycerin injection determined by gas chromatography. Am J Hosp Pharm. 1978; 35:537–41. [PubMed 418678]

  • 507.

    Fung HL. Potency and stability of extemporaneously prepared nitroglycerin intravenous solutions (editorial). Am J Hosp Pharm. 1978; 35:528–9. [PubMed 418677]

  • 508.

    Grouthamel WG, Dorsch B, Shangraw R. Loss of nitroglycerin from plastic intravenous bags. N Engl J Med. 1978; 299:262.

  • 509.

    Cossum PA, Galbraith AJ, Roberts MS et al. Loss of nitroglycerin from intravenous infusion sets. Lancet. 1978; 2:349–50. [PubMed 79713]

  • 510.

    Boylan JC, Robison RL. Stability of nitroglycerin solutions in Viaflex plastic containers. Am J Hosp Pharm. 1978; 35:1031. [PubMed 100007]

  • 511.

    Ludwig DJ, Ueda CT. Apparent stability of nitroglycerin in dextrose 5% in water. Am J Hosp Pharm. 1978; 35:541–4. [PubMed 418679]

  • 512.

    Brillaud AR. Interaction of platinol (cisplatin) and the metal aluminum. Syracuse, NY: Bristol Laboratories; 1979 Jul.

  • 513.

    Baxter Healthcare, Clintec Nutrition Division, Product information on Intralipid 10% and 20%. Deerfield IL; 2007 Apr.

  • 515.

    Sewell DL, Golper TA. Stability of antimicrobial agents in peritoneal dialysate. Antimicrob Agents Chemother. 1982; 21:528–9. [PubMed 7103451][Free Fulltext PMC]

  • 516.

    El-Mallakh R. Incompatibilities with cimetidine hydrochloride injection. Am J Hosp Pharm. 1979; 36:1024. [PubMed 484555]

  • 517.

    Cutie MR. Letters. Hosp Formul. 1980; 15:502–3.

  • 518.

    Tung EC, Gurwich EL, Sula JA et al. Stability of five antibiotics in plastic intravenous solution containers of dextrose and sodium chloride. Drug Intell Clin Pharm. 1980; 14:848–50.

  • 519.

    Benvenuto JA, Anderson RW, Kerkof K et al. Stability and compatibility of antitumor agents in glass and plastic containers. Am J Hosp Pharm. 1981; 38:1914–8. [PubMed 7325172]

  • 520.

    Jhunjhunwala VP, Bhalla HL. Compatibility of mephentermine sulfate with hydrocortisone sodium succinate or aminophylline in 5% dextrose injection. Am J Hosp Pharm. 1981; 38:1922–4. [PubMed 7325174]

  • 521.

    Jhunjhunwala VP, Bhalla HL. Compatibility of aminophylline with hydrocortisone sodium succinate or dexamethasone sodium phosphate in 5% dextrose injection. Am J Hosp Pharm. 1981; 38:900–1. [PubMed 7246567]

  • 522.

    Lee YC, Malick AW, Amann AH et al. Bretylium tosylate intravenous admixture compatibility. II. Dopamine, lidocaine, procainamide and nitroglycerin. Am J Hosp Pharm. 1981; 38:183–7. [PubMed 6782870]

  • 523.

    Colvin M, Hartner J. Stability of carmustine in the presence of sodium bicarbonate. Am J Hosp Pharm. 1980; 37:677–8. [PubMed 7386477]

  • 524.

    Dorr RT. Incompatibilities with parenteral anticancer drugs. Am J IV Ther. 45, 46, 52 (Feb-Mar) 1979; 6:42.

  • 525.

    Das Gupta V, Stewart KR. Stability of cefamandole nafate and cefoxitin sodium solutions. Am J Hosp Pharm. 1981; 38:875–9. [PubMed 7246563]

  • 526.

    Poochikian GK, Cradock JC. Stability of anthracycline antitumor agents in four infusion fluids. Am J Hosp Pharm. 1981; 38:483–6. [PubMed 6945043]

  • 527.

    Newton DW, Fung EYY. Stability of five catecholamines and terbutaline sulfate in 5% dextrose injection in the absence and presence of aminophylline. Am J Hosp Pharm. 1981; 38:1314–9. [PubMed 7282714]

  • 528.

    Neil JM. A rational approach to intravenous additives. Proc Guild. 1979; 7:3–33.

  • 529.

    Otterman GE, Samuelson DW. Incompatibility between carbenicillin injection and promethazine injection. Am J Hosp Pharm. 1979; 36:1156. [PubMed 495611]

  • 530.

    Marshall TR, Ling IT, Follis G et al. Pharmacological incompatibility of contrast media with various drugs and agents. Radiology. 1965; 84:536–9. [PubMed 14280732]

  • 531.

    Monder C. Stability of corticosteroids in aqueous solutions. Endocrinology. 1968; 82:318–26. [PubMed 4951278]

  • 532.

    Kleinberg ML, Stauffer GL, Prior RB et al. Stability of antibiotics frozen and stored in disposable hypodermic syringes. Am J Hosp Pharm. 1980; 37:1087–8. [PubMed 7405937]

  • 533.

    Butler LD, Munson JM. Effect of inline filtration on the potency of low-dose drugs. Am J Hosp Pharm. 1980; 37:935–41. [PubMed 7395887]

  • 534.

    Allen LV, Stiles ML. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Part 2. Am J Hosp Pharm. 1981; 38:380–1. [PubMed 7223755]

  • 535.

    Kleinberg, ML, Stauffer GL et al. Stability of five liquid drug products after unit dose repackaging. Am J Hosp Pharm. 1980; 37:680–2. [PubMed 7386479]

  • 536.

    Kowaluk EA, Roberts MS, Blackburn HD et al. Interactions between drugs and polyvinyl chloride infusion bags. Am J Hosp Pharm. 1981; 38:1308–14. [PubMed 7282713]

  • 537.

    Zatz L, Sethia P. Stability of refrigerated aminophylline in 5% dextrose in water: a 96–hour study. Hosp Pharm. 1981; 16:548.

  • 538.

    Scott KR, Bell AF. Drug interactions I: Folic acid and calcium gluconate. J Pharm Sci. 1980; 69:234. [PubMed 6767014]

  • 539.

    Jurgens RW, DeLuca PP. Compatibility of amphotericin B with certain large-volume parenterals. Am J Hosp Pharm. 1981; 38:377–8. [PubMed 7223753]

  • 540.

    Gotz VP, Mar DD. Compatibility of amphotericin B with drugs used to reduce adverse reactions. Am J Hosp Pharm. 1981; 38:378–9. [PubMed 7223754]

  • 541.

    Lee YC, Baaske DM, Amann AH et al. Bretylium tosylate intravenous admixture compatibility. I. Stability in common large-volume parenteral solutions. Am J Hosp Pharm. 1980; 37:803–8. [PubMed 7395875]

  • 542.

    Yuhas EM, Lofton FT, Baldinus JG et al. Cimetidine hydrochloride compatibility with preoperative medications. Am J Hosp Pharm. 1981; 38:1173–4. [PubMed 7270564]

  • 543.

    Smith FM, Nuessle NO. Stability of lidocaine hydrochloride in 5% dextrose injection in plastic bags. Am J Hosp Pharm. 1981; 38:1745–7. [PubMed 7304630]

  • 544.

    Finch ME. Sodium thiopental in 5% dextrose in lactated Ringer’s precipitate. Hosp Pharm. 1979; 14:559–60.

  • 545.

    Kirschenbaum HL, Lesko LJ, Mendes RW et al. Stability of procainamide in 0.9% sodium chloride or dextrose 5% in water. Am J Hosp Pharm. 1979; 36:1464–5. [PubMed 517523]

  • 546.

    Baaske DM, Malick AW. Stability of procainamide hydrochloride in dextrose solutions. Am J Hosp Pharm. 1980; 37:1050–2. [PubMed 7405932]

  • 547.

    Jeglum EL, Winter E. Nafcillin sodium incompatibility with acidic solutions. Am J Hosp Pharm. 1981; 38:462. [PubMed 7282668]

  • 548.

    Cutie MR, Lordi NG. Compatibility of verapamil hydrochloride injection in commonly used large-volume parenterals. Am J Hosp Pharm. 1980; 37:675–6. [PubMed 7386476]

  • 549.

    Rosenberg HA, Dougherty JT, Mayron D et al. Cimetidine hydrochloride compatibility I: Chemical aspects and room temperature stability in intravenous infusion fluids. Am J Hosp Pharm. 1980; 37:390–3. [PubMed 7369222]

  • 550.

    Yuhas EM, Lofton FT, Mayron D et al. Cimetidine hydrochloride compatibility II: Room temperature stability in intravenous infusion fluids. Am J Hosp Pharm. 1981; 38:879–81. [PubMed 7246564]

  • 551.

    Yuhas EM, Lofton FT, Rosenberg HA et al. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm. 1981; 38:1919–22. [PubMed 7325173]

  • 552.

    Dahlin PA, Paredes SM. Visual compatibility of dobutamine with seven parenteral drug products. Am J Hosp Pharm. 1980; 37:460. [PubMed 7377204]

  • 553.

    Lesko LJ, Marion A, Ericson J et al. Stability of trimethoprim-sulfamethoxazole injection in two infusion fluids. Am J Hosp Pharm. 1981; 38:1004–6. [PubMed 7258196]

  • 554.

    Holmes CJ, Ausman RK, Walter CW et al. Activity of antibiotic admixtures subjected to different freeze-thaw treatments. Drug Intell Clin Pharm. 1980; 14:353–7. [PubMed 10247478]

  • 555.

    Holmes CJ, Ausman RK, Kundsin RB et al. Effect of freezing and microwave thawing on the stability of six antibiotic admixtures in plastic bags. Am J Hosp Pharm. 1982; 39:104–8. [PubMed 6798865]

  • 556.

    Boddapati S, Yang K. Physiochemical properties of aminophylline-dextrose injection admixtures. Am J Hosp Pharm. 1982; 39:108–12. [PubMed 7055136]

  • 557.

    Canton EM, Baluch WM. Effect of freezing on particle formation in three antibiotic injections. Am J Hosp Pharm. 1982; 39:124–5. [PubMed 7055139]

  • 558.

    Chaudry IA, Bruey KP, Hurlburt LE et al. Compatibility of netilmicin sulfate injection with commonly used intravenous injections and additives. Am J Hosp Pharm. 1981; 38:1737–42. [PubMed 7304628]

  • 559.

    Cutie MR. Effects of cold and freezing temperatures on pharmaceutical dosage forms. US Pharmacist. 1979; 4:38–40.

  • 560.

    Gove L, Walls ADF. Mixing parenteral nutrition products. Pharm J. 1979; 223:587.

  • 561.

    Lauder AD. Mixing parenteral nutrition products. Pharm J. 1979; 223:587.

  • 562.

    Hardin TC, Clibon U. Stability of 5-fluorouracil in a crystalline amino acid solution. Am J IV Ther Clin Nutr. 1982; 9:39–40.

  • 563.

    Yamaji A, Fujii Y, Kurata Y et al. Stability of pyridoxine hydrochloride in infusion solution under practical circumstances in wards. Yakuzaigaku. 1980; 40:143–50.

  • 564.

    Dony J, Devleeschouwer MJ. Etude de la degradation photochimique de macrolides en presence de riboflavine. J Pharm Belg. 1976; 31:479–84. [PubMed 993969]

  • 565.

    Parker WA, Shearer CA. Metoclopramide compatibility. Can J Hosp Pharm. 1979; 32:38.

  • 566.

    Parker WA. Compatibility of perphenazine and butorphanol admixtures. Can J Hosp Pharm. 1980; 33:152.

  • 567.

    Stiles ML, Allen LV. Retention of drugs during inline filtration of parenteral solutions. Infusion. 1979; 3:67–9.

  • 568.

    Somani P, Leathem WD, Barlow AL. Safflower oil emulsion: single and multiple infusions with or without added heparin in normal human volunteers. JPEN J Parenter Enteral Nutr. 1980; 4:307–11. [PubMed 6772813]

  • 569.

    Rubin M, Bilik R, Gruenewald Z et al. Use of 5-micron filter in administering ‘all-in-one’ mixtures for total parenteral nutrition. Clin Nutr. 1985; 4:163–8. [PubMed 16831726]

  • 570.

    Moore RA, Feldman S, Treuting J et al. Cimetidine and parenteral nutrition. JPEN J Parenter Enteral Nutr. 1981; 5:61–3. [PubMed 6785475]

  • 571.

    Das Gupta V, Stewart KR. Stability of haloperidol in 5% dextrose injection. Am J Hosp Pharm. 1982; 39:292–4. [PubMed 7058800]

  • 572.

    Cutie MR, Waranis R. Compatibility of hydromorphone hydrochloride in large-volume parenterals. Am J Hosp Pharm. 1982; 39:307–8. [PubMed 6174044]

  • 573.

    Mirtallo JM, Caryer K, Schneider PJ et al. Growth of bacteria and fungi in parenteral nutrition solutions containing albumin. Am J Hosp Pharm. 1981; 38:1907–10. [PubMed 6798862]

  • 574.

    Holt HA, Broughall JM, McCarthy MM et al. Interactions between aminoglycoside antibiotics and carbenicillin or ticarcillin. Infection. 1976; 4:107–9. [PubMed 7534]

  • 575.

    Pickering LK, Gearhart P. Effect of time and concentration upon interaction between gentamicin, tobramycin, netilmicin, or amikacin and carbenicillin or ticarcillin. Antimicrob Agents Chemother. 1979; 15:592–6. [PubMed 464591][Free Fulltext PMC]

  • 576.

    Pieper JA, Vidal RA. Animal model distinguishing in vitro from in vivo carbenicillin-aminoglycoside interactions. Antimicrob Agents Chemother. 1980; 18:604–9. [PubMed 6969576][Free Fulltext PMC]

  • 577.

    Sturgeon RJ, Athanikar NK, Henry RS et al. Titratable acidities of crystalline amino acid admixtures. Am J Hosp Pharm. 1980; 37:388–90. [PubMed 6768289]

  • 578.

    Ausman RK, Kerkhof K, Holmes CJ et al. Frozen storage and microwave thawing of parenteral nutrition solutions in plastic containers. Drug Intell Clin Pharm. 1981; 15:440–3.

  • 579.

    Tortorici MP, Fearing D, Inman M et al. Photoreaction involving essential amino acid injection. Am J Hosp Pharm. 1978; 35:1030. [PubMed 696737]

  • 580.

    West KR, Sansom LN, Cosh DG et al. Some aspects of the stability of parenteral nutrition solutions. Pharm Acta Helv. 1976; 51(1):19–22. [PubMed 821062]

  • 581.

    Jurgens RW, Henry RS. Amino acid stability in a mixed parenteral nutrition solution. Am J Hosp Pharm. 1981; 38:1358–9. [PubMed 6792912]

  • 582.

    Mirtallo JM, Rogers KR, Johnson JA et al. Stability of amino acids and the availability of acid in total parenteral nutrition solutions containing hydrochloric acid. Am J Hosp Pharm. 1981; 38:1729–31. [PubMed 6795923]

  • 583.

    Rusho WJ, Standish R. A comparison of crystalline amino acid solutions for total parenteral nutrition. Hosp Formul. 1981; 16:29–33.

  • 584.

    Anon. Guidelines for essential trace element preparations for parenteral use. A statement by an expert panel. AMA Department of Foods and Nutrition. JAMA. 1979; 241:2051–54. [PubMed 107339]

  • 585.

    Freund H, Atamian S, Fischer JE. Chromium deficiency during total parenteral nutrition. JAMA. 1979; 241:496–8. [PubMed 104057]

  • 586.

    Heller RM, Kirchner SG, O’Neill JA et al. Skeletal changes of copper deficiency in infants receiving prolonged total parenteral nutrition. J Pediatr. 1978; 92:947–9. [PubMed 96240]

  • 587.

    Moran DM, Russo J. Zinc deficiency dermatitis accompanying parenteral nutrition supplemented with trace elements. Clin Pharm. 1982; 1:169–76. [PubMed 6821033]

  • 588.

    Askari A, Long CL, Blakemore WS. Zinc, copper, and parenteral nutrition in cancer. A review. JPEN J Parenter Enteral Nutr. 1980; 4:561–71. [PubMed 6780709]

  • 589.

    Wolman SL, Anderson GH, Marliss EB et al. Zinc in total parenteral nutrition: requirements and metabolic effects. Gastroenterology. 1979; 76:458–67. [PubMed 107057]

  • 590.

    Fliss DM, Lamy PP. Trace elements and total parenteral nutrition. Hosp Formul. 1979; 14:698–717.

  • 591.

    Schneider PJ. Total parenteral nutrition: Part II: What goes into parenteral nutrition solutions?. J Postgrad Pharm (Hosp Ed). 1979; 1:18–27.

  • 592.

    Isaacs JW, Millikan WJ, Stackhouse J et al. Parenteral nutrition of adults with a 900 milliosmolar solution via peripheral veins. Am J Clin Nutr. 1977; 30:552–9. [PubMed 403755]

  • 593.

    Romankiewicz JA, McManus J, Gotz VP et al. Medications not to be refrigerated. Am J Hosp Pharm. 1979; 36:1541–5. [PubMed 517543]

  • 594.

    Swerling R. Dilution of oral and intravenous aminophylline preparations. Am J Hosp Pharm. 1981; 38:1359–60. [PubMed 7282723]

  • 595.

    Alcorn BT, Barnes SG. Pharmacy-initiated intravenous infusion guidelines. Hosp Pharm. 1982; 17:60–76. [PubMed 10254548]

  • 596.

    Bowtle WJ, Heasman MJ, Prince AP et al. Compatibility of the cephalosporin, cefamandole nafate, with injections. Int J Pharm. 1980; 4:263–5.

  • 597.

    Anon. I.V. dosage guidelines for theophylline products. FDA Drug Bull. 1980; 10:4–5. [PubMed 7358241]

  • 598.

    Tipple M, Shadomy S. Availability of active amphotericin B after filtration through membrane filters. Am Rev Resp Dis. 1977; 115:879–81. [PubMed 857722]

  • 599.

    Maddux MS, Barriere SL. A review of complications of amphotericin B therapy: recommendations for prevention and management. Drug Intell Clin Pharm. 1980; 14:177–81.

  • 600.

    Lufter CH, Ball WD. Activity of amphotericin B after filtration. Drug Intell Clin Pharm. 1980; 14:719.

  • 601.

    Kuchinskas EJ, Levy GN. Comparative stabilities of ampicillin and hetacillin in aqueous solutions. J Pharm Sci. 1972; 61:727–9. [PubMed 4338497]

  • 602.

    Schwartz MA, Hayton WL. Relative stability of hetacillin and ampicillin in solution. J Pharm Sci. 1972; 61:906–9. [PubMed 4339954]

  • 603.

    Bundgaard H. Polymerization of penicillins: kinetics and mechanism of di- and polymerization of ampicillin in aqueous solution. Acta Pharm Suec. 1976; 13:9–26. [PubMed 3942]

  • 604.

    Stjernstrom G, Olson OT, Nyqvist H et al. Studies on the stability and compatibility of drugs in infusion fluids 6. Factors affecting the stability of ampicillin. Acta Pharm Suec. 1978; 15:33–50. [PubMed 25558]

  • 605.

    Johnson CA, Porter WA. Compatibility of azathioprine sodium with intravenous fluids. Am J Hosp Pharm. 1981; 38:871–5. [PubMed 7246562]

  • 606.

    Kowaluk EA, Roberts MS. Interactions between drugs and intravenous delivery systems. Am J Hosp Pharm. 1982; 39:460–7. [PubMed 7072732]

  • 607.

    Bryan CK, Darby MH. Bretylium tosylate: a review. Am J Hosp Pharm. 1979; 36:1189–92. [PubMed 386786]

  • 608.

    Henry RS, Jurgens RW, Sturgeon R et al. Compatibility of calcium chloride and calcium gluconate with sodium phosphate in a mixed TPN solution. Am J Hosp Pharm. 1980; 37:673–4. [PubMed 6770681]

  • 609.

    Eggert LD, Rusho WJ, MacKay MW et al. Calcium and phosphorus compatibility in parenteral nutrition solutions for neonates. Am J Hosp Pharm. 1982; 39:49–53. [PubMed 6798868]

  • 610.

    Robinson LA, Wright BT. Central venous catheter occlusion caused by body-heat-mediated calcium phosphate precipitation. Am J Hosp Pharm. 1982; 39:120–1. [PubMed 6798866]

  • 611.

    Tuttle CB. Guidelines for phenytoin infusions. Can J Hosp Pharm. 1984; 37:137–9. [PubMed 10269318]

  • 612.

    Stewart P, Lourwood D. Guidelines for the administration of a phenytoin loading dose via IVPB. Hosp Pharm. 1986; 21:1003–4.

  • 613.

    Goldschmied S. An evaluation of the stability and safety of phenytoin infusion. NY State J Pharm. 1987; 7:45–7.

  • 614.

    Kradjan WA, Burger R. In vivo inactivation of gentamicin by carbenicillin and ticarcillin. Arch Intern Med. 1980; 140:1668–70. [PubMed 7458498]

  • 615.

    Young LS, Decker G. Inactivation of gentamicin by carbenicillin in the urinary tract. Chemotherapy. 1974; 20:212–20. [PubMed 4413818]

  • 616.

    Henderson JL, Polk RE. In vitro inactivation of gentamicin, tobramycin, and netilmicin by carbenicillin, azlocillin, or mezlocillin. Am J Hosp Pharm. 1981; 38:1167–70. [PubMed 6455916]

  • 617.

    Flournoy DJ. Inactivation of netilmicin by carbenicillin. Infection. 1978; 6:241. [PubMed 730393]

  • 618.

    Russo ME. Penicillin-aminoglycoside inactivation: another possible mechanism of interaction. Am J Hosp Pharm. 1980; 37:702–4. [PubMed 7386483]

  • 619.

    Laskar PA, Ayres JW. Degradation of carmustine in aqueous media. J Pharm Sci. 1977; 66:1073–6. [PubMed 19612]

  • 620.

    Cardi V, Willcox GS. Reconstituting cefamandole and protecting from light. Am J Hosp Pharm. 1980; 37:334. [PubMed 7369213]

  • 621.

    Kaiser GV, Gorman M. Cefamandole—a review of chemistry and microbiology. J Infect Dis. 1978; 137:S10–S16. [PubMed 565798]

  • 622.

    Wold JS, Joost RR, Black HR et al. Hydrolysis of cefamandole nafate to cefamandole in vivo. J Infect Dis. 1978; 137:S17–S24. [PubMed 650001]

  • 623.

    Palmer MA, Fraterrigo CC. Clarification of “explosive-like’’ reaction occurring when reconstituted cefamandole nafate was stored in syringes. Am J Hosp Pharm. 1979; 36:1025. [PubMed 484557]

  • 624.

    Fites AL. Reconstituting cefamandole and protecting from light. Am J Hosp Pharm. 1980; 37:334.

  • 625.

    Foster TS, Shrewsbury RP, Coonrod JD. Bioavailability and pain study of cefamandole nafate. J Clin Pharmacol. 1980; 20:526–33. [PubMed 7000857]

  • 626.

    Indelicato JM, Stewart BA. Formylation of glucose by cefamandole nafate at alkaline pH. J Pharm Sci. 1980; 69:1183–8. [PubMed 7420288]

  • 627.

    Tomecko GW, Kleinberg ML, Latiolais CL et al. Stability of cefazolin sodium admixtures in plastic bags after thawing by microwave radiation. Am J Hosp Pharm. 1980; 37:211–5. [PubMed 7361792]

  • 628.

    Janousek JP, Minisci MP. An evaluation of cefazolin sodium injection in an IV piggyback bottle. Infusion. 1978; 2:67–73.

  • 629.

    Stiles ML. Effect of microwave radiation on the stability of frozen cefoxitin sodium solution in plastic bags. Am J Hosp Pharm. 1981; 38:1743–5. [PubMed 7304629]

  • 630.

    Oberholtzer ER, Brenner GS. Cefoxitin sodium: solution and solid state chemical stability studies. J Pharm Sci. 1979; 68:863–6. [PubMed 458604]

  • 631.

    Bray RJ, Davies PA. The stability of preservative-free morphine in plastic syringes. Anaesthesia. 1986; 41:294–5. [PubMed 3963333]

  • 632.

    Walker SE, Paton TW, Fabian TM et al. Stability and sterility of cimetidine admixtures frozen in minibags. Am J Hosp Pharm. 1981; 38:881–3. [PubMed 7246565]

  • 633.

    Cohen MR. Error 148—More on cisplatin storage. Hosp Pharm. 1980; 15:158–9.

  • 634.

    LeRoy AF. Some quantitative data on cis-dichlorodiammineplatinum (II) species in solution. Cancer Treat Rep. 1979; 63:231–3. [PubMed 36228]

  • 635.

    Hincal AA, Long DF. Cis-platin stability in aqueous parenteral vehicles. J Parenter Drug Assoc. 1979; 33:107–16. [PubMed 256991]

  • 636.

    Mariani EP, Southard BJ, Woolever JT, et al. Physical compatibility and chemical stability of cisplatin in various diluents and in large-volume parenteral solutions. In: Cisplatin current status and new developments. New York, NY: Academic Press; 1980:305–16.

  • 637.

    Repta AJ, Long DF. cis-Dichlorodiammineplatinum (II) stability in aqueous vehicles. Cancer Treat Rep. 1979; 63:229–30. [PubMed 445501]

  • 638.

    Gamble JA, Dundee JW, Assaf RA. Plasma diazepam levels after single dose oral and intramuscular administration. Anaesthesia. 1975; 30:164–9. [PubMed 1093427]

  • 639.

    Langdon DE, Harlan JR, Bailey RL. Thrombophlebitis with diazepam used intravenously. JAMA. 1973; 223:184–5. [PubMed 4569819]

  • 640.

    Dam M, Christiansen J. Diazepam: intravenous infusion in the treatment of status epilepticus. Acta Neurol Scand. 1976; 54:278–80. [PubMed 961379]

  • 641.

    Huber JW, Raymond GG. Additional conclusions on diazepam injectable precipitate: GC-MS confirmation. Clin Toxicol. 1979; 14:439–44. [PubMed 466985]

  • 642.

    Raymond G, Huber JW. Identification of injectable Valium precipitate. Drug Intell Clin Pharm. 1979; 13:612.

  • 643.

    Newton DW, Driscoll DF, Goudreau JL et al. Solubility characteristics of diazepam in aqueous admixture solutions: theory and practice. Am J Hosp Pharm. 1981; 38:179–82. [PubMed 7211883]

  • 644.

    Mason NA, Cline S, Hyneck ML et al. Factors affecting diazepam infusion: solubility, administration-set composition, and flow rate. Am J Hosp Pharm. 1981; 38:1449–54. [PubMed 7294034]

  • 645.

    MacKichan J, Duffner PK. Adsorption of diazepam to plastic tubing. N Engl J Med. 1979; 301:332–3. [PubMed 450030]

  • 646.

    Parker WA, MacCara ME. Compatibility of diazepam with intravenous fluid containers and administration sets. Am J Hosp Pharm. 1980; 37:496–500. [PubMed 7377212]

  • 647.

    Cloyd JC, Vezeau C. Availability of diazepam from plastic containers. Am J Hosp Pharm. 1980; 37:492–6. [PubMed 7377211]

  • 648.

    Cloyd JC. Diluting diazepam injection. Am J Hosp Pharm. 1981; 38:32.

  • 649.

    Dasta JF, Brier K. Loss of diazepam to drug delivery systems. Am J Hosp Pharm. 1980; 37:1176. [PubMed 7416168]

  • 650.

    Boatman JA, Johnson JB. A four-stage approach to new-drug development. Pharm Tech. 1981; 5:46–56.

  • 651.

    Martin CM. Chemical incompatibility of Renografin 76 and protamine sulfate. Am Heart J. 1976; 91:675–7. [PubMed 1266726]

  • 652.

    Hoffman DM, Grossano DD, Damin L et al. Stability of refrigerated and frozen solutions of doxorubicin hydrochloride. Am J Hosp Pharm. 1979; 36:1536–8. [PubMed 517541]

  • 653.

    Gardiner WA. Possible incompatibility of doxorubicin hydrochloride with aluminum. Am J Hosp Pharm. 1981; 38:1276. [PubMed 7282707]

  • 654.

    Pfaller MA, Granich GG, Valdes R et al. Comparative study of the ability of four aminoglycoside assay techniques to detect the inactivation of aminoglycosides by beta-lactam antibiotics. Diagn Microbiol Infect Dis. 1984; 2:93–100. [PubMed 6370573]

  • 655.

    Hospira Inc. Product information on Liposyn III 10%, 20%, and 30%. Lake Forest, IL; 2005 Aug/Sep.

  • 656.

    Black CD, Popovich NG. Study of intravenous emulsion compatibility: effects of dextrose, amino acids and selected electrolytes. Drug Intell Clin Pharm. 1981; 15:184–93. [PubMed 7274033]

  • 657.

    Black CD, Popovich NG. Comment on intravenous emulsion compatibility. Drug Intell Clin Pharm. 1981; 15:908–9. [PubMed 7297424]

  • 658.

    Pelham LD. Rational use of intravenous fat emulsions. Am J Hosp Pharm. 1981; 38:198–208. [PubMed 6782871]

  • 659.

    Solussol C. Long-term parenteral nutrition: an artificial gut. Int Surg. 1976; 61:266–70. [PubMed 819387]

  • 660.

    Wretlind A. Current status of intralipid and other fat emulsions. In: Fat emulsion in parenteral nutrition. Chicago, IL: American Medical Association; 1975:109–19.

  • 661.

    Higbee KC, Lamy PP. Use of Intralipid in neonates and infants. Hosp Formul. (Feb) 1980; 15:117–9, 122, 127.

  • 662.

    Kleinberg ML, Stauffer GL. Effect of microwave radiation on redissolving precipitated matter in fluorouracil injection. Am J Hosp Pharm. 1980; 37:678–9. [PubMed 7386478]

  • 663.

    Driessen O, deVos D. Adsorption of fluorouracil on glass surfaces. J Pharm Sci. 1978; 67:1494–5. [PubMed 702318]

  • 664.

    Ghanekar AG, Das Gupta V. Stability of furosemide in aqueous systems. J Pharm Sci. 1978; 67:808–11. [PubMed 660463]

  • 665.

    McLaughlin JE, Reeves DS. Gentamicin plus carbenicillin. Lancet. 1971; 1:864–5. [PubMed 4102117]

  • 666.

    Young LS, Decker G. Inactivation of gentamicin by carbenicillin in the urinary tract. Chemotherapy. 1974; 20:212–20. [PubMed 4413818]

  • 667.

    Murillo J, Standiford HC, Schimpff SC et al. Gentamicin and ticarcillin serum levels. JAMA. 1979; 241:2401–3. [PubMed 439317]

  • 668.

    Storey P, Hill HH, St. Louis RH, et al. Subcutaneous infusions for control of cancer symptoms. J Pain Symptom Manag. 1990; 5:33–41.

  • 669.

    Edwards ND, Fletcher A, Cole JR et al. Combined infusions of morphine and ketamine for postoperative pain in elderly patients. Anaesthesia. 1993; 48:124–7. [PubMed 8460758]

  • 670.

    Dormarunno CG (Associate Medical Information Scientist, Medical and Drug Information, Pharmacia Corp., Kalamazoo, MI): Personal communication; 2002 Mar 21.

  • 671.

    Liles S (Department of Pharmacy, Christ Hospital, Cincinnati, OH): Personal communication; 2002 Feb 20.

  • 672.

    Hayes DM, Reilly RM. The pharmaceutical stability of deferoxamine mesylate. Can J Hosp Pharm. 1994; 47:9–14.

  • 673.

    Downie G, McRae N. Leaching of plasticizers by fat emulsion from polyvinyl chloride. Br J Parenter Ther. 1985; 6:142–4.

  • 674.

    Anderson W, Harthill JE, Couper IA et al. Heparin stability in dextrose solutions [proceedings]. J Pharm Pharmacol. 1977; 29:31P. [PubMed 22661]

  • 675.

    Bowie HM, Haylor V. Stability of heparin in sodium chloride solution. J Clin Pharm. 1978; 3:211–4.

  • 676.

    Tunbridge LJ, Lloyd JV, Penhall RK et al. Stability of diluted heparin sodium stored in plastic syringes. Am J Hosp Pharm. 1981; 38:1001–4. [PubMed 7258195]

  • 677.

    Deeb EN, DiMattia PE. Standardization of heparin-lock maintenance solution. N Engl J Med. 1976; 294:448. [PubMed 1246325]

  • 678.

    Holford NHG, Vozeh S, Coates P et al. More on heparin lock. N Engl J Med. 1977; 296:1300–1. [PubMed 859528]

  • 679.

    Lynch CL, Linder GE. Frequently asked questions about insulin. Hosp Pharm. 1980; 15:213–4.

  • 680.

    Graham DT, Pomeroy AR. Effects of freezing on commercial insulin suspensions. Int J Pharm. 1978; 1:315–22.

  • 681.

    Hill JB. Adsorption of insulin to glass. Proc Soc Exp Biol Med. 1959; 102:75–7. [PubMed 13852370]

  • 682.

    Hill JB. The adsorption of I131-insulin to glass. Endocrinology. 1959; 65:515–7. [PubMed 13852371]

  • 683.

    Wiseman R, Baltz BE. Prevention of insulin-I131 adsorption to glass. Endocrinology. 1961; 68:354–6. [PubMed 13786004]

  • 684.

    Sonksen PH, Ellis JP, Lowy C et al. Quantitative evaluation of the relative efficiency of gelatine and albumin in preventing insulin adsorption to glass. Diabetologia. 1965; 1:208–10.

  • 685.

    Suess V, Froesch ER. Zur therapie des coma diabeticum: quantitative bedeutung des insulinuerlusts am infusionsbesteck. Schweizer Med Wochanschr. 1975; 105:1315–8.

  • 686.

    Okamoto H, Kikuchi T. Adsorption of insulin to infusion bottles and plastic intravenous tubing. Yakuzaigaku. 1979; 39:107–11.

  • 687.

    Wingert TD, Levin SR. Insulin adsorption to an air-eliminating inline filter. Am J Hosp Pharm. 1981; 38:382–3. [PubMed 7013477]

  • 688.

    Hirsch JI, Wood JH. Insulin adsorption to polyolefin infusion bottles and polyvinyl chloride administration sets. Am J Hosp Pharm. 1981; 38:995–7. [PubMed 7020415]

  • 689.

    Kerchner J, Cocaluca DM. Effect of whole blood on insulin adsorption onto intravenous infusion systems. Am J Hosp Pharm. 1980; 37:1323–5. [PubMed 6999896]

  • 690.

    Galloway JA, Bressler R. Insulin treatment in diabetes. Med Clin N Am. 1978; 62:663–80. [PubMed 98674]

  • 691.

    Anon. Letter: Carrier solutions for low-level intravenous insulin infusion. Br Med J. 1976; 1:151–2.

  • 692.

    Wan KK, Tsallas G. Dilute iron dextran formulation for addition to parenteral nutrient solutions. Am J Hosp Pharm. 1980; 37:206–10. [PubMed 6767401]

  • 693.

    Bornstein M, Lo AY, Thomas PN et al. Moxalactam disodium compatibility with intramuscular and intravenous diluents. Am J Hosp Pharm. 1982; 39:1495–8. [PubMed 6215859]

  • 694.

    Kleinberg ML, Latiolais CJ. Use of a microwave oven to redissolve crystallized mannitol injection (25%) in ampuls. Hosp Pharm. 1979; 14:391–2.

  • 695.

    Hanson GG. Microwave oven explosion. Hosp Pharm. 1979; 14:612.

  • 696.

    Kleinberg ML, Latiolais CJ. Microwave oven explosion. Hosp Pharm. 1979; 14:612.

  • 697.

    Kana MJ. Microwave oven explosion. Hosp Pharm. 1980; 15:104.

  • 698.

    Post RE, Stephen SP. A warming cabinet for storing mannitol ampuls. Hosp Pharm. 1975; 10:102–3. [PubMed 10237869]

  • 699.

    Scott KR, Bell AF, Thomas AJ. Warming kettle for storing mannitol injection. Am J Hosp Pharm. 1980; 37:16.

  • 700.

    Herring P. Keeping mannitol in solution. Hosp Pharm. 1980; 15:530–1.

  • 701.

    Church JJ. Continuous narcotic infusions for relief of postoperative pain. Br Med J. 1979; 1:977–9. [PubMed 435951][Free Fulltext PMC]

  • 702.

    Townsend RJ, Puchala AH. Stability of methylprednisolone sodium succinate in small volumes of 5% dextrose and 0.9% sodium chloride injections. Am J Hosp Pharm. 1981; 38:1319–22. [PubMed 7025616]

  • 703.

    Knutsen CV, Epps DR, McCormick DC et al. Total nutrient admixture guidelines. Drug Intell Clin Pharm. 1984; 18:253–4. [PubMed 6421559]

  • 704.

    Riggle MA, Brandt RB. Decomposition of TPN solutions. J Pediatr. 1982; 100:670. [PubMed 7062224]

  • 705.

    Freund HR, Rimon B, Muggia-Sullam M, et al. The “All in one” system for TPN causes increased rates of catheter blockade. J Parenter Enteral Nutr. 1986; 10:543.

  • 706.

    Cohen MR. Hazard warning—Flagyl IV (metronidazole hydrochloride) product reconstitution. Hosp Pharm. 1981; 16:398.

  • 707.

    Little GB, Boylan JC. I.V. Flagyl reacts with aluminum. Hosp Pharm. 1981; 16:627.

  • 708.

    Carmichael RR, Mahoney CD. Solubility and stability of phenytoin sodium when mixed with intravenous solutions. Am J Hosp Pharm. 1980; 37:95–8. [PubMed 7361779]

  • 709.

    Salem RB, Yost RL, Torosian G et al. Investigation of the crystallization of phenytoin in normal saline. Drug Intell Clin Pharm. 1980; 14:605–8.

  • 710.

    Pfeifle CE, Adler DS. Phenytoin sodium solubility in three intravenous solutions. Am J Hosp Pharm. 1981; 38:358–2. [PubMed 7223749]

  • 712.

    Gupta VD, Stewart KR. Stability of cefuroxime sodium in some aqueous buffered solutions and intravenous admixtures. J Clin Hosp Pharm. 1986; 11:47–54. [PubMed 3958213]

  • 713.

    Newton DW, Kluza RB. Prediction of phenytoin solubility in intravenous admixtures: physicochemical theory. Am J Hosp Pharm. 1980; 37:1647–51. [PubMed 7446539]

  • 714.

    Cohen MR. Make sure your nurses mix drug additions to infusing I.V. solutions. Hosp Pharm. 1981; 16:164.

  • 715.

    Schuna A, Nappi J, Kolstad J. Potassium pooling in non-rigid parenteral fluid containers. J Parenter Drug Assoc. 1979; 33:184–6. [PubMed 260935]

  • 716.

    McCloskey WW, Jeffrey LP. Rational ordering of phosphate supplements. Hosp Pharm. 1979; 14:486–7.

  • 717.

    Herman JJ. Phosphate: its valence and methods of quantification in parenteral solutions. Drug Intell Clin Pharm. 1979; 13:579–85.

  • 718.

    Benderev K. Hypophosphatemia and phosphorus supplementation. Hosp Pharm. 1980; 15:611–3.

  • 719.

    Swerling R. Use and preparation of cardioplegic solutions in cardiac surgery. Hosp Pharm. 1980; 15:497–503.

  • 720.

    Loucas SP, Mehl B, Maager P et al. Stability of procaine HCl in a buffered cardioplegia formulation. Am J Hosp Pharm. 1981; 38:1924–8. [PubMed 7325175]

  • 721.

    Amann AH, Baaske DM. Plastic i.v. container for nitroglycerin. Am J Hosp Pharm. 1980; 37:618. [PubMed 6770680]

  • 722.

    Cacace LG, Harralson A, Clougherty T. Stability of NTG. Am Heart J. 1979; 97:817–8. [PubMed 107777]

  • 723.

    Yuen PH, Denman SL, Sokoloski TD et al. Loss of nitroglycerin from aqueous solution into plastic intravenous delivery systems. J Pharm Sci. 1979; 68:1163–6. [PubMed 115988]

  • 724.

    Baaske DM, Amann AH, Wagenknecht DM et al. Nitroglycerin compatibility with intravenous fluid filters, containers, and administration sets. Am J Hosp Pharm. 1980; 37:201–5. [PubMed 6767400]

  • 725.

    Roberts MS, Cossum PA, Galbraith AJ et al. Availability of nitroglycerin from parenteral solutions. J Pharm Pharmacol. 1980; 32:237–44. [PubMed 6103051]

  • 726.

    Christiansen H, Skobba TJ, Andersen R et al. Nitroglycerin infusion—factors influencing the concentration of nitroglycerin available to the patient. J Clin Hosp Pharm. 1980; 5:209–15.

  • 727.

    Sokoloski TD, Wu CC. Rapid adsorptive loss of nitroglycerin from aqueous solution to plastic. Int J Pharm. 1980; 6:63–76.

  • 728.

    Baaske DM, Amann AH, Karnatz NN et al. Administration set for use with intravenous nitroglycerin. Am J Hosp Pharm. 1982; 39:121–2. [PubMed 6798867]

  • 729.

    Little LA, Hatheway GJ. Problems with administration devices for commercially available nitroglycerin injection. Am J Hosp Pharm. 1982; 39:400. [PubMed 6803587]

  • 730.

    Schad RF, Jennings R. Problems with administration devices for commercially available nitroglycerin injection. Am J Hosp Pharm. 1982; 39:400. [PubMed 6803587]

  • 731.

    Turco SJ. Problems with administration devices for commercially available nitroglycerin injection. Am J Hosp Pharm. 1982; 39:977. [PubMed 6808836]

  • 732.

    Vesey CJ, Batistoni GA. Determination and stability of sodium nitroprusside in aqueous solutions (determination and stability of SNP). J Clin Pharm. 1977; 2:105–7.

  • 733.

    Milewski B, Jones D. Photodecomposition. Hosp Pharm. 1981; 16:178.

  • 734.

    Nolly RJ, Stach PE, Latiolais CJ et al. Stability of thiamine hydrochloride repackaged in disposable syringes. Am J Hosp Pharm. 1982; 39:471–4. [PubMed 7072734]

  • 735.

    Polk RE, Kline BJ. Mail order tobramycin serum levels: low values caused by ticarcillin. Am J Hosp Pharm. 1980; 37:920. [PubMed 7395883]

  • 736.

    Seitz DJ, Archambault JR, Kresel JJ et al. Stability of tobramycin sulfate in plastic syringes. Am J Hosp Pharm. 1980; 37:1614–5. [PubMed 7446535]

  • 737.

    Levison ME, Knight R. In vitro evaluation of tobramycin, a new aminoglycoside antibiotic. Antimicrob Agents Chemother. 1972; 1:381–4. [PubMed 4670478][Free Fulltext PMC]

  • 738.

    Svensson LA. Stressed oxidative degradation of terbutaline in aqueous solution. Acta Pharm Suec. 1972; 9:141–6. [PubMed 5030542]

  • 739.

    Cutie MR. Compatibility of verapamil with other additives. Am J Hosp Pharm. 1981; 38:231. [PubMed 7211888]

  • 740.

    Lederle Laboratories. Hospital formulary monograph—Pipracil. Wayne, NJ; 1981 Nov.

  • 741.

    Chan KK, Giannini DD, Staroscik JA et al. 5-Azacytidine hydrolysis kinetics measured by high-pressure liquid chromatography and 13C-NMR spectroscopy. J Pharm Sci. 1979; 68:807–12. [PubMed 88514]

  • 742.

    Rubin M, Bilik R, Aserin A et al. Catheter obstruction: analysis of filter content of total nutrient admixture. J Parenter Enteral Nutr. 1989; 13:641–3.

  • 743.

    Flora KP, Smith SL. Application of a simple high-performance liquid chromatographic method for the determination of melphalan in the presence of its hydrolysis products. J Chromatogr. 1979; 177:91–7. [PubMed 536450]

  • 744.

    Palmer AJ, Sewell GJ, Rowland CG. Qualitative studies on ;ga-interferon-2b in prolonged continuous infusion regimes using gradient elution high-performance liquid chromatography. J Clin Pharm Ther. 1988; 13:225–31. [PubMed 3209630]

  • 745.

    Morris ME, Parker WA. Compatibility of chlordiazepoxide HCl injection following dilution. Can J Pharm Sci. 1981; 16:43–5.

  • 746.

    Cummings DS, Park MK. Compatibility of propranolol hydrochloride injection with intravenous infusion fluids in plastic containers. Am J Hosp Pharm. 1982; 39:1685–7. [PubMed 7148843]

  • 747.

    Deans KW, Lang JR. Stability of trimethoprim-sulfamethoxazole injection in five infusion fluids. Am J Hosp Pharm. 1982; 39:1681–4. [PubMed 6983297]

  • 748.

    Munson JW, Kubiak EJ. Cytosine arabinoside stability in intravenous admixtures with sodium bicarbonate and in plastic syringes. Drug Intell Clin Pharm. 1982; 16:765–7. [PubMed 6291888]

  • 749.

    Kirschenbaum HL, Aronoff W, Perentesis GP et al. Stability of dobutamine hydrochloride in selected large-volume parenterals. Am J Hosp Pharm. 1982; 39:1923–5. [PubMed 7148861]

  • 750.

    Ray JB, Newton DW, Nye MT et al. Droperidol stability in intravenous admixtures. Am J Hosp Pharm. 1983; 40:94–7. [PubMed 6823997]

  • 751.

    Das Gupta V, Stewart KR. Stability of cefotaxime sodium and moxalactam disodium in 5% dextrose and 0.9% sodium chloride injections. Am J IV Ther Clin Nutr. 27–9 (Jan) 1983; 10:20.

  • 752.

    Jett S, Eng SS. Prochlorperazine edisylate incompatibility. Am J Hosp Pharm. 1983; 40:210. [PubMed 6829573]

  • 753.

    Porter WR, Johnson CA, Cohon MS et al. Compatibility and stability of clindamycin phosphate with intravenous fluids. Am J Hosp Pharm. 1983; 40:91–4. [PubMed 6823996]

  • 754.

    Hittel WP, Iafrate RP, Karnes HT et al. Stability of pentobarbital sodium in 5% dextrose injection and 0.9% sodium chloride injection. Am J Hosp Pharm. 1983; 40:294–6. [PubMed 6829585]

  • 755.

    Niemiec PW, Vanderveen TW, Hohenwarter MW et al. Stability of aminophylline injection in three parenteral nutrition solutions. Am J Hosp Pharm. 1983; 40:428–32. [PubMed 6405614]

  • 756.

    Perentesis GP, Piltz GW, Kirschenbaum HL et al. Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives. Am J Hosp Pharm. 1983; 40:1010–2. [PubMed 6869385]

  • 757.

    Yuen PC, Taddei CR, Wyka BE et al. Compatibility and stability of labetalol hydrochloride in commonly used intravenous solutions. Am J Hosp Pharm. 1983; 40:1007–9. [PubMed 6869384]

  • 758.

    Pyter RA, Hsu LCC. Stability of methylprednisolone sodium succinate in 5% dextrose and 0.9% sodium chloride injection. Am J Hosp Pharm. 1983; 40:1329–33. [PubMed 6351604]

  • 759.

    Gannon PM, Sesin GP. Stability of cytarabine following repackaging in plastic syringes and glass containers. Am J IV Ther Clin Nutr. 1983; 10:11–6.

  • 760.

    Sesin GP, Millette LA. Stability study of 5-fluorouracil following repackaging in plastic disposable syringes and multidose vials. Am J IV Ther Clin Nutr. 29–30 (Sep) 1982; 9:23–5.

  • 761.

    Parker WA. Compatibility of perphenazine and butorphanol admixtures. Can J Hosp Pharm. 1981; 34:38.

  • 762.

    Jump WG, Plaza VM. Compatibility of nalbuphine hydrochloride with other preoperative medications. Am J Hosp Pharm. 1982; 39:841–3. [PubMed 7081259]

  • 763.

    Dorr RT, Peng YM, Alberts DS. Bleomycin compatibility with selected intravenous medications. J Med. 1982; 13(1–:2):121–30.

  • 764.

    Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm. 1983; 40:1205–7. [PubMed 6881161]

  • 765.

    Shively CD, Redford A. Flagyl I.V., drug-drug physical compatibility. Am J IV Ther Clin Nutr. 1981; 8:9–16.

  • 766.

    Souney PF, Steele L. Effect of vitamin B complex and ascorbic acid on the antimicrobial activity of cefazolin sodium. Am J Hosp Pharm. 1982; 39:840–1. [PubMed 7081258]

  • 767.

    Keller JH, Ensminger WD. Stability of cancer chemotherapeutic agents in a totally implanted drug delivery system. Am J Hosp Pharm. 1982; 39:1321–3. [PubMed 6214944]

  • 768.

    Rodanelli R, Comelli M, Pascale W et al. Clinical pharmacology of some antibiotics: problems relating to their intravenous use in hospitals. Farmaco Ed Prat. 1982; 37:185–8.

  • 769.

    Kowaluk EA, Roberts MS. Drug loss in polyolefin infusion systems. Am J Hosp Pharm. 1983; 40:118–9. [PubMed 6823983]

  • 770.

    Illum L, Bundgaard H. Sorption of drugs by plastic infusion bags. Int J Pharm. 1982; 10:339–51.

  • 771.

    Pfizer Laboratories. Vistaril IM, table of physical compatibilities. New York, NY; 1979 Jul.

  • 772.

    Abbott Laboratories. Package insert on Neut. North Chicago, IL; 1988 Oct.

  • 773.

    Jhunjhuowala VP, Bhalla HL. Sodium ampicillin: its stability in some large volume parenteral solutions. Indian J Hosp Pharm. 1981; 8:55–7.

  • 774.

    Scheiner JM, Araujo MM. Thiamine destruction by sodium bisulfite in infusion solutions. Am J Hosp Pharm. 1981; 38:1911–3. [PubMed 7325171]

  • 775.

    Kirschenbaum HL, Aronoff W, Perentesis GP et al. Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drug additives. Am J Hosp Pharm. 1982; 39:1013–5. [PubMed 7102682]

  • 776.

    Lackner TE, Baldus D, Butler CD et al. Lidocaine stability in cardioplegic solution stored in glass bottles and polyvinyl chloride bags. Am J Hosp Pharm. 1983; 40:97–101. [PubMed 6823998]

  • 777.

    Russell WJ, Meyer-Witting M. The stability of atracurium in clinical practice. Anaesth Intens Care. 1990; 18:550–2.

  • 778.

    Shank WA, Coupal JJ. Stability of digoxin in common large-volume injections. Am J Hosp Pharm. 1982; 39:844–6. [PubMed 7081261]

  • 779.

    Solomon DA, Nasinnyk KK. Compatibility of haloperidol lactate and heparin sodium. Am J Hosp Pharm. 1982; 39:843–4. [PubMed 7081260]

  • 780.

    Elliott GT, McKenzie MW, Curry SH et al. Stability of cimetidine hydrochloride in admixtures after microwave thawing. Am J Hosp Pharm. 1983; 40:1002–6. [PubMed 6869383]

  • 781.

    Tsallas G, Allen LC. Stability of cimetidine hydrochloride in parenteral nutrition solutions. Am J Hosp Pharm. 1982; 39:484–5. [PubMed 6803588]

  • 782.

    Roberts MS, Cossum PA, Kowaluk EA et al. Plastic syringes and intravenous infusions. Med J Aust. 1981; 2:580–1. [PubMed 6801447]

  • 783.

    Das Gupta V, Stewart KR. Effect of tobramycin on the stability of carbenicillin disodium. Am J Hosp Pharm. 1983; 40:1013–6. [PubMed 6869386]

  • 784.

    Simmons A, Allwood MC. Sorption to plastic syringes of drugs administered by syringe pump. J Clin Hosp Pharm. 1981; 6:71–3. [PubMed 7345099]

  • 785.

    Nicholas E, Hess G. Degradation of penicillin, ticarcillin and carbenicillin resulting from storage of unit doses. N Engl J Med. 1982; 306:547–8. [PubMed 7057866]

  • 786.

    Carpenter JP, Gomez EA. Administration of lorazepam injection through intravenous tubing. Am J Hosp Pharm. 1981; 38:1514–6. [PubMed 6117200]

  • 787.

    Newton DW, Narducci WA, Leet WA et al. Lorazepam solubility in and sorption from intravenous admixture solutions. Am J Hosp Pharm. 1983; 40:424–7. [PubMed 6133447]

  • 788.

    Frable RA, Klink PR, Engel GL et al. Stability of cefamandole nafate injection with parenteral solutions and additives. Am J Hosp Pharm. 1982; 39:622–7. [PubMed 7082453]

  • 789.

    Kirschenbaum HL, Aronoff W, Piltz GW et al. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm. 1983; 40:1690–1. [PubMed 6638033]

  • 790.

    Bosch EH, van Doorne H, Brouwers JRBJ et al. Vermindering van het sufentanilgehalte bij de bereiding en tijdens het gebruik van een epidurale toedieningsvorm. Een orienterend onderzoek. Ziekenhuisfarmacie. 1993; 9:97–101.

  • 791.

    Cairns CJ. Incompatibility of amiodarone. Pharm J. 1986; 236:68.

  • 792.

    Roney JV (Scientific Services, Hoechst-Roussel Pharmaceuinticals, Somerville, NJ): Personal communication; 1983 Dec 4.

  • 793.

    Berge SM, Henderson NL. Kinetics and mechanism of degradation of cefotaxime sodium in aqueous solution. J Pharm Sci. 1983; 72:59–63. [PubMed 6298400]

  • 794.

    Smith FM, Nuessle NO. Stability of diazepam injection repackaged in glass unit-dose syringes. Am J Hosp Pharm. 1982; 39:1687–90. [PubMed 7148844]

  • 795.

    Cossum PA, Roberts MS. Availability of isosorbide dinitrate, diazepam and chlormethiazole from I.V. delivery systems. Eur J Clin Pharmacol. 1981; 19:181–5. [PubMed 7215415]

  • 796.

    Smith A, Bird G. Compatibility of diazepam with infusion fluids and their containers. J Clin Hosp Pharm. 1982; 7:181–6. [PubMed 7174833]

  • 797.

    Yliruusi JK, Sothmann AG, Laine RH et al. Sorptive loss of diazepam and nitroglycerin from solutions to three types of containers. Am J Hosp Pharm. 1982; 39:1018–21. [PubMed 6808834]

  • 798.

    Kuhlman J, Abshagen U. Cleavage of glycosidic bonds of digoxin and derivatives as function of pH and time. Naunyn Schmiedebergs Arch Pharmacol. 1973; 276:149–56. [PubMed 4268465]

  • 799.

    Gault MH, Charles JD, Sugden DL et al. Hydrolysis of digoxin by acid. J Pharm Pharmacol. 1977; 29:27–32. [PubMed 13178]

  • 800.

    Sternson LA, Shaffer RD. Kinetics of digoxin stability in aqueous solution. J Pharm Sci. 1978; 67:327–30. [PubMed 25324]

  • 801.

    Khalil SA, El-Masry S. Instability of digoxin in acid medium using a nonisotopic method. J Pharm Sci. 1978; 67:1358–60. [PubMed 29955]

  • 802.

    Fagerman KE, Dean RE. Daily digoxin administration in parenteral nutrition solution. Am J Hosp Pharm. 1981; 38:1955. [PubMed 6798864]

  • 803.

    Patterson MJ, Tjokrosetio R. Stability of adrenaline injection BP following resterilization. Aust J Hosp Pharm. 1981; 11:21–2.

  • 804.

    Nazeravich DR, Otlen NHH. Effect of inline filtration on delivery of gentamicin at a slow infusion rate. Am J Hosp Pharm. 1983; 40:1961–4. [PubMed 6650527]

  • 805.

    Zell M, Paone RP. Stability of insulin in plastic syringes. Am J Hosp Pharm. 1983; 40:637–8. [PubMed 6342381]

  • 806.

    Benvenuto JA. Errors in oncolytic agent stability study. Am J Hosp Pharm. 1983; 40:1628. [PubMed 6638024]

  • 807.

    Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol. 1983; 37:129–132. [PubMed 6620045]

  • 808.

    Gove L. Antibiotic interactions. Pharm J. 1983; 231:233.

  • 809.

    Ennis CE, Merritt RJ, Neff DN. In vitro study of in line filtration of medications commonly administered to pediatric cancer patients. JPEN J Parenter Enteral Nutr. 1983; 7:156–8. [PubMed 6406704]

  • 810.

    Buxton PC, Conduit SM. Stability of parentrovite in infusion fluids. Br J IV Ther. 1983; 4:5.

  • 811.

    Das Gupta V, Stewart KR. Stability of dobutamine hydrochloride and verapamil hydrochloride in 0.9% sodium chloride and 5% dextrose injections. Am J Hosp Pharm. 1984; 41:686–9. [PubMed 6720710]

  • 812.

    Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm. 1984; 41:949–51. [PubMed 6731457]

  • 813.

    Souney PF, Colucci RD, Mariani G et al. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm. 1984; 41:323–4. [PubMed 6702842]

  • 814.

    Lundergan FS, Lombardi TP, Neilan GE et al. Stability of tobramycin sulfate mixed with oxacillin sodium and nafcillin sodium in human serum. Am J Hosp Pharm. 1984; 41:144–5. [PubMed 6695930]

  • 815.

    Parker WA. Physical compatibility update of preoperative medications. Hosp Pharm. 1984; 19:475–8.

  • 816.

    Hale DC, Jenkins R. In-vitro inactivation of aminoglycoside antibiotics by piperacillin and carbenicillin. Am J Clin Pathol. 1980; 74:316–9. [PubMed 6447998]

  • 817.

    Rank DM, Packer AM. In vitro inactivation of tobramycin by penicillins. Am J Hosp Pharm. 1984; 41:1187–8. [PubMed 6741967]

  • 818.

    Karlsen J, Thonnesen HH, Olsen IR et al. Stability of cytotoxic intravenous solutions subjected to freeze-thaw treatment. Nor Pharm Acta. 1983; 45:61–7.

  • 819.

    Cheung YW, Vishnuvajjala BR. Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures. Am J Hosp Pharm. 1984; 41:1802–6. [PubMed 6496516]

  • 820.

    Bundgaard H, Larsen C. Influence of carbohydrates and polyhydric alcohols on the stability of cephalosporins in aqueous solution. Int J Pharm. 1983; 16:319–25.

  • 821.

    Hamilton G. Adverse reactions to intravenous pyelography contrast agents. Can Med Assoc J. 1983; 129:405–6. [PubMed 6883227][Free Fulltext PMC]

  • 822.

    Miller B, Pesko L. Effect of freezing on particulate matter concentrations in five antibiotic solutions. Am J IV Ther Clin Nutr. 1984; 11:19–22.

  • 823.

    Wagman GH, Bailey JV. Binding of aminoglycoside antibiotics to filtration materials. Antimicrob Agents Chemother. 1975; 7:316–319. [PubMed 1137384][Free Fulltext PMC]

  • 824.

    Tindula RJ, Ambrose PJ. Aminoglycoside inactivation by penicillins and cephalosporins and its impact on drug-level monitoring. Drug Intell Clin Pharm. 1983; 17:906–8. [PubMed 6653408]

  • 825.

    Gillies IR. Physical stability of Intralipid following drug addition. Aust J Hosp Pharm. 1980; 10:118–20.

  • 826.

    Hardin TC, Clibon U, Page CP et al. Compatibility of 5-fluorouracil and total parenteral nutrition solutions. JPEN J Parenter Enteral Nutr. 1982; 6:163–5. [PubMed 6808179]

  • 827.

    Gaj E, Sesin GP. Evaluation of growth of five microorganisms in doxorubicin and floxuridine media. Pharm Manufacturing. 1984; 1:52–3.

  • 828.

    Gaj E, Griffin RE. Evaluation of growth of six microorganisms in fluorouracil, bacteriostatic sodium chloride 0.9% and sodium chloride 0.9% media. Hosp Pharm. 1983; 18:348–9.

  • 829.

    Turco SJ. Drug adsorption to membrane filters. Am J IV Ther Clin Nutr. 1982; 9:6.

  • 830.

    Robinson WA, Krebs LU. The “real stuff” for intrathecal injection during leukaemia therapy. Lancet. 1982; 1:283. [PubMed 6120300]

  • 831.

    Frear RS. Cefoperazone-aminoglycoside incompatibility. Am J Hosp Pharm. 1983; 40:564. [PubMed 6221660]

  • 832.

    O’Bey KA, Jim LK, Gee JP et al. Temperature dependence of the stability of tobramycin mixed with penicillins in human serum. Am J Hosp Pharm. 1982; 39:1005–8. [PubMed 7102681]

  • 833.

    Bhatia J, Mims LC. Effect of phototherapy on amino acid solutions containing multivitamins. J Pediatr. 1980; 96:284–6. [PubMed 7351598]

  • 834.

    Koshiro A, Fujita T. Interaction of penicillins with the components of plasma expanders. Drug Intell Clin Pharm. 1983; 17:351–6. [PubMed 6861624]

  • 835.

    Szucsova S, Slana M. Stability of infusion mixtures of 5% glucose solution with injection solutions. Farm Obzor. 1983; 52:209–13.

  • 836.

    Gillis J, Jones G, Pencharz P. Delivery of vitamins A, D, and E in total parenteral nutrition solutions. JPEN J Parenter Enteral Nutr. 1983; 7:11–4. [PubMed 6403727]

  • 837.

    Farago S. Compatibility of antibiotics and other drugs in total parenteral nutrition solutions. Can J Hosp Pharm. 1983; 36:43–51.

  • 838.

    Gaj E, Sesin GP. Compatibility of doxorubicin hydrochloride and vinblastine sulfate—stability of a solution stored in Cormed reservoir bags or Monoject plastic syringes. Am J IV Ther Clin Nutr. 13–14, 19–20 (May) 1984; 11:8–9.

  • 839.

    Bar-Or D, Kulig K, Marx JA et al. Precipitation of verapamil. Ann Intern Med. 1982; 97:619. [PubMed 6289717]

  • 840.

    Tucker R, Gentile JF. Precipitation of verapamil with nafcillin. Am J Hosp Pharm. 1984; 41:2588. [PubMed 6517077]

  • 841.

    Hasegawa GR, Eder JF. Dobutamine-heparin mixture inadvisable. Am J Hosp Pharm. 1984; 41:2588. [PubMed 6517078]

  • 842.

    Chen MF, Boyce HW, Triplett L. Stability of the B vitamins in mixed parenteral nutrition solution. JPEN J Parenter Enteral Nutr. 1983; 7:462–4. [PubMed 6417365]

  • 843.

    Bowman BB, Nguyen P. Stability of thiamin in parenteral nutrition solutions. JPEN J Parenter Enteral Nutr. 1983; 7:567–8. [PubMed 6418915]

  • 844.

    Newton DW. Physicochemical determinants of incompatibility and instability in injectable drug solutions and admixtures. Am J Hosp Pharm. 1978; 35:1213–22. [PubMed 358828]

  • 845.

    Newton DW. Physicochemical determinants of incompatibility and instability of drugs for injection and infusion. In: Trissel LA. Handbook on injectable drugs. 3rd ed. Bethesda, MD: American Society of Hospital Pharmacists; 1983:XI-XXI.

  • 846.

    Raymond G, Day P. Sodium content of commonly administered intravenous drugs. Hosp Pharm. 1982; 17:560–1.

  • 847.

    Rich DS. Recent information about inactivation of aminoglycosides by carbenicillin and ticarcillin: clinical implications. Hosp Pharm. 1983; 18:41–3.

  • 848.

    Lawrence RI, Flukes WK, Rust VJ et al. Total parenteral nutrition using a combined nutrient solution. Aust J Hosp Pharm. 1981; 11:540–2.

  • 849.

    Davis SS, Galloway M. Total parenteral nutrition. Pharm J. 1983; 6 (Jan 1 & 8):230.

  • 850.

    Travenol Laboratories. 3-in-1 admixture guide from Travenol. 1983 Nov.

  • 851.

    Chan JC, Malekzadeh M, Hurley H. pH and titratable acidity of amino acid mixtures used in hyperalimentation. JAMA. 1972; 220:1119–20. [PubMed 4623730]

  • 852.

    Kirk B, Sprake JM. Stability of aminophylline. Br J IV Ther. (Nov) 1982; 3:4, 6, 8.

  • 853.

    Vogenberg FR, Souney PF. Stability guidelines for routinely refrigerated drug products. Am J Hosp Pharm. 1983; 40:101–2. [PubMed 6823978]

  • 854.

    Niemiec PW, Vanderveen TW. Compatibility considerations in parenteral nutrient solutions. Am J Hosp Pharm. 1984; 41:893–911. [PubMed 6328980]

  • 855.

    Irving JD, Reynolds PV. Disposable syringe danger. Lancet. 1966; 1:362.

  • 856.

    Salter F (Bristol-Myers Squibb, Princeton, NJ): Personal communication; 1991 Feb 27.

  • 857.

    Hopefl AW. Clinical use of intravenous acyclovir. Drug Intell Clin Pharm. 1983; 17:623–8. [PubMed 6311503]

  • 858.

    Larsen C, Bundgaard H. Polymerization of penicillins VI. Time-course of formation of antigenic di- and polymerization products in aqueous ampicillin sodium solutions. Arch Pharm Chemi Sci Ed. 1977; 5:201–9.

  • 859.

    Carthy BJ, Hill GT. Some aspects of the analysis and stability of atracurium besylate. Anal Proc. 1983; 20:177–9.

  • 860.

    D’Arcy PF. Comment on handling of anticancer drugs. Drug Intell Clin Pharm. 1984; 18:417.

  • 861.

    Adams J, Wilson JP. Instability of bleomycin in plastic containers. Am J Hosp Pharm. 1982; 39:1636. [PubMed 6183973]

  • 862.

    Levin VA, Zackheim HS. Stability of carmustine for topical application. Arch Dermatol. 1982; 118:450–1. [PubMed 7092265]

  • 863.

    Chan KK, Zackheim HS. Stability of nitrosourea solutions. Arch Dermatol. 1973; 107:298. [PubMed 4685589]

  • 864.

    Teil SM, Arwood LL. Stability of gentamicin and cefamandole in serum. Am J Hosp Pharm. 1982; 39:485–6. [PubMed 7072738]

  • 865.

    Portnoff JB, Henley MW. Development of sodium cefoxitin as a dosage form. J Parenter Sci Technol. 1983; 37:180–5. [PubMed 6655535]

  • 866.

    Vaughan LM, Poon CY. Stability of ceftazidime and vancomycin alone and in combination in heparinized and nonheparinized peritoneal dialysis solution. Ann Pharmacother. 1994; 28:572–6. [PubMed 8068991]

  • 867.

    Muller RH, Heinemann S. Fat emulsions for parenteral nutrition. IV. Lipofundin MCT/LCT regimens for total parenteral nutrition (TPN) with high electrolyte load. Int J Pharm. 1994; 107:121–32.

  • 868.

    Sorkin EM, Darvey DC. Review of cimetidine drug interactions. Drug Intell Clin Pharm. 1983; 17:110–20. [PubMed 6130930]

  • 869.

    Raymond G, Day P. Multiple sources of sodium in injectable drugs. Drug Intell Clin Pharm. 1982; 16:703. [PubMed 7128464]

  • 870.

    Eshaque M, McKay MJ. D-Mannitol platinum complexes. Wadley Med Bull. 1977; 7:338–48.

  • 871.

    Ferguson DE. Degradation of clindamycin in frozen admixtures. Am J Hosp Pharm. 1982; 39:1156. [PubMed 7114056]

  • 872.

    Ausman RK, Holmes CJ, Kundsin RB et al. Degradation of clindamycin in frozen admixtures. Am J Hosp Pharm. 1982; 39:1156. [PubMed 7114056]

  • 873.

    Cairns CJ, Robertson J. Incompatibility of ceftazidime and vancomycin. Pharm J. 1987; 238:577.

  • 874.

    Sandoz. Sandimmune—pharmacy fact sheet. East Hanover, NJ; 1983 Nov.

  • 875.

    Senholzi CS, Kerus MP. Crystal formation after reconstituting cefazolin sodium with 0.9% sodium chloride injection. Am J Hosp Pharm. 1985; 42:129–30. [PubMed 3970029]

  • 876.

    Thompson DF, Allen LV, Desai SR et al. Compatibility of furosemide with aminoglycoside admixtures. Am J Hosp Pharm. 1985; 42:116–9. [PubMed 3970026]

  • 877.

    Geary TG, Akood MA, Jensen JB. Characteristics of chloroquine binding to glass and plastic. Am J Trop Med Hyg. 1983; 32:19–23. [PubMed 6824125]

  • 878.

    Yayon A, Ginsburg A. A method for the measurement of chloroquin uptake in erythrocytes. Anal Biochem. 1980; 107:332–6. [PubMed 7435966]

  • 879.

    D’Arcy PF. Drug interactions with medical plastics. Drug Intell Clin Pharm. 1983; 17:726–31. [PubMed 6414793]

  • 880.

    Kowaluk EA, Roberts MS. Factors affecting the availability of diazepam stored in plastic bags and administered through intravenous sets. Am J Hosp Pharm. 1983; 40:417–23. [PubMed 6846350]

  • 881.

    Kasahara K, Ruiz-Torres A. Einwirkung der verdauungssafe auf die bestandigkeit des digoxin-und digitoxin-molekuls. Klin Wochenschr. 1969; 47:1109–11. [PubMed 5381993]

  • 882.

    Berman W, Whitman V, Marks KH et al. Inadvertent overadministration of digoxin to low-birth-weight infants. J Pediatr. 1978; 92:1024–5. [PubMed 660345]

  • 883.

    Berman W, Dubynsky O, Whitman V et al. Digoxin therapy in low-birth-weight infants with patent ductus arteriosus. J Pediatr. 1978; 93:652–5. [PubMed 702246]

  • 884.

    Hajratwala BR. Stability of prostaglandins. Aust J Pharm Sci. 1975; NS5(Jun):39–41.

  • 885.

    Roseman TJ, Sims B. Stability of prostaglandins. Am J Hosp Pharm. 1973; 30:236–9. [PubMed 4690482]

  • 886.

    Gupta VD, Stewart KR. Stability of cefsulodin in aqueous buffered solutions and some intravenous admixtures. J Clin Hosp Pharm. 1984; 9:21–7. [PubMed 6715559]

  • 887.

    Williamson MJ, Luce JK. Doxorubicin hydrochloride-aluminum interaction. Am J Hosp Pharm. 1983; 40:214. [PubMed 6829575]

  • 888.

    Chin TH (Professional Services, Miles Inc., West Haven, CT): Personal communication; 1993 Dec 3.

  • 889.

    Hausrani PK, Davis SS. Preparation and properties of sterile intravenous emulsions. J Parenter Sci Technol. 1983; 37:145–50. [PubMed 6620048]

  • 890.

    Gray MS, Singleton WS. Creaming of phosphatide stabilized fat emulsions by electrolyte solutions. J Pharm Sci. 1967; 56:1429–31. [PubMed 6072761]

  • 891.

    Knutsen C, Miller P. Compatibility, stability, and effect of mixing 10% fat emulsion in TPN solutions. JPEN J Parenter Enteral Nutr. 1981; 5:579.

  • 892.

    Burnham WR, Hansrani PK, Knott CE et al. Stability of a fat emulsion based intravenous feeding mixture. Int J Pharm. 1983; 13:9–22.

  • 893.

    Hardin TC. Complex parenteral nutrition solutions: II. Addition of fat emulsions. Nutr Supp Serv. 1983; 3:50–51.

  • 894.

    Quebbeman EJ, Hamid AAR, Hoffman NE et al. Stability of fluorouracil in plastic containers used for continuous infusion at home. Am J Hosp Pharm. 1984; 41:1153–6. [PubMed 6741959]

  • 895.

    Barker A, Hebron BS, Beck PR et al. Folic acid and total parenteral nutrition. JPEN J Parenter Enteral Nutr. 1984; 8:3–8. [PubMed 6422069]

  • 896.

    Louie N, Stennett DJ. Stability of folic acid in 25% dextrose, 3.5% amino acids, and multivitamin solution. JPEN J Parenter Enteral Nutr. 1984; 8:421–6. [PubMed 6540318]

  • 897.

    Koshiro A, Oie S, Harima Y et al. Compatibility of gentamicin sulfate injection in parenteral solutions. Jap J Hosp Pharm. 1982; 7:377–80.

  • 898.

    Godefroid RJ. Intravenous gentamicin dilution requirements. Am J Hosp Pharm. 1982; 39:1457. [PubMed 7137180]

  • 899.

    Godefroid RJ. Comment on IV guidelines. Drug Intell Clin Pharm. 1984; 18:925.

  • 900.

    Matthews H. Heparin anticoagulant activity in intravenous fluids utilising a chromagenic substrate assay method. Aust J Hosp Pharm. 1982; 12:S17–S22.

  • 901.

    Turco SJ. Heparin locks. Am J IV Ther Clin Nutr. 1983; 10:9.

  • 902.

    Swerling R: Normal saline or dilute heparin for heparin lock flush? Infusion. 1982; 6:123–124.

  • 903.

    Epperson EL. Efficacy of 0.9% sodium chloride injection with and without heparin for maintaining indwelling intermittent injection sites. Clin Pharm. 1984; 3:626–9. [PubMed 6509875]

  • 904.

    Kanke M, Eubanks JL. Binding of selected drugs to a “treated” inline filter. Am J Hosp Pharm. 1983; 40:1323–8. [PubMed 6225336]

  • 905.

    Anderson W, Harthill JE. Anticoagulant activity of heparins in dextrose solutions. J Pharm Pharmacol. 1982; 34:90–6. [PubMed 6121887]

  • 906.

    Enderlin G. Discoloration of hydralazine injection. Am J Hosp Pharm. 1984; 41:634. [PubMed 6720700]

  • 907.

    Pingel M, Volund A. Stability of insulin preparations. Diabetes. 1972; 21:805–13. [PubMed 5039832]

  • 908.

    Weber SS, Wood WA. Insulin adsorption controversy. Drug Intell Clin Pharm. 1976; 10:232–3.

  • 909.

    Schildt B, Ahlgren T, Berghem L et al. Adsorption of insulin by infusion materials. Acta Anaesthesiol Scand. 1978; 22:556–62. [PubMed 696219]

  • 910.

    Mitrano FP, Newton DW. Factors affecting insulin adherence to type I glass bottles. Am J Hosp Pharm. 1982; 39:1491–5. [PubMed 6753574]

  • 911.

    Twardowski ZJ, Nolph KD, McGary TJ et al. Insulin binding to plastic bags: a methodologic study. Am J Hosp Pharm. 1983; 40:575–9. [PubMed 6342377]

  • 912.

    Twardowski ZJ, Nolph KD, McGary TJ et al. Nature of insulin binding to plastic bags. Am J Hosp Pharm. 1983; 40:579–82. [PubMed 6342378]

  • 913.

    Twardowski ZJ, Nolph KD, McGary TJ et al. Influence of temperature and time on insulin adsorption to plastic bags. Am J Hosp Pharm. 1983; 40:583–6. [PubMed 6342379]

  • 914.

    Sato S, Ebert CD. Prevention of insulin self-association and surface adsorption. J Pharm Sci. 1983; 72:228–32. [PubMed 6341536]

  • 915.

    Phillips NC, Lauper RD. Review of etoposide. Clin Pharm. 1983; 2:112–9. [PubMed 6309469]

  • 916.

    McCollam PL, Garrison TJ. Etoposide: A new chemotherapeutic agent. Am J IV Ther Clin Nutr. 27–28 (Mar) 1984; 11:24.

  • 917.

    Stroup JW, Mighton-Eryou LM. Expiry date guidelines for a centralized IV admixture service. Can J Hosp Pharm. 1986; 39:57–9. [PubMed 10311616]

  • 918.

    Bishop BG. Adsorption of iron-dextran on membrane filters. NZ Pharm. 1981; 1:49.

  • 919.

    Reed MD, Bertino JS. Use of intravenous iron dextran injection in children receiving total parenteral nutrition. Am J Dis Child. 1981; 135:829–31. [PubMed 6792906]

  • 920.

    Halpin TC. Use of intravenous iron dextran in sick patients receiving TPN. Nutr Supp Serv. 1982; 2:19–20.

  • 921.

    Shimada A. Adverse reactions to total-dose infusion of iron dextran. Clin Pharm. 1982; 1:248–9. [PubMed 7185520]

  • 922.

    Thompson DF, Shimanek M. Stability of sterility study with magnesium sulfate admixtures. Infusion. 86 (May-June) 1983; 7:83.

  • 923.

    Ausman RK, Crevar GE, Hagedorn H et al. Studies in the pharmacodynamics of mechlorethamine and AB100. J Am Med Assoc. 1961; 178:143–6.

  • 924.

    A.H. Robins Pharmaceutical Division. Compatibility chart for reglan injectable 5 mg/mL. Richmond, VA; 1983 Oct.

  • 925.

    Bonati M, Gaspari F, D’Aranno V et al. Physicochemical and analytical characteristics of amiodarone. J Pharm Sci. 1984; 73:829–31. [PubMed 6737273]

  • 926.

    Feroz RM, Puppala S, Chaudhry MA, et al. Compatibility of M.V.C. 9+3 (multivitamin concentrate for infusion) in different large volume parenteral solutions. LyphoMed, Inc., 1984.

  • 927.

    Alam AS. Identification of labetalol precipitate. Am J Hosp Pharm. 1984; 41:74. [PubMed 6695936]

  • 928.

    Wagenknecht DM, Baaske DM, Alam AS et al. Stability of nitroglycerin solutions in polyolefin and glass containers. Am J Hosp Pharm. 1984; 41:1807–11. [PubMed 6437221]

  • 929.

    Klamerus KJ, Ueda CT. Stability of nitroglycerin in intravenous admixtures. Am J Hosp Pharm. 1984; 41:303–5. [PubMed 6422753]

  • 930.

    Scheife AH, Grisafe JA. Stability of intravenous nitroglycerin solutions. J Pharm Sci. 1982; 71:55–9. [PubMed 6799641]

  • 931.

    Ingram JK, Miller JD. Plastic absorption adsorption of nitroglycerin solution. Anesthesiology. 1979; 51:S132.

  • 932.

    Mathot F, Bonnard J, Hans P et al. Les perfusions de nitroglycerine: Etude de l’absorption par differents materiaux plastiques. J Pharm Belg. 1980; 35:389–93. [PubMed 6778985]

  • 933.

    Sokoloski TD, Wu CC. Nitroglycerin stability: effects on bioavailability, assay and biological dissolution. J Clin Hosp Pharm. 1981; 6:227–32. [PubMed 6802877]

  • 934.

    Cawello VW, Bonn R. Bioverfugbarkeitseinflusse durch die wahl des infusionsmaterials bei der therapie mit nitroglycerin. Arzneimittelforschung. 1983; 33:595–7. [PubMed 6409129]

  • 935.

    Rock CM, Gull J. Reducing IV-nitroglycerin loss to an intravenous administration set by preliminary preparation. Am J IV Ther Clin Nutr. 40–42 (Oct) 1982; 9:36.

  • 936.

    Nix DE, Tharpe WN. Effects of presaturation on nitroglycerin delivery by polyvinyl chloride infusion sets. Am J Hosp Pharm. 1984; 41:1835–7. [PubMed 6437222]

  • 937.

    Jacobi J, Dasta JF, Reilley TE et al. Loss of nitroglycerin to pulmonary artery delivery systems. Am J Hosp Pharm. 1983; 40:1980–2. [PubMed 6418004]

  • 938.

    Jacobi J, Dasta JF, Wu LS et al. Loss of nitroglycerin to central venous pressure catheter. Drug Intell Clin Pharm. 1982; 16:331–2. [PubMed 7067623]

  • 939.

    Dasta JF, Jacobi J, Sokolowski TD et al. Loss of nitroglycerin to cardiopulmonary bypass apparatus. Crit Care Med. 1983; 11:50–2. [PubMed 6401237]

  • 940.

    Dasta JF, Jacobi J, Sokoloski TD et al. Extraction of nitroglycerin by a membrane oxygenator. J Extra-Corp Tech. 1983; 15:101–3.

  • 941.

    St. Peter JV, Cochran TG. Nitroglycerin loss from intravenous solutions administered with a volumetric infusion pump. Am J Hosp Pharm. 1982; 39:1328–30. [PubMed 6812416]

  • 942.

    Hola ET. Loss of nitroglycerin during microinfusion. Am J Hosp Pharm. 1984; 41:142–4. [PubMed 6421154]

  • 943.

    Yacobi A, Amann AH. Pharmaceutical considerations of nitroglycerin. Drug Intell Clin Pharm. 1983; 17:255–63. [PubMed 6404619]

  • 944.

    Malick AW, Amann AH, Baaske DM et al. Loss of nitroglycerin from solutions to intravenous plastic containers: a theoretical treatment. J Pharm Sci. 1981; 70:798–800. [PubMed 6790697]

  • 945.

    Amann AH, Baaske DM. Loss of nitroglycerin from intravenous administration sets during infusion: a theoretical treatment. J Pharm Sci. 1982; 71:473–4. [PubMed 6806460]

  • 946.

    Neftel KA, Walti M, Spengler H et al. Effect of storage of penicillin G solutions on sensitization to penicillin G after intravenous administration. Lancet. 1982; 1:986–8. [PubMed 6122846]

  • 947.

    Salem RB, Wilder BJ, Yost RL et al. Rapid infusion of phenytoin sodium loading doses. Am J Hosp Pharm. 1981; 38:354–7. [PubMed 7223748]

  • 948.

    Gannaway WL, Wilding DC, Siepler JK et al. Clinical use of intravenous phenytoin sodium infusions. Clin Pharm. 1983; 2:135–8. [PubMed 6883941]

  • 949.

    Boike SC, Rybak MJ, Tintinalli JE et al. Evaluation of a method for intravenous phenytoin infusion. Clin Pharm. 1983; 2:444–6. [PubMed 6627872]

  • 950.

    Earnest MP, Marx JA, Drury LR. Complications of intravenous phenytoin for acute treatment of seizures. JAMA. 1983; 249:762–5. [PubMed 6823029]

  • 951.

    Giacona N, Bauman JL. Crystallization of three phenytoin preparations in intravenous solutions. Am J Hosp Pharm. 1982; 39:630–4. [PubMed 7081239]

  • 952.

    Lau A, Lee M, Flascha S et al. Effect of piperacillin on tobramycin pharmacokinetics in patients with normal renal function. Antimicrob Agents Chemother. 1983; 24:533–7. [PubMed 6651279][Free Fulltext PMC]

  • 953.

    Autian J, Dhorda CN. Evaluation of disposable plastic syringes as to physical incompatibilities with parenteral products. Am J Hosp Pharm. 1959; 16:176–9.

  • 954.

    Addy DP, Alesbury P. Paraldehyde and plastic syringes. Br Med J. 1978; 2:1434. [PubMed 719445][Free Fulltext PMC]

  • 955.

    Fenton-May V, Lee F. Paraldehyde and plastic syringes. Br Med J. 1978; 2:1166. [PubMed 709291][Free Fulltext PMC]

  • 956.

    Evans RJ. Effect of paraldehyde on disposable syringes and needles. Lancet. 1961; 2:1451.

  • 957.

    Johnson CE, Vigoreaux JA. Compatibility of paraldehyde with plastic syringes and needle hubs. Am J Hosp Pharm. 1984; 41:306–8. [PubMed 6702838]

  • 958.

    Mahony C, Brown JE, Starget WW et al. In vitro stability of sodium nitroprusside solutions for intravenous administration. J Pharm Sci. 1984; 73:838–9. [PubMed 6737276]

  • 959.

    Fricker MP, Swerling R. Sodium nitroprusside reconstitution and administration. Infusion. 1981; 5:56.

  • 960.

    Boehm JJ, Dutton DM. Shelf life of unrefrigerated succinylcholine chloride injection. Am J Hosp Pharm. 1984; 41:300–2. [PubMed 6702837]

  • 961.

    Roach M. IV tetracycline. Pharm J. 1978; 220:143.

  • 962.

    Chow MS, Qwintiliani R, Nightingale CH. In vivo inactivation of tobramycin by ticarcillin. A case report. JAMA. 1982; 247:658–9. [PubMed 6798229]

  • 963.

    Baumgartner TG, Russell WL. Intravenous trimethoprim-sulfamethoxazole administration alert. Am J IV Ther Clin Nutr. 1983; 10:14–5.

  • 964.

    Hiskey CF, Bullock E. Spectrophotometric study of aqueous solutions of warfarin sodium. J Pharm Sci. 1962; 51:43–6. [PubMed 13907774]

  • 965.

    Nahata MC. Stability of ceftriaxone sodium in intravenous solutions. Am J Hosp Pharm. 1983; 40:2193–4. [PubMed 6318556]

  • 966.

    Smith BR. Effect of storage temperature and time on stability of cefmenoxime, ceftriaxone, and cefotetan in 5% dextrose injection. Am J Hosp Pharm. 1983; 40:1024–5. [PubMed 6307045]

  • 967.

    Vishnuvajjala BR, Cradock JC. Compatibility of plastic infusion devices with diluted N-methylformamide and N,N-dimethylacetamide. Am J Hosp Pharm. 1984; 41:1160–3. [PubMed 6741960]

  • 968.

    Godefroid RJ. Vindesine: A new antineoplastic drug. Cancer Chemother Update. 1984; 2:4–7.

  • 969.

    Cheung YW, Vishnuvajjala BR, Morris NL et al. Stability of azacitidine in infusion fluids. Am J Hosp Pharm. 1984; 41:1156–9. [PubMed 6204528]

  • 970.

    Bosanquet AG. Stability of melphalan solutions during preparation and storage. J Pharm Sci. 1985; 74:348–51. [PubMed 4009450]

  • 971.

    Tabibi SE, Cradock JC. Stability of melphalan in infusion fluids. Am J Hosp Pharm. 1984; 41:1380–2. [PubMed 6465155]

  • 972.

    Teresi M, Allison J. Interaction between vancomycin and ticarcillin. Am J Hosp Pharm. 1985; 42:2420. [PubMed 4073055]

  • 973.

    Jorgensen JH, Crawford SA. Selective inactivation of aminoglycosides by newer beta-lactam antibiotics. Curr Ther Res Clin Exp. 1982; 32:25–35.

  • 974.

    Bhatia J, Stegink LD, Ziegler EE. Riboflavin enhances photo-oxidation of amino acids under simulated clinical conditions. JPEN J Parenter Enteral Nutr. 1983; 7:277–9. [PubMed 6683335]

  • 975.

    Smith G, Hasson K. Effects of ascorbic acid and disodium edetate on the stability of isoprenaline hydrochloride injection. J Clin Hosp Pharm. 1984; 9:209–15. [PubMed 6436321]

  • 976.

    Hutchinson SM. Heparin and aminoglycosides instability. Drug Intell Clin Pharm. 1986; 20:886.

  • 977.

    Johnston-Early A, McKenzie MA, Krasnow SH et al. Drug trapping in intravenous infusion side arms. JAMA. 1984; 252:2392. [PubMed 6481925]

  • 978.

    Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm. 1985; 38:160–1.

  • 979.

    Das Gupta V, Stewart KR. Chemical stabilities of cefamandole nafate and metronidazole when mixed together for intravenous infusion. J Clin Hosp Pharm. 1985; 10:379–83. [PubMed 4093509]

  • 980.

    Cohen MH, Johnston-Early A, Hood MA et al. Drug precipitation within iv tubing: a potential hazard of chemotherapy administration. Cancer Treat Rep. 1985; 69:1325–6. [PubMed 4092196]

  • 981.

    Marble DA, Bosso JA. Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions. Drug Intell Clin Pharm. 1986; 20:960–3. [PubMed 3816545]

  • 982.

    Gove LF, Gordon NH, Miller J et al. Pre-filled syringes for self-administration of epidural opiates. Pharm J. 1985; 234:378–9.

  • 983.

    Bosso JA, Townsend RJ. Stability of clindamycin phosphate and ceftizoxime sodium, cefoxitin sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions. Am J Hosp Pharm. 1985; 42:2211–4. [PubMed 3864367]

  • 984.

    Nahata MC, Durrell DE. Stability of tobramycin sulfate in admixtures with calcium gluconate. Am J Hosp Pharm. 1985; 42:1987–8. [PubMed 3901742]

  • 985.

    Baker DE, Yost GS, Craig VL et al. Compatibility of heparin sodium and morphine sulfate. Am J Hosp Pharm. 1985; 42:1352–5. [PubMed 4014252]

  • 986.

    Carlson GH, Matzke GR. Particle formation of third-generation cephalosporin injections. Am J Hosp Pharm. 1985; 42:1578–9. [PubMed 4025360]

  • 987.

    Nieves-Cordero AL, Luciw HM. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm. 1985; 42:1108–9. [PubMed 4003421]

  • 988.

    Ogawa GS, Young R. Dispensing-pin problems. Am J Hosp Pharm. 1985; 42:1042. [PubMed 4003409]

  • 989.

    Conklin CA, Kerege JF. Stability of an analgesic-sedative combination in glass and plastic single-dose syringes. Am J Hosp Pharm. 1985; 42:339–42. [PubMed 3976682]

  • 990.

    Thompson M, Smith M, Gragg R et al. Stability of nitroglycerin and dobutamine in 5% dextrose and 0.9% sodium chloride injection. Am J Hosp Pharm. 1985; 42:361–2. [PubMed 3919576]

  • 991.

    Rhodes RS, Rhodes PJ. Stability of meperidine hydrochloride, promethazine hydrochloride, and atropine sulfate in plastic syringes. Am J Hosp Pharm. 1985; 42:112–5. [PubMed 3970025]

  • 992.

    Kiel D, Connolly BJ. Visual compatibility of amrinone lactate with various i.v. secondary additives. Parenterals. (May-June) 1985; 3:1, 5–6.

  • 993.

    Das Gupta V, Stewart KR. Chemical stabilities of hydrocortisone sodium succinate and several antibiotics when mixed with metronidazole injection for intravenous infusion. J Parenter Sci Technol. 1985; 39:145–8. [PubMed 3998970]

  • 994.

    Foley PT, Bosso JA, Bair JN et al. Compatibility of clindamycin phosphate with cefotaxime sodium or netilmicin sulfate in small-volume admixtures. Am J Hosp Pharm. 1985; 42:839–43. [PubMed 4014236]

  • 995.

    Mansur JM, Abramowitz PW, Lerner SA et al. Stability and cost analysis of clindamycin-gentamicin admixtures given every eight hours. Am J Hosp Pharm. 1985; 42:332–5. [PubMed 3976680]

  • 996.

    Quock JR, Sakai RI. Stability of cytarabine in a parenteral nutrient solution. Am J Hosp Pharm. 1985; 42:592–4. [PubMed 3920905]

  • 997.

    Walker SE, Bayliff CD. Stability of ranitidine hydrochloride in total parenteral nutrient solution. Am J Hosp Pharm. 1985; 42:590–2. [PubMed 3920904]

  • 998.

    Baptista RJ, Palumbo JD, Tahan SR et al. Stability of cimetidine hydrochloride in a total nutrient admixture. Am J Hosp Pharm. 1985; 42:2208–10. [PubMed 3933337]

  • 999.

    Das Gupta V, Stewart KR. pH-Dependent effect of magnesium sulfate on the stability of penicillin G potassium solution. Am J Hosp Pharm. 1985; 42:598–602. [PubMed 3985024]

  • 1000.

    Macias JM, Martin WJ. Stability of morphine sulfate and meperidine hydrochloride in a parenteral nutrient formulation. Am J Hosp Pharm. 1985; 42:1087–94. [PubMed 3923832]

  • 1001.

    James MJ, Riley CM. Stability of intravenous admixtures of aztreonam and ampicillin. Am J Hosp Pharm. 1985; 42:1095–110. [PubMed 4039889]

  • 1002.

    James MJ, Riley CM. Stability of intravenous admixtures of aztreonam and clindamycin phosphate. Am J Hosp Pharm. 1985; 42:1984–6. [PubMed 4050817]

  • 1003.

    Thompson DF, Thompson GD. Effect of inline filtration on pediatric doses of gentamicin and tobramycin. Infusion. 1984; 8:31–2.

  • 1004.

    Alexander SR, Arena R. Predicting calcium phosphate precipitation in premature infant parenteral nutrition solutions. Hosp Pharm. 1985; 20:656–8.

  • 1005.

    Spruill WJ, McCall CY. In vitro inactivation of tobramycin by cephalosporins. Am J Hosp Pharm. 1985; 42:2506–9. [PubMed 3907338]

  • 1006.

    Stevenson JG, Patriarca C. Incompatibility of morphine sulfate and prochlorperazine edisylate in syringes. Am J Hosp Pharm. 1985; 42:2651. [PubMed 4083284]

  • 1007.

    Beijnen JH, Rosing H, deVries PA et al. Stability of anthracycline antitumor agents in infusion fluids. J Parenter Sci Technol. 1985; 39:220–2. [PubMed 3867751]

  • 1008.

    Baptista RJ, Lawrence RW. Compatibility of total nutrient admixtures and secondary antibiotic infusions. Am J Hosp Pharm. 1985; 42:362–3. [PubMed 3919577]

  • 1009.

    Baptista RJ, Dumas GJ, Bistrian BR et al. Compatibility of total nutrient admixtures and secondary cardiovascular medications. Am J Hosp Pharm. 1985; 42:777–8. [PubMed 3925765]

  • 1010.

    Bullock L, Parks RB, Lampasona V et al. Stability of ranitidine hydrochloride and amino acids in parenteral nutrient solutions. Am J Hosp Pharm. 1985; 42:2683–7. [PubMed 3936354]

  • 1011.

    Henann NE, Jacks TT. Compatibility and availability of sodium bicarbonate in total parenteral nutrient solutions. Am J Hosp Pharm. 1985; 42:2718–20. [PubMed 3002174]

  • 1012.

    Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solutions. JPEN J Parenter Enteral Nutr. 1985; 9:220–4. [PubMed 3921739]

  • 1013.

    Turner SA. Stability and clinical use of intravenous admixtures containing lipid emulsion. Pharm J. 1985; 234:799–800.

  • 1014.

    El Eini D, Knott CE. Stability of iv lipid emulsions. Pharm J. 1985; 235:170.

  • 1015.

    Hobbiss JH. Stability of iv lipid emulsions. Pharm J. 1985; 235:170.

  • 1016.

    Allwood MC. Drop size of infusions containing fat emulsion. Br J Parenter Ther. 1984; 5:113–4.

  • 1017.

    Iliano L, Delanghe M, van Den Baviere H et al. Effect of electrolytes in the presence of some trace elements on the stability of all-in-one emulsion mixtures for total parenteral nutrition. J Clin Hosp Pharm. 1984; 9:87–93. [PubMed 6430967]

  • 1018.

    Whateley TL, Steele G, Urwin J et al. Particle size stability of Intralipid and mixed total parenteral nutrition mixtures. J Clin Hosp Pharm. 1984; 9:113–26. [PubMed 6430965]

  • 1019.

    Harrie KR, Jacob M, McCormick D et al. Comparison of total nutrient admixture stability using two intravenous fat emulsions, Soyacal and Intralipid 20%. JPEN J Parenter Enteral Nutr. 1986; 10:381–7. [PubMed 3747094]

  • 1020.

    Riley CM, James MJ. Stability of intravenous admixtures containing aztreonam and cefazolin. Am J Hosp Pharm. 1986; 43:925–7. [PubMed 3706339]

  • 1021.

    Kuhn RJ, Nahata MC. Stability of netilmicin sulfate in admixtures with calcium gluconate and aminophylline. Am J Hosp Pharm. 1986; 43:1241–2. [PubMed 3717181]

  • 1022.

    Johnson CE, Cohen IA, Craft DA et al. Compatibility of aminophylline and methylprednisolone sodium succinate intravenous admixtures. Am J Hosp Pharm. 1986; 43:1482–5. [PubMed 3524206]

  • 1023.

    Bell RG, Lipford LC, Massanari MJ et al. Stability of intravenous admixtures of aztreonam and cefoxitin, gentamicin, metronidazole, or tobramycin. Am J Hosp Pharm. 1986; 43:1444–53. [PubMed 3728479]

  • 1024.

    Fitzgerald KA, MacKay MW. Calcium and phosphate solubility in neonatal parenteral nutrient solutions containing TrophAmine. Am J Hosp Pharm. 1986; 43:88–93. [PubMed 3082196]

  • 1025.

    Sayeed FA, Johnson HW, Sukumaran KB et al. Stability of Liposyn II fat emulsion in total nutrient admixtures. Am J Hosp Pharm. 1986; 43:1230–5. [PubMed 3087165]

  • 1026.

    Marble DA, Bosso JA. Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium, or piperacillin sodium in two intravenous solutions. Am J Hosp Pharm. 1986; 43:1732–6. [PubMed 3529949]

  • 1027.

    Lee MG. Sorption of four drugs to polyvinyl chloride and polybutadiene intravenous administration sets. Am J Hosp Pharm. 1986; 43:1945–50. [PubMed 3092648]

  • 1028.

    Riley CM, Lipford LC. Interaction of aztreonam with nafcillin in intravenous admixtures. Am J Hosp Pharm. 1986; 43:2221–4. [PubMed 3766577]

  • 1029.

    Walker PC, Kaufmann RE. Compatibility of cefazolin and gentamicin in peritoneal dialysis solutions. Drug Intell Clin Pharm. 1986; 20:697–700. [PubMed 3757783]

  • 1030.

    Beijnen JH, Neef C, Menwissen OJAT et al. Stability of intravenous admixtures of doxorubicin and vincristine. Am J Hosp Pharm. 1986; 43:3022–7. [PubMed 3812509]

  • 1031.

    Campbell S, Nolan PE, Bliss M et al. Stability of amiodarone hydrochloride in admixtures with other injectable drugs. Am J Hosp Pharm. 1986; 43:917–21. [PubMed 3706337]

  • 1032.

    Hasegawa GR, Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm. 1984; 41:1379–80. [PubMed 6465154]

  • 1033.

    Allwood MC. Sorption of drugs to intravenous delivery systems. Pharm Int. 1983; 4:83–5.

  • 1034.

    Khue NV, Jung L. Study of the retention of child-dose drugs on cellulose ester membranes during inline intravenous filtration. S-T-P-Pharma. 1985; 1:201–7.

  • 1035.

    Das Gupta V, Shah KA. Stability of ampicillin sodium and penicillin G potassium solutions using high-pressure liquid chromatography. Can J Pharm Sci. 1981; 16:61–5.

  • 1036.

    Janknegt R, Neil MJLE. De verenigbaarheid van antimicrobiele middelen in infusievloeistoffen. Pharm Weekbl. 1985; 120:638–40.

  • 1037.

    Bouma J, Beijnen JH, Bult A et al. Anthracycline antitumor agents, a review of physicochemical, analytical and stability properties. Pharm Weekbl [Sci]. 1986; 8:109–33.

  • 1038.

    Howard L, Chu R, Feman S et al. Vitamin A deficiency from long-term parenteral nutrition. Ann Intern Med. 1980; 93:576–7. [PubMed 6776861]

  • 1039.

    Shenai JP, Stahlman MT. Vitamin A delivery from parenteral alimentation solution. J Pediatr. 1981; 99:661–3. [PubMed 6792338]

  • 1040.

    Kishi H, Yamaji A, Kataoka K et al. Vitamin A and E requirements during total parenteral nutrition. JPEN J Parenter Enteral Nutr. 1981; 5:420–3. [PubMed 6796716]

  • 1041.

    Knight P, Heer D, Abdenour G. CaxP and Ca/P in the parenteral feeding of preterm infants. JPEN J Parenter Enteral Nutr. 1983; 7:110–4. [PubMed 6406695]

  • 1042.

    Poole RK, Rupp CA, Kerner JA Jr. Calcium and phosphorus in neonatal parenteral nutrition solutions. JPEN J Parenter Enteral Nutr. 1983; 7:358–60. [PubMed 6413711]

  • 1043.

    Ritschel WA, Alcorn GJ, Streng WH et al. Cimetidine-theophylline complex formation. Methods Find Exp Clin Pharmacol. 1983; 5:55–8. [PubMed 6855344]

  • 1044.

    Glew RH, Pavuk RA. Stability of vancomycin and aminoglycoside antibiotics in peritoneal dialysis concentrate. Nephron. 1981; 28:241–3.

  • 1045.

    Kamen BA, Gunther N, Sowinsky N et al. Analysis of antibiotic stability in a parenteral nutrition solution. Pediatr Infect Dis. 1985; 4:387–9. [PubMed 3927270]

  • 1046.

    Baumgartner TG, Sitren HS, Hall J et al. Stability of urokinase in parenteral nutrition solutions. Nutr Supp Serv. 1985; 5:41–3.

  • 1047.

    Allwood MC. Influence of light on vitamin A degradation during administration. Clin Nutr. 1982; 1:63–70. [PubMed 16829368]

  • 1048.

    Allwood MC, Plane JH. Degradation of vitamin A exposed to ultraviolet radiation. Int J Pharm. 1984; 19:207–13.

  • 1049.

    Riggle MA, Brandt RB. Decrease of available vitamin A in parenteral nutrition solutions. JPEN J Parenter Enteral Nutr. 1986; 10:388–92. [PubMed 3091863]

  • 1050.

    McKenna MC, Bieri JC. Loss of vitamin A from total parenteral nutrition (TPN) solutions. Fed Proc. 1980; 39:561.

  • 1051.

    Bryant CA, Neufeld NJ. Differences in vitamin A content of enteral feeding solutions following exposure to a polyvinyl chloride enteral feeding system. JPEN J Parenter Enteral Nutr. 1982; 6:403–5. [PubMed 6818368]

  • 1052.

    Riff LJ, Thomason JL. Comparative aminoglycoside inactivation by beta-lactam antibiotics—effect of cephalosporin and six penicillins on five aminoglycosides. J Antibiot (Tokyo). 1982; 35:850–7. [PubMed 7174538]

  • 1053.

    Schutz VH, Schroder F. Heparin-natrium kompatibilitat bei gleichzeitiger applikation anderer pharmaka. Krankenhauspharmazie. 1985; 6:7–11.

  • 1054.

    Wermeling DP, Rapp RP, DeLuca PP et al. Osmolality of small-volume intravenous admixtures. Am J Hosp Pharm. 1985; 42:1739–44. [PubMed 4036971]

  • 1055.

    Johnston SJ. Stability of tryptophan in total parenteral nutrient solutions. Am J Hosp Pharm. 1986; 43:1424. [PubMed 3088991]

  • 1056.

    Allwood MC. Factors influencing the stability of ascorbic acid in total parenteral nutrition infusions. J Clin Hosp Pharm. 1984; 9:75–85. [PubMed 6430966]

  • 1057.

    Parr MD, Bertch KE. Amino acid stability and microbial growth in total parenteral nutrient solutions. Am J Hosp Pharm. 1985; 42:2688–91. [PubMed 3936355]

  • 1058.

    Nordfjeld K, Rasmussen M. Storage of mixtures for total parenteral nutrition: long-term stability of a total parenteral nutrition mixture. J Clin Hosp Pharm. 1983; 8:265–74. [PubMed 6415118]

  • 1059.

    Nordfjeld K, Pedersen JL, Rasmussen M et al. Storage of mixtures for total parenteral nutrition III. Stability of vitamins in TPN mixtures. J Clin Hosp Pharm. 1984; 9:293–301. [PubMed 6441814]

  • 1060.

    Das Gupta V. Stability of vitamins in total parenteral nutrient solutions. Am J Hosp Pharm. 1986; 43:2132. [PubMed 3094368]

  • 1061.

    Allwood MC. Stability of vitamins in total parenteral nutrient solutions. Am J Hosp Pharm. 1986; 43:2138.

  • 1062.

    Louie N. Stability of vitamins in total parenteral nutrient solutions. Am J Hosp Pharm. 1986; 43:2138.

  • 1063.

    Shine B, Farwell JA. Stability and compatibility in parenteral nutrition solutions. Br J Parenter Ther. 44–46, 50 (Mar) 1984; 5:4.

  • 1064.

    Pamperl H, Kleinberger G. Stability of intravenous fat emulsions. Arch Surg. 1982; 117:859–860. [PubMed 7082174]

  • 1065.

    Hardy G, Cotter R, Dawe R. The stability and comparative clearance of TPN mixtures with lipid. In: Johnson ID, ed. Advances in Clinical Nutrition: Selected Proceedings of the 2nd International Symposium. Lancaster, England: MTP Press; 1983:241–60.

  • 1066.

    Hardy G, Klim RA. Stability studies of parenteral nutrition mixtures with lipids. JPEN J Parenter Enteral Nutr. 1981; 5:569.

  • 1067.

    Jeppsson RI, Sjoberg B. Compatibility of parenteral nutrition solutions when mixed in a plastic bag. Clin Nutr. 1984; 2:149–58. [PubMed 16829426]

  • 1068.

    Parry VA, Harrie KR. Effect of various nutrient ratios on the emulsion stability of total nutrient admixtures. Am J Hosp Pharm. 1986; 43:3017–22. [PubMed 3101495]

  • 1069.

    Bettner FS, Stennett DJ. Effects of pH, temperature, concentration, and time on particle counts in lipid-containing total parenteral nutrition admixtures. JPEN J Parenter Enteral Nutr. 1986; 10:375–80. [PubMed 3091862]

  • 1070.

    Schneider PJ. Three-in-one TPN formulations. Infusion. (May-June) 1984; 8:94–5, 101.

  • 1071.

    Ernst JA, Williams JM, Glick MR et al. Osmolality of substances used in the intensive care nursery. Pediatrics. 1983; 72:347–52. [PubMed 6889039]

  • 1072.

    Connors KA, Amidon GL, Stella VJ. Chemical stability of pharmaceuticals: a handbook for pharmacists. New York: John Wiley & Sons; 1986.

  • 1073.

    Bosanquet AG. Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays II. Assay methods, adriamycin and the other antitumor antibiotics. Cancer Chemother Pharmacol. 1986; 17:1–10. [PubMed 2421936]

  • 1074.

    Grant AM (Medical Affairs, Abbott Laboratories, Abbott Park, IL): Personal communication; 1987 Mar 23.

  • 1075.

    Bornstein M, Templeton RJ. Crystal formation after reconstituting cefazolin sodium with 0.9% sodium chloride injection. Am J Hosp Pharm. 1985; 42:2436. [PubMed 4073058]

  • 1076.

    White JR, Campbell RK. Guide to mixing insulins. Hosp Pharm. 1991; 26:1046–48.

  • 1077.

    Das Gupta V. Stability of cefotaxime sodium as determined by high-performance liquid chromatography. J Pharm Sci. 1984; 73:565–7. [PubMed 6327966]

  • 1078.

    Carlson GH, Matzke GR. Particle formation of ceftizoxime sodium injections. Am J Hosp Pharm. 1985; 42:2651–2. [PubMed 3866491]

  • 1079.

    Swenson E, Gooch WM. Visual compatibility of ceftizoxime sodium in four electrolyte injections. Am J Hosp Pharm. 1986; 43:2242–4. [PubMed 3766586]

  • 1080.

    Barbero JR, Marino EL. Accelerated stability studies on Rocephin by high-efficiency liquid chromatography. Int J Pharm. 1984; 19:199–206.

  • 1081.

    Smith RC. Overfill in cefuroxime sodium vials. Am J Hosp Pharm. 1985; 42:1045–6. [PubMed 4003410]

  • 1082.

    Smith RC. No more overfill in cefuroxime sodium vials. Am J Hosp Pharm. 1986; 43:2154. [PubMed 3766566]

  • 1083.

    DeVane CL, Wailand LA. Stability of chlorpromazine in five milliliter vials. Can J Hosp Pharm. 1984; 37:9.

  • 1084.

    Mu-Chow KJ, Baptista RJ. Cost-effectiveness of parenteral nutrient solutions containing cimetidine hydrochloride. Am J Hosp Pharm. 1984; 41:1321. [PubMed 6431804]

  • 1085.

    Parasrampuria J, Das Gupta V. Stability of acetazolamide sodium in 5% dextrose or 0.9% sodium chloride injection. Am J Hosp Pharm. 1987; 44:358–60. [PubMed 3565398]

  • 1086.

    Zuber DE. Compatibility of morphine sulfate injections and prochlorperazine edisylate injections. Am J Hosp Pharm. 1987; 44:67. [PubMed 3826088]

  • 1087.

    Cheung YW, Cradock JC, Vishnuvajjala BR et al. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous infusion solutions. Am J Hosp Pharm. 1987; 44:124–30. [PubMed 3548341]

  • 1088.

    LaFollette JM, Arbus MH. Stability of cisplatin admixtures in polyvinyl chloride bags. Am J Hosp Pharm. 1985; 42:2652. [PubMed 4083285]

  • 1089.

    Hussain AA, Haddadin M. Reaction of cis-platinum with sodium bisulfite. J Pharm Sci. 1980; 69:364. [PubMed 7189779]

  • 1090.

    Kirk B, Melia CD, Wilson JV et al. Chemical stability of cyclophosphamide injection. Br J Parenter Ther. 1984; 5:90–7.

  • 1091.

    Ptachcinski RJ, Logue LW, Burckart GJ et al. Stability and availability of cyclosporine in 5% dextrose injection or 0.9% sodium chloride injection. Am J Hosp Pharm. 1986; 43:94–7. [PubMed 3953588]

  • 1092.

    Venkataramanan R, Burckart GJ, Ptachcinski RJ et al. Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous cyclosporine solution. Am J Hosp Pharm. 1986; 43:2800–2. [PubMed 3799618]

  • 1093.

    Stevens MF, Peatey L. Photodegradation of solutions of the antitumour drug DTIC [proceedings]. J Pharm Pharmacol. 1978; 30(Suppl):47P. [PubMed 32303]

  • 1094.

    Williams BA, Tritton TR. Photoinactivation of anthracyclines. Photochem Photobiol. 1981; 34:131–4.

  • 1095.

    Maloney TJ. Dilution of diazepam injection prior to intravenous administration. Aust J Hosp Pharm. 1983; 13:79.

  • 1096.

    Hancock BG, Black CD. Effect of polyethylene-lined administration set on the availability of diazepam injection. Am J Hosp Pharm. 1985; 42:335–9. [PubMed 3976681]

  • 1097.

    Yliruusi JK, Uotila JA. Effect of tubing length on adsorption of diazepam to polyvinyl chloride administration sets. Am J Hosp Pharm. 1986; 43:2789–94. [PubMed 3799616]

  • 1098.

    Yliruusi JK, Uotila JA. Effect of flow rate and type of i.v. container on adsorption of diazepam to i.v. administration systems. Am J Hosp Pharm. 1986; 43:2795–9. [PubMed 3799617]

  • 1099.

    Bell HE, Bertino JS. Constant diazepam infusion in the treatment of continuous seizure activity. Drug Intell Clin Pharm. 1984; 18:965–70. [PubMed 6391884]

  • 1100.

    Dandurand KR, Stennett DJ. Stability of dopamine hydrochloride exposed to blue-light phototherapy. Am J Hosp Pharm. 1985; 42:595–7. [PubMed 3985023]

  • 1101.

    Pluta PL, Morgan PK. Stability of erythromycin in intravenous admixtures. Am J Hosp Pharm. 1986; 43:2732. [PubMed 3799601]

  • 1102.

    Deitel M, Faksa M, Kaminsky VM et al. Growth of microorganisms in soybean oil emulsion and clinical implications. Int Surg. 1979; 64:27–32. [PubMed 119714]

  • 1103.

    Keammerer D, Mayhall CG, Hall GO et al. Microbial growth patterns in intravenous fat emulsions. Am J Hosp Pharm. 1983; 40:1650–3. [PubMed 6416063]

  • 1104.

    Kim CH, Lewis DE. Bacterial and fungal growth in intravenous fat emulsions. Am J Hosp Pharm. 1983; 40:2159–61. [PubMed 6660230]

  • 1105.

    Allwood MC. Release of DEHP plasticizer into fat emulsion from iv administration sets. Pharm J. 1985; 235:600.

  • 1106.

    Driscoll DF, Baptista RJ, Bistrian BR et al. Practical considerations regarding the use of total nutrient admixtures. Am J Hosp Pharm. 1986; 43:416–9. [PubMed 3082199]

  • 1107.

    Morgan DE, Bergdale S. Effect of syringe-pump position on infusion of fat emulsion with a primary solution. Am J Hosp Pharm. 1985; 42:1110–1. [PubMed 4003422]

  • 1108.

    Neil JM, Fell AF. Evaluation of the stability of frusemide in intravenous infusions by reversed-phase high-performance liquid chromatography. Int J Pharm. 1984; 22:105–26.

  • 1109.

    Dean T, Ridley P. Use of 0.9% sodium chloride injection without heparin for maintaining indwelling intermittent injection sites. Clin Pharm. 1985; 4:488. [PubMed 4053520]

  • 1110.

    Chantelau EA, Berger M. Pollution of insulin with silicone oil, a hazard of disposable plastic syringes. Lancet. 1985; 1:1459. [PubMed 2861406]

  • 1111.

    Furberg H, Jensen AK. Effect of pretreatment with 0.9% sodium chloride or insulin solutions on the delivery of insulin from an infusion system. Am J Hosp Pharm. 1986; 43:2209–13. [PubMed 3766574]

  • 1112.

    Kane M, Jay M. Binding of insulin to a continuous ambulatory peritoneal dialysis system. Am J Hosp Pharm. 1986; 43:81–8. [PubMed 3513553]

  • 1113.

    Hutchinson KG. Assessment of gelling in insulin solutions for infusion pumps. J Pharm Pharmacol. 1985; 37:528–31. [PubMed 2864410]

  • 1114.

    Kamerman B. Dissolving mannitol crystals. Hosp Pharm. 1985; 20:360.

  • 1115.

    Cano SB, Glogiewicz FL. Storage requirements for metronidazole injection. Am J Hosp Pharm. 1986; 43:2983. [PubMed 3812502]

  • 1116.

    Schell KH, Copland JR. Metronidazole hydrochloride-aluminum interaction. Am J Hosp Pharm. 1985; 42:1040. [PubMed 4003408]

  • 1117.

    Struthers BJ, Parr RJ. Clarifying the metronidazole hydrochloride-aluminum interaction. Am J Hosp Pharm. 1985; 42:2660. [PubMed 4083286]

  • 1118.

    Quebbeman EJ, Hoffman NE, Ausman RK et al. Stability of mitomycin admixtures. Am J Hosp Pharm. 1985; 42:1750–4. [PubMed 4036973]

  • 1119.

    Edwards D, Selkirk AB. Determination of the stability of mitomycin C by high-performance liquid chromatography. Int J Pharm. 1979; 4:21–6.

  • 1120.

    Young JB, Pratt CM, Farmer JA et al. Specialized delivery systems for intravenous nitroglycerin. Are they necessary?. Am J Med. 1984; 76:27–37. [PubMed 6430075]

  • 1121.

    Nix DE, Tharpe WN. Intravenous nitroglycerin delivery: dynamics and cost considerations. Hosp Pharm. 1985; 20:230–2. [PubMed 10311085]

  • 1122.

    Schaber DE, Uden DL. Nitroglycerin adsorption to a combination polyvinyl chloride, polyethylene intravenous administration set. Drug Intell Clin Pharm. 1985; 19:572–5. [PubMed 3928309]

  • 1123.

    Mendel S, Green JA. Comment: Nitroglycerin iv tubing adsorption. Drug Intell Clin Pharm. 1985; 19:946–7. [PubMed 3936690]

  • 1124.

    Tarr BD, Campbell RK. Stability and sterility of biosynthetic human insulin stored in plastic insulin syringes for 28 days. Am J Hosp Pharm. 1991; 48:2631–4. [PubMed 1814206]

  • 1125.

    Rayani S, Fakhreddin J. Stability of penicillin G sodium in 5% dextrose in water minibags after freezing. Can J Hosp Pharm. 1985; 38:162–3.

  • 1126.

    Das Gupta V, Davis DD. Stability of piperacillin sodium in dextrose 5% and sodium chloride 0.9% injections. Am J IV Ther Clin Nutr. (Feb) 1984; 11:14–5, 18–19.

  • 1127.

    Deardorff DL, Schmidt CN. Mixing additives by squeezing plastic bags. Am J Hosp Pharm. 1985; 42:533–4.

  • 1128.

    Synave R, Vergote A. Stability of procaine hydrochloride in a cardioplegic solution containing bicarbonate. J Clin Hosp Pharm. 1985; 10:385–8. [PubMed 4093510]

  • 1129.

    Raymond G, DeGennaro M. Effect of Neut on the pH of some commercially available intravenous solutions. Infusion. 1985; 9:144–6.

  • 1130.

    Sewell GJ, Forbes DR. Stability of sodium nitroprusside infusion during the administration by motorized syringe-pump. J Clin Hosp Pharm. 1985; 10:351–60. [PubMed 4093505]

  • 1131.

    Baaske DM, Smith MD, Karnatz N et al. High-performance liquid chromatographic determination of sodium nitroprusside. J Chromatogr. 1981; 212:339–46. [PubMed 7263803]

  • 1132.

    Elenbaas JK, Lander RD. Effect of inline filtration on tobramycin delivery. Drug Intell Clin Pharm. 1985; 19:122–5. [PubMed 3882376]

  • 1133.

    Mehta J, Searcy CJ. Stability of terbutaline sulfate admixtures stored in polyvinyl chloride bags. Am J Hosp Pharm. 1986; 43:1760–2. [PubMed 3752119]

  • 1134.

    Das Gupta V, Stewart KR. Stability of vancomycin hydrochloride in 5% dextrose and 0.9% sodium chloride injections. Am J Hosp Pharm. 1986; 43:1729–31. [PubMed 3752110]

  • 1135.

    Hazlet TK, Tankersley DL. Possible incompatibilities with immune globulin for i.v. use. Am J Hosp Pharm. 1993; 50:654, 659–60. [PubMed 8470675]

  • 1136.

    Richardson BL, Woodford JD, Andrews GD. Pharmacy of ceftazidime. J Antimicrob Chemother. 1981; 8:233–6. [PubMed 19802991]

  • 1137.

    Cox ME, Roesner M. Production of carbon dioxide gas after reconstitution of ceftazidime. Am J Hosp Pharm. 1986; 43:1422. [PubMed 3088990]

  • 1138.

    Fites AL. Production of carbon dioxide gas after reconstitution of ceftazidime. Am J Hosp Pharm. 1986; 43:1422–3. [PubMed 3088990]

  • 1139.

    Marwaha RK, Johnson BF. Simple stability-indicating assay for histamine solutions. Am J Hosp Pharm. 1985; 42:1568–71. [PubMed 4025356]

  • 1140.

    Marwaha RK, Johnson BF. Long-term stability study of histamine in sterile bronchoprovocation solutions. Am J Hosp Pharm. 1986; 43:380–3. [PubMed 3953600]

  • 1141.

    Bigley FP, Forsyth RJ. Compatibility of imipenem–cilastatin sodium with commonly used intravenous solutions. Am J Hosp Pharm. 1986; 43:2803–9. [PubMed 3467590]

  • 1142.

    De NC, Alam AS. Stability of pentamidine isethionate in 5% dextrose and 0.9% sodium chloride injec